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Abstract 
 
The development of a palladium-catalysed C–H carbonylation of hindered secondary amines is 
described.  Central to this strategy is the temporary conversion of simple ketones into hindered 
secondary amines that facilitates a sterically promoted palladium-catalysed C–H activation.  A 
range of functional groups are shown to be compatible with this catalytic process, and with 
exclusive regioselectivity for the terminal ethyl sp3 C–H in most cases.  This method allows an 
overall incorporation of a carboxyl group to the -position of terminal ketones, generating 1,4-
dicarbonyl moieties which are important synthetic building blocks. 
 
 
The sterically promoted C–H functionalisation strategy has been employed as the key step in the 
synthesis of a functionalised analogue of astemizole, a pharmaceutical agent which suffers from 
undesired hERG activity.  The increased steric bulk around the tertiary amine, coupled with 
introduction of a polar hydroxyl group via the C–H acetoxylation reaction, is proposed to reduce 
binding to the hERG channel.  The hERG profile of this analogue is not yet established.  
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Ac Acetyl 
Aq. Aqueous 
BINAP 2,2′-Bis(diphenylphosphino)-1,1′-binaphthalene 
Bn Benzyl 
Boc tert-Butyloxycarbonyl 
br Broad 
Bz Benzoyl 
cod 1,5-Cyclooctadiene 
d Doublet  
dba Dibenzylideneacetone 
DBU 1,8-Diazabicycloundec-7-ene 
DCE 1,2-Dichloroethane 
DCM Dichloromethane 
DEMS Diethoxymethylsilane 
DMF N,N-Dimethylformamide 
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DPEphos Bis-[2-(diphenylphosphino)phenyl]ether 
DPPPent 1,3-Bis(diphenylphosphino)propane 
°C               Degree centigrade 
EDC N-ethyl-N’-dimethylaminopropylcarbodiimide 
Equiv Equivalents  
ESI Electrospray ionisation 
Et Ethyl 
Gly Glycine 
h Hour 
HBTU  O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HFIP Hexafluoro-2-propanol 
HOBT Hydroxybenzotriazole 
HRMS High resolution mass spectrometry 
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Hz Hertz 
iPr Iso-propyl 
IPA Iso-propanol 
IR Infrared 
J Coupling constant 
LCMS Liquid chromatography-mass spectrometry 
Leu Leucine 
m Multiplet 
M.p. Melting point 
Me Methyl  
mg Milligram 
mins Minutes  
mL Millilitre 
mM Millimolar  
mmol Millimole 
mol Mole 
MS Molecular sieves 
m/z Mass spectrum 
NBE Norbornene 
NMO N-methylmorpholine 
NMP N-Methyl-2-pyrrolidone 
NMR Nuclear magnetic resonance 
nOe Nuclear overhauser effect 
PA Picolinamide 
Ph Phenyl 
Phe Phenylalanine 
Phth Phthalic 
PIDA Phenyl iodo(III)diacetate 
PIFA Phenyl iodo(III)bis(trifluoroacetate) 
PMP p-Methoxyphenyl 
Pin Pinacol 
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Ppy 2-Phenylpyridine 
Py Pyridine 
rac Racemic 
rt Room temperature 
s Singlet 
SM Starting material 
SNAr Nucleophilic aromatic substitution 
t Triplet 
TBS Tert-butyl silyl 
t-amyl Tert-amyl 
t-Bu Tert-butyl 
t-Leu Tert-leucine 
Tf Trifluoromethanesulfonyl 
TFEol 2,2,2-Trifluoroethanol 
TFA Trifluoroacetic acid or Trifluoroacetate 
THF Tetrahydrofuran 
TIPS Tri-isopropylsilyl 
TMS Trimethylsilyl 
TMP 2,2,6,6-Tetramethylpiperidine 
TPAP Tetrapropylammonium perruthenate 
TLC Thin layer chromatography 
Ts p-Toluenesulfonyl 
Tyr Tyrosine 
Val Valine 
δ Chemical shifts 
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1 Introduction  
 
1.1 Introduction to C–H bond functionalisation 
 
The realisation of transition-metal-catalysed functionalisation reactions has transformed organic 
synthesis.  In particular, palladium-catalysed cross-coupling reactions are now essential tools for 
the construction of complex molecules.  The impact of this methodology was widely recognised 
with the 2010 Nobel Prize being awarded to Ei-ichi Negishi,1–3 Richard F.Heck4,5 and Akira 
Suzuki6–8 for “palladium-catalysed cross couplings in organic synthesis”.  Whilst this approach 
remains the benchmark for building complexity into molecules, a conceptual advance would be 
to exploit the ubiquitous nature of C–H bonds in organic molecules for direct C–H bond 
functionalisation.  This advance would provide a complementary method for C–C and C–
X(heteroatom) bond formation, with the potential to streamline existing syntheses of complex 
molecules and change the way chemists think about reactivity and plan syntheses. 
  
Whilst the area of direct functionalisation of arenes and heteroaromatic C–H bonds have been 
well established, direct functionalisation of aliphatic C–H bonds remains a formidable challenge 
in synthetic organic chemistry.9,10  In general, sp3 C–H bonds are less susceptible to activation 
than sp2 C–H bonds.  The unreactive nature of aliphatic C–H bonds is attributed to (i) the low 
polarity of these substrates and the lack of π-orbitals that can interact with empty d-orbitals of the 
metal centre, (ii) the high homolytic strength of C–H bonds, with typical bond dissociation 
energies range from 95–105 kcal mol-1,11 and iii) pKa values are greater than 40, thereby 
rendering heterolytic cleavage by a strong base unviable.11,12  The ubiquitous nature of C–H 
bonds also poses selectivity issues, as they are often in similar electronic and spatial 
environments and so selective activation/functionalisation of a single C–H bond presents a 
significant challenge. 
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1.2  Transition metal-catalysed C–H functionalisation  
 
Over the past 50 years, transition metals have become widely used to convert inert C–H bonds to 
more reactive carbon-metal (C–[M]) bonds (known as C–H activation) that can subsequently be 
functionalised to afford the desired product (Scheme 1). The success of this approach is in part 
attributed to the ease in which transition metals cycle between their available oxidations states.   
 
Scheme 1:  Concept of transition metal-catalysed C–H functionalisation 
 
The studies into reactions of unactivated C–H bonds with transition metals have led to the 
identification of four main mechanistic pathways for the transformation of C–H bonds into C–
[M] bonds (Scheme 2): a) oxidative addition, b) -bond metathesis, c) electrophilic substitution, 
and d) concerted metallation-deprotonation (CMD).13–16  
 
Scheme 2:  Overview of the four main modes of C–H activation: a) oxidative addition, b) -bond 
metathesis, c) electrophilic substitution, d) concerted metallation-deprotonation. 
 
Oxidative addition is a mechanism where an electron rich metal reacts with a C–H bond to form a 
C[M] and [M]–H bond via a three-membered transition state (Scheme 2a).  Studies showed that 
the formation of reactive 16 electron complexes prior to C–H activation was a common feature of 
this reaction.17–19  This mechanism is common for low valent transition metals such as Ru(0), 
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Ir(I) and Rh(I).  -bond metathesis is a one-step reaction by which two -bonds are broken and 
two new -bonds are formed in a concerted manner without change of the metal oxidation state 
(Scheme 2b).  This process is known for early d0 transition metal complexes such as Zr(II) where 
a change in oxidation state is not possible.16  The electrophilic substitution mechanism effects 
metallation by having an electron rich π-system attacking an electropositive metal centre, 
followed by loss of protons to restore the π-system (Scheme 2c).  This mechanism is common for 
late transition metals such as Pd(II) and Ni(II).  A number of palladium-catalysed sp2 C–H 
functionalisation reactions were shown to follow this mechanism.14,20,21   
 
With the concerted metallation-deprotonation mechanism, a term coined by Fagnou and 
Echavarren, C–H bond cleavage has been proposed to occur by a simultaneous metallation and 
intramolecular deprotonation by an anionic ligand, typically a carboxylate ion (Scheme 2d).22–24  
For example, the pivalate ligand has been demonstrated to facilitate the arylation of benzene 
(Scheme 3).25  In this example, experimental and computational evidence indicated that the 
pivalate anion lowered the energy required for C−H bond cleavage and acted as a catalytic proton 
shuttle from benzene to the stoichiometric carbonate base. 
 
 
Scheme 3:  Fagnou's arylation of benzene via concerted metallation-deprotonation25 
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1.3 Cyclometallation as a strategy for selective C–H functionalisation 
 
In order to achieve selective functionalisation of a single C–H bond within a complex molecule, 
the most common and successful strategy involves the use of substrates that contain coordinating 
ligands (also known as directing groups – DG).  These directing groups bind to the metal catalyst 
and selectively deliver the catalyst to a proximal C–H bond, facilitating a directed C–H activation 
event (also known as cyclometallation) (Scheme 4).  The resulting metallacycle can react with an 
external agent, which leads to an overall C–H functionalisation of a specific C–H bond.  The use 
of directing groups to assist cyclometallation is assumed to lower both the enthalpic and entropic 
costs of the C–H activation event, and accounts for why kinetically favoured five-membered-ring 
metallacycles are preferred over metallacycles of other ring sizes. 
 
Scheme 4:  Directing group-assisted C–H bond cyclometallation strategy 
 
Although many different transition metals including ruthenium, rhodium and platinum have been 
demonstrated to undergo cyclometallation, palladium has undoubtedly been the most studied 
transition metal for this process and so this chapter will focus primarily on the use of palladium 
in cyclometallation and the subsequent functionalisations.26–31 
 
Early studies of cyclometallation with palladium (known as cyclopalladation) focused on 
nitrogen-based directing groups.  Pioneering work by Cope and Siekman in 1965 showed that 
azobenzene 1 could be cyclopalladated selectively at the ortho-position in high yield using 
palladium(II) chloride (Scheme 5).26  A subsequent report by Cope and Friedrich has shown that 
N,N-dimethylbenzylamine could also be cyclopalladated at the ortho-position.32 
 
Scheme 5:  Cope and Siekman's ortho-palladation of azobenzene26 
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Following on from these initial reports, the first example of catalytic C–H activation came in 
1970 when Fahey reported the palladium(II)-catalysed ortho-chlorination of azobenzene.33  One 
plausible mechanistic pathway for this reaction involves the oxidation of palladacycle 4 to a 
palladium(IV) species 5, followed by reductive elimination of the carbon-chlorine bond to 
generate the ortho-chlorinated product 6 and releases the palladium(II) complex back into the 
catalytic cycle (Scheme 6). 
 
Scheme 6:  Proposed palladium(II)/(IV) pathway for ortho-chlorination of azobenzene by Fahey33 
 
Another early example of palladium-catalysed C–H functionalisation was the ortho-methylation 
of acetanilide 7 reported by Tremont and Rahman (Scheme 7).34  This represented the first 
catalytic process leading to carbon–carbon bond formation.  A palladium(II)/(IV) cycle was 
proposed, in which the ortho-palladated acetanilide 8 reacted with methyl iodide to form 
palladium(IV) species 9, followed by reductive elimination to form the ortho-methylated product 
10.  Silver acetate was thought to regenerate the catalytically active palladium(II) acetate via 
ligand exchange.  
 
Scheme 7:  Tremont and Rahman’s palladium(II)-catalysed ortho-methylation of acetanilide34 
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Further work by Canty and co-workers provided evidence for the proposed oxidative addition of 
methyl iodide to palladium(II) metallacycles.  Canty reported that dimethyl(2,2’-
bipyridyl)palladium(II) complex 11 could undergo oxidation addition with excess methyl iodide 
to generate the trimethylpalladium(IV) complex 12, which was isolated and characterised by X-
ray crystallography.  Furthermore, it was observed that reductive amination of ethane to provide 
palladium(II) complex 13 took place upon standing at ambient temperature (Scheme 8).35  Later 
studies by Canty have greatly enhanced our understanding of oxidative addition and reductive 
elimination surrounding palladium(IV) species, with a number of organo-palladium(IV) 
complexes isolated and characterised.36 
 
Scheme 8:  Mechanistic studies of oxidative addition of methyl iodide to a palladium(II) complex by 
Canty and co-workers35 
 
Despite these pioneering reports, progress in palladium-catalysed C–H transformations has been 
slow, possibly owing to the lack of detailed mechanistic understanding on the reactivity of 
palladium towards C–H bonds.  It wasn’t until 1985 when the first in-depth kinetic and 
mechanistic studies were reported by Ryabov and co-workers on the ortho-palladation of N,N-
dimethylbenzylamine 14.37  NMR and kinetic measurements obtained from the reaction 
intermediates enabled Ryabov and co-workers to propose a likely reaction pathway (Scheme 9).  
Treatment of amine 14 with the palladium(II) salt generates initially the stable trans-bis-amine 
complex 15.  Subsequent dissociation of an amine allows the acetate group to migrate via a κ2 
binding mode 16, and generates a vacant coordination site cis- to the amine in mono-amine 
complex 17.  Kinetic isotope effect and entropy of activation calculations for mono-amine 
complex 17 suggested a highly ordered, compact transition state 18 whereby the leaving H atom 
is intramolecularly abstracted by an acetate ligand (concerted metallation-deprotonation), 
forming palladacycle 19. 
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Scheme 9:  Proposed reaction pathway for the stoichiometric ortho-palladation of N,N-
dimethylbenzylamines by Ryabov and co-workers37 
 
The postulated reaction pathway has been supported by recent computational work undertaken by 
Davies and Macgregor (Scheme 10).38  They suggested that an additional agostic interaction 
between the sp2 C–H bond and palladium (in 20) polarised the bond and formed a six-membered 
transition state.  This rendered the C–H bond more acidic and facilitated deprotonation by the 
acetate base, with almost no activation barrier. 
 
Scheme 10:  Favourable C–H agostic interaction facilitates deprotonation by an acetate base38 
 
Whilst the directing group-assisted palladium-catalysed C–H functionalisations reported by 
Fahey and Tremont represent examples of catalytic processes which proceed via a 
palladium(II)/(IV) cycle after cyclopalladation, another common mechanistic pathway involves a 
palladium(II)/(0) catalytic cycle (Scheme 11).  In this process, palladacycle 21, formed after a 
directed C–H activation, undergoes a ligand exchange or transmetallation process to form 
palladium(II) species 22, which after reductive elimination, releases the product 23 and the 
reduced palladium(0).  An external oxidant is then required to oxidise palladium(0) back to 
palladium(II) to re-enter the catalytic cycle. 
Introduction 
17| 
 
Scheme 11:  Representative palladium(II)/(0) catalytic cycle for C–H functionalisation (L = directing 
group; FG = functional group) 
 
One such example of palladium-catalysed C–H functionalisation reactions which follows the 
palladium(II)/(0) pathway is the palladium(II)-catalysed sp3 C–H arylation of carboxylic acids 
with arylboronic esters reported by Yu and co-workers (Scheme 12).39  Silver carbonate provided 
the terminal oxidant required to regenerate the catalytically active palladium(II) species.  
Interestingly, it was reported that other silver oxidants such as silver(I) oxide or silver(I) acetate 
gave <5% of the desired product 26. 
 
Scheme 12:  Yu's palladium(II)-catalysed sp3 C–H arylation of carboxylic acids39 
 
Apart from carboxylic acids, a number of other directing groups such as, oxazolines,40–42 
amides,43–48 pyridines49,50 and oximes51,52 have been successfully employed in palladium-
catalysed sp2 and sp3 C–H functionalisation reactions (Scheme 13).  Compared to all the well-
established directing groups, use of amines as directing groups has been a relatively under-
researched area until recent times.  The use of unprotected amines or amine-derived auxiliaries as 
directing groups in palladium-catalysed C–H functionalisations will form the basis of discussion 
in the following section. 
 
Scheme 13:  Well-established directing groups in palladium-catalysed sp2 and sp3 C–H functionalisation 
reactions 
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1.4 Amines as directing groups in palladium-catalysed CH functionalisation 
1.4.1 Background 
 
Despite recent advances in the field of C–H activation, the range of functional groups capable of 
directing C–H functionalisation still remains limited.  The majority of directing groups used to 
facilitate C–H functionalisation processes are auxiliaries or protecting groups that need to be 
added and then removed from the substrate, thereby reducing the efficiency of the overall 
process.  In recent years, significant efforts and much research have been put into employing 
native functionalities, such as carboxylic acids,39,53–56 ketones57 and alcohols,58,59 to direct 
cyclometallation.  This approach allows C–H functionalisation where site-selectivity is directed 
by common functional groups contained in both the reactant and the desired product.  Such a 
process that utilises these simple moieties to direct C–H activation is desirable as it eliminates the 
requirement for any pre-functionalisation of starting materials, allowing for very simple, readily 
available material to be transformed into complex molecular architectures.  The use of native 
directing groups also allows further manipulations to be easily carried out on the compound after 
the C–H functionalisation event.  Considering the advantages of utilising the simple native 
functionalities found in common molecules as directing groups, there are clearly many benefits to 
be gained from developing transformations in this class. 
 
Aliphatic amines are a broad class of molecules which have relevance to pharmaceuticals, 
agrochemicals, surfactants and textiles, to name but a few.60  Despite their utility as synthetic 
intermediates and products, aliphatic amines have rarely been exploited in C–H functionalisation 
processes.  There are two main reasons for this (Scheme 14).  Firstly, aliphatic amines (especially 
primary and secondary amines) are excellent coordinating groups for palladium(II) centre and 
form coordinately saturated stable bis-amine complexes.  The thermodynamic stability of these 
complexes precludes C–H activation through the lack of a vacant site at the metal centre, thereby 
preventing cyclometallation from taking place.31,32,61  Secondly, aliphatic amines with -
hydrogen atoms readily undergo degradation by -hydride elimination to form the corresponding 
imines.62 
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Scheme 14:  Factors which disfavour the use of aliphatic amines as directing groups in C–H 
functionalisation 
 
Various strategies have been developed that relied on diminishing the basicity of the nitrogen 
atom by adding an electron-withdrawing auxiliary.  Addition of such an auxiliary also renders the 
N–H bond more acidic, hence allowing deprotonation to occur under mild conditions.   
 
1.4.2 Auxiliary-directed amine C–H functionalisation via palladium catalysis 
 
1.4.2.1  Picolinamides 
 
Seminal work into the development of amine-derived auxiliary was reported by Daugulis and co-
workers in 2005, where a picolinamide (PA) auxiliary was attached to primary aliphatic amines 
to enable sp2 and sp3 C–H arylation (Scheme 15).63 
 
Scheme 15:  Daugulis' picolinamide-directed sp2 and sp3 C–H arylation63 
 
The chelating pyridine-functionality is believed to facilitate both the C–H activation64 and the 
subsequent oxidative addition,65 based on the assumption that the reaction proceeded via a 
palladium(II)/(IV) pathway.  In this reaction, the picolinamide-protected amine 27 could be 
arylated selectively in the -position to give 28 in good yield.  Remarkably, the picolinamide 
group was also able to promote arylation of methylene sp3 C–H bonds, which are known to be 
harder to activate than the methyl counterparts.  Moreover, the ortho-arylation of picolinamide-
Introduction 
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protected benzylamines were achieved in good yields.  Speculative mechanistic discussion 
suggested that the reaction proceeded via an initial formation of 5,5-fused ring cyclopalladation 
complex 29.   
 
The reactivity of N-picolinoyl-protected benzylamines was further exploited by two different 
research groups.  For example, Liang and co-workers have shown that N-picolinoyl-protected 
benzylamine 30 could undergo ortho-acetoxylation using PhI(OAc)2 as oxidants.66  Chen and co-
workers have shown that benzylamide 32 could perform ortho-alkylation using simple alkyl 
halides to give mono-ortho-alkylated benzylamide 33 in excellent yields (Scheme 16).67  In the 
ortho-alkylation, potassium carbonate and sodium triflate were found to be important in 
suppressing the side reaction of the nucleophilic acetate ligands reacting with alkyl halide 
electrophiles, causing the premature termination of the catalytic C–H alkylation.  Further studies 
by Chen have shown that ortho-alkenylations and ortho-alkynylations are amenable to the N-
picolinoyl-protected benzylamines system.68  As an extension to the ortho-functionalisations, 
Chen has demonstrated that alkylation could also be performed on sp3 C–H of N-picolinoyl-
protected aliphatic amines.69 
 
Scheme 16:  Picolinamide-directed ortho-acetoxylation (Liang)66 and ortho-alkylation (Chen)67 
 
To further broaden the scope of sp3 C–H functionalisation using this auxiliary, Chen reported a 
practical synthetic strategy based on the palladium-catalysed arylation and alkenylation of the 
remote sp3 C–H bonds of a variety of N-picolinoyl-protected aliphatic amine substrates, using 
aryl and alkenyl halides under mild conditions.70  Though this presented a general strategy for 
remote methyl and methylene sp3 C–H functionalisation, the authors recognised that cleavage of 
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the picolinamide auxiliary was difficult and challenging.  To overcome this issue, a more readily 
cleavable version of the auxiliary was developed by the group (Scheme 17).  The new 
picolinamide auxiliary featured a methylene hydroxyl group at the ortho-position (in 34).  After 
undergoing site-selective sp3 C–H arylation to provide arylated amide 35, the deprotection of this 
new auxiliary was conducted under mild acidic conditions, driven by the formation of the five-
membered -lactone 37, affording the desired amine 36 in 70% yield. 
Scheme 17:  Chen's sp3 C–H arylation of a modified N-picolinoyl-protected amine70 
 
The utility of this auxiliary was further established by both Chen71 and Daugulis72 with the 
synthesis of nitrogen-containing heterocycles (such as azetidine 39 and pyrrolidine 42) via 
reductive elimination of the C–N bonds from the palladium(IV) species 40 and 43, respectively 
(Scheme 18).  Chen has subsequently reported an improved protocol for the intramolecular 
amination of -sp2-C–H bonds to form indolines, with a much lower loading of palladium(II) 
acetate required (0.5 mol%).73 
  
Scheme 18:  Intramolecular amination of sp2 and sp3 C–H Bonds at γ- and δ-positions of N-picolinoyl-
protected aliphatic amines (Chen and Daugulis)71,72 
 
Whilst investigating the C−H intramolecular amination reaction mentioned above, Chen made the 
intriguing observation of the acetoxylated product 46 (Scheme 19a).  Subsequent investigation 
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into the feasibility of a C–H alkoxylation reaction led to the discovery of a remote sp3 and sp2 C–
H alkoxylation of N-picolinoyl-protected aliphatic amines.74  After a brief optimisation, it was 
found that replacing acetic acid with alcohols/xylene (1:4) as solvents led to the formation of the 
corresponding alkoxylated products such as 47 in good yields (Scheme 19b). 
 
Scheme 19:  Picolinamide-directed sp3 and sp2 C–H alkoxylation of aliphatic amines. a) initial 
observations; b) optimised conditions for C–H alkoxylation74 
 
In 2014, Zhao and co-workers reported a picolinamide-directed remote sp3 C–H arylation of 
3-pinanamine 48 with aryl iodides (Scheme 20), where analogues of this amine motif had been 
shown to exhibit potent anti-influenza A activity.75  Notably, arylation took place exclusively at 
the more hindered -methylene sp3 C–H bonds, with no arylation observed at the adjacent -
methyl sp3 C–H bonds.  The authors proposed that the remarkable selectivity stemmed from the 
strain-induced proximity of the -methylene sp3 C−H bond to the picolinamide directing group, 
hence facilitating cyclopalladation.  For the same reason, stereoselective arylation at the 
methylene C–H bond pointing to the amino group was observed.  The reaction displayed a broad 
substrate scope with both electron-rich and electron-deficient aryl halides well tolerated in the 
reaction to generate a range of arylated products such as 50 in moderate to good yields.  
 
Scheme 20:  Zhao'spicolinamide-directed -methylene sp3 C–H arylation of 3-pinanamine75   
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1.4.2.2  Trifluoromethanesulfonamides 
 
An alternative strategy for functionalisation of aliphatic amines was reported by Yu and co-
workers in 2008.76  After a survey of different electron withdrawing protecting groups, it was 
found that trifluoromethanesulfonamide (triflamide, NHTf) derivative 51 was able to direct sp2 
C–H iodination.  The resulting iodoarene 52 could subsequently undergo an Ullmann-type 
coupling to give indoline 53 after an intramolecular C–N bond reductive amination (Scheme 21).  
It was proposed that the increased acidity of the N–H bond would maintain coordination between 
the amine and the palladium catalyst whilst sufficient electrophilicity of the palladium(II) centre 
is preserved (54).  Soon after this initial report, a ‘direct’ intramolecular amination procedure 
using single- or two-electrons oxidants was also reported.77 
 
Scheme 21:  Yu’s triflamide-directed tandem sp2 C–H iodination/intramolecular amination to give 
indolines76 
 
Yu was also able to combine the triflamide-directed C–H activation with Heck coupling to 
generate tetrahydroisoquinoline 56, after a tandem C–H alkenylation and aza-Michael addition 
process starting from N-triflyl-protected amino acid derivative 55 (Scheme 22).76  It should be 
noted that the reactive triflate group was well-tolerated in the reaction, allowing further 
functionalisation.  
 
Scheme 22:  Yu’s triflamide-directed tandem sp2 C–H alkenylation/aza-Michael addition to give 
tetrahydroisoquinolines76 
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The use of N-triflyl-protected amines as directing groups was further exploited in a range of C–H 
functionalisations, such as ortho-fluorination78 and enantioselective ortho-iodination79 of N-
triflyl-protected benzylamines (Scheme 23).  With the enantioselective ortho-iodination to 
synthesise chiral diarylmethylamines such as 60, chiral mono-N-benzoyl-protected amino acid 63 
was deployed as the ligand to impart enantioselectivity.  Furthermore, it had been shown 
previously within the group that this type of amino acid ligand had an accelerating effects on 
certain C–H functionalisations.80  Although the exact origin of the enantioselectivity was unclear, 
Yu hypothesised that the directing group coordinates with palladium(II) as a neutral -donor 
similar to pyridine, carbonyl and imidate, and subsequently proposed the structure of a possible 
intermediate 62.  This enantioselective C–H iodination has been successfully employed in kinetic 
resolution of chiral amines where one of the enantiomers of a racemic benzylic amine substrate 
undergoes faster aryl C–H activation than the other.81 
 
Scheme 23:  Yu’s triflamide-directed ortho-fluorination78 and enantioselective ortho-iodination79 
 
Recently, the utility of the triflamide directing group has been extended to sp3 C–H 
functionalisations.  First, in 2014, Yu reported a ligand-enabled C–H arylation via 
palladium(II)/(0) catalysis, using N-triflyl-protected amine 64 and a range of arylboronic esters, 
to deliver a range of arylated products such as 66 in good yields (Scheme 24).82  Both electron-
rich and electron-deficient arylboronic acids were well tolerated under the reactions conditions.  
Remarkably, no background reaction was observed in the absence of the mono-N-protected 
amino acid ligand 67, which implied that this type of ligand could be potentially used to impart 
enantioselectivity in the activation of sp3 C–H bonds.   
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Scheme 24:  Yu’s sp3 C-H arylation via palladium(II)/(0) catalysis82 
 
Encouraged by those findings, the first example of enantioselective C–H arylation via 
palladium(II)/(IV) catalysis was reported a year later.83 N-triflyl-protected cyclopropylmethyl- 
amine 68 could be arylated on the cyclopropyl methylene sp3 C–H to afford arylated sulfonamide 
70 in 81% yield and 99% ee (Scheme 25).   
 
Scheme 25:  Yu’s enantioselective sp3 C–H arylation via palladium(II)/(IV) catalysis 
 
With substrate already containing a stereogenic centre, it was found that the ligand could override 
the inherent diastereoselectivity imparted by the substrate (Scheme 26).  Treatment of 
cyclopropylmethyl sulfonamide 72 with either the L- or D-enantiomer of the ligand could yield 
the two different diastereoisomers (73a or 73b) with excellent diastereocontrol, albeit in lower 
yields (entries 1 and 2). 
 
Scheme 26:  Overriding the diastereoselectivity with the ligand 
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1.4.2.3  Miscellaneous auxiliaries  
 
A modification to Yu’s triflamide directing group was reported by Carretero and co-workers in 
2013.84  N-(2-pyridyl)sulfonyl were employed to direct -sp3-C–H arylation in - and -amino 
acid derivatives, thereby allowing expedient synthesis of non-natural amino acids.  Upon 
treatment of sulfonamides such 74 with an aryl iodide, the corresponding arylated product 75 was 
obtained in 75% yield (Scheme 27).  The auxiliary could subsequently be easily removed using 
zinc powder under mild conditions to reveal the desired primary amine, with no loss of 
stereochemical integrity.  Though the reaction was tolerant of electron-rich and electron-deficient 
aryl iodides, mixtures of mono- and di-arylated products were often obtained.  Mechanistic 
investigation undertaken by the group has revealed the formation of a bi-metallic five-membered 
ring cyclopalladation complex 76, as confirmed by X-ray crystallography, showing chelation to 
both the amine and the 2-pyridylsulfonyl auxiliary. 
 
Scheme 27:  Carretero’s N-(2-pyridyl)sulfonyl-directed sp3 C–H arylation of amino acid derivatives84 
 
Yu has subsequently shown that this auxiliary could direct C–H intramolecular amination 
reaction for the synthesis of indolines,85 and this approach was an improvement to his previous 
report of the same reaction using the N-triflyl directing group (Scheme 28)(section 1.4.2.2).77  
This reaction uses the readily available phenyl iodo(III)diacetate instead of the expensive 
electrophilic fluorinating reagent as an oxidant; the reactions typically reach completion within a 
shorter time period of 4 hours.   
 
Scheme 28:  Yu’s sp2 C–H intramolecular amination of N-(2-pyridyl)sulfonyl-protected 
phenylethylamines85 
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Recently, Zhao and co-workers reported a synthesis of pyrrolidinones via oxalyl amide-directed 
-sp3 C–H carbonylation of aliphatic amines such as 79 (Scheme 29).86  Both γ-methyl and 
cyclopropyl methylene C–H bonds were able to be activated to obtain the corresponding 
pyrrolidinones in moderate to excellent yields.  Aliphatic, allyl and benzyl amines bearing a 
range of functional groups such as esters, nitriles, protected alcohols could be tolerated under the 
reaction conditions. Although the exact role of 3-(trifluoromethyl)benzoic acid is unclear, the 
authors postulate that it aids stabilisation of the palladium intermediate formed during the 
catalytic cycle. 
 
Scheme 29:  Zhao’s sp3 C–H carbonylation of oxalyl amide-protected aliphatic amines86 
 
As mentioned previously, one of the main challenges in C–H activation is site selectivity, 
especially in remote positions relative to the functional groups.  To address this problem, Yu 
devised a strategy to achieve meta-selective sp2 C–H acetoxylation of benzylamine derivatives 
via the use of a conformationally-rigid nitrile-containing template (Scheme 30).87  Upon 
treatment of benzylamine derivative 81 with phenyl iodo(III)diacetate, the acetoxylated product 
82 was obtained in 58% yield with high level of meta selectivity (m:o >96:4).  The authors 
postulate that the high level of site selectivity is due to the use of the amino acid ligand 83, which 
amplifies the pre-existing conformational bias in the template towards C–H insertion in the meta 
position. 
 
Scheme 30:  Yu’s template-directed meta-selective sp2 C-H acetoxylation of benzylamines87 
 
Despite the advances made in the auxiliary-directed approach to C–H functionalisation of 
aliphatic amines, the additional synthetic steps and the often harsh conditions required for the 
installation and removal of the auxiliaries still render this approach impractical. Therefore, direct 
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C–H functionalisation of unprotected amines are highly desirable and this is an area of extensive 
research in recent years.  The following section documents the progress made in sp2 and sp3 C–H 
functionalisation of unprotected amines. 
 
1.4.3 Unprotected amine-directed C–H functionalisation via palladium catalysis 
 
1.4.3.1  sp2 C–H arylation of unprotected amines 
 
An early example of catalytic sp2 C–H activation was the direct ortho-arylation of benzylamines 
reported in 2006 by Daugulis and co-workers (Scheme 31).88  Primary and secondary 
benzylamines such as 84 could be arylated to afford di-arylated products such as 86 in moderate 
to good yields.  Di-arylation was observed in all cases except when meta-substituents were 
present, presumably owing to the steric effect.  Excess aryl iodides were added to ensure di-
arylation in cases where mono-arylation could not be achieved selectively.  The reaction 
displayed a broad functional group tolerance although the reaction proceeded faster with more 
electron-rich benzylamines.  Importantly, it was found that the amount of trifluoroacetic acid 
strongly influenced the results, with 5 equivalents of the acid gave the best reaction yields.   
 
Scheme 31:  Daugulis’ C–H ortho-arylation of benzylamines88 
 
In 2013, Zhang and co-workers reported a copper(II)-promoted palladium-catalysed C−H ortho-
arylation of N,N‑dimethylbenzylamines.  Upon treatment of amine substrate 14 with an aryl 
iodide, in the presence of the copper(II) additive, the corresponding di-arylated product 87 was 
obtained in 61% yield (Scheme 32).89  Similar to Daugulis’ reaction above, mono-arylation was 
only observed with meta-substituted benzylamines.  Although both electron-rich and electron-
deficient benzylamine and aryl iodide partners were tolerated, the main drawback of this reaction 
was the long reaction time required (60 hours).  Copper(II) acetate monohydrate was found to be 
an important additive to improve the yields in this transformation. Although the role of the 
copper salt is not entirely clear, the authors speculate that it is acting as a Lewis acid which may 
serve to liberate the palladium(II) species from the palladacycle complex. 
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Scheme 32:  Zhang's copper(II)-promoted palladium-catalysed C–H ortho-arylation of N,N-
dimethylbenzylamines89 
 
In 2015, Dixon and co-workers demonstrated that nitrogen-containing heterocycles such as 
piperidines were capable of directing C–H ortho-arylation of benzylamines, using arylboronic 
acid pinacol esters.90  Both para- and meta-arylboronic esters gave mono-arylation in good yields 
with piperidine substrate 88.  Ortho-arylboronic esters showed poor reactivity (<20% yields) 
except when the substituent was an ester group, which gave the desired arylated product 90 in 
78% yield (Scheme 33).  Heterocyclic boronic esters were found to be completely unreactive.  
The reaction was also compatible with other heterocycles such as pyrrolidine, morpholine and 
piperazine as native directing groups, but generally lower reactivity was observed. 
 
Scheme 33:  Dixon's N-heterocycle-directed C–H ortho-arylation of benzylamines90 
 
While ortho-selective arene functionalisation methods have been extensively developed, meta-
selective functionalisation of electronically unbiased arenes remains a difficult task.87,91  To 
address this problem, Dong and co-workers have recently reported a highly meta-selective amine-
directed arylation using norbornene as a transient mediator (Scheme 34).92  In this study, ortho-
substituted aryl iodides were employed as the coupling partner and a range of functionalities on 
the aryl iodides could be tolerated under the reaction conditions, yielding the desired meta-
arylated benzylamines such as 93 in good yields. 
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Scheme 34:  Dong's norbornene-mediated meta-arylation of N,N-dimethylbenzylamines92 
 
The reaction employs a palladium/norbornene catalyst system which contributes to the site 
selectivity of the reaction and is based on seminal works published by Catellani and latterly 
Lautens.93,94  The reaction was found to be promoted by triphenylarsenic together with an ‘acetate 
cocktail’, although their exact roles are not clear.  The proposed mechanism for this reaction is 
shown in Scheme 35.  Initial coordination of the palladium(II) salt with norbornene (NBE) 
followed by an electrophilic palladation gives the palladated species 94.  Carbopalladiation 
followed by cyclopalladation, in an analogous fashion to the Catellani reaction, affords the key 
NBE-bridged five-membered palladacycle 96.  This palladacycle is expected to react with an aryl 
iodide through either a palladium(IV) intermediate (oxidative addition followed by reductive 
elimination) or a transmetallation pathway, to generate a meta-arylated complex 97.  The 
resulting palladium(II) intermediate undergoes a -hydride elimination to give the arylated 
palladated species 98, which after proto-depalladation, furnishes the meta-arylated benzylamine 
93 and releases palladium(II) back into the catalytic cycle. 
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Scheme 35:  Proposed mechanism of norbornene-mediated meta-arylation of N,N-dimethylbenzylamines92 
 
1.4.3.2  sp2 C–H carbonylation of unprotected amines 
 
Early examples of palladium-catalysed amine-directed sp2 C–H carbonylation were published by 
Orito and co-workers.95,96  In 2004, they reported a C–H carbonylation procedure for the 
formation of 5- or 6-membered benzolactams such as 100 from N-alkyl-ω-arylalkylamines 
(Scheme 36).95  Though benzylamines with both electron-rich and electron-deficient substituents 
were tolerated in the reaction, the reactions often suffered from poor regioselectivity with 
substituted substrates.  It was observed that carbonylation of benzylamines to afford the 
corresponding five-membered benzolactams proceeded significantly faster than that of 
phenylethylamines to afford six-membered benzolactams. 
 
Scheme 36:  Orito's amine-directed sp2 C–H carbonylation to give benzolactams95 
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Orito later found that primary aliphatic amines were shown to undergo carbonylation to give 
symmetrical N,N’-disubstituted ureas such as 102 in good yields instead of formation of 
benzolactams (Scheme 37).96 
 
Scheme 37:  Orito's carbonylation of primary amines to give symmetrical N,N’-disubstituted ureas96 
 
In 2011, Gaunt and co-workers reported the palladium(II)-catalysed C–H carbonylation of β-
arylethylamines under ambient conditions (Scheme 38).97  Treatment of a range of β-
arylethylamines such as 103 under the optimised carbonylation conditions delivered synthetically 
versatile dihydro-2-quinolones 104 in good yields.  It was proposed that the p-methoxyphenyl 
(PMP) group would diminish the nucleophilicity of the nitrogen atom such that it would 
disfavour the formation of bis-amino-palladium(II) complex that would have prevented 
cyclopalladation.  Moreover, the increased acidity of the aryl N–H bond in the cyclopalladation 
complex may assist the deprotonation step that must accompany the C–H bond functionalisation.  
The β-arylethylamine scaffold could also undergo C–H arylation and amination processes, 
generating products such as 105 and 106 with diverse structures. 
 
Scheme 38:  Gaunt's C–H functionalisation of β-arylethylamines under ambient conditions97 
 
A recent report by Rodriguez and co-workers has shown that phenethylamines bearing ,-
disubstituted centres such as 107 could be carbonylated to the corresponding benzolactams 108 in 
excellent yields (Scheme 39).98,99  The ,-disubstitution in 107 was found to be critical to the 
success of the reaction, either by sterically disfavouring the formation of the catalytically inactive 
bis-amine complex,100 or through the Thorpe-Ingold effect,10,101 which favours cyclisation by 
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lowering the entropic cost of the reaction.  The use of 1,4-benzoquinone as an oxidant proved 
important for the catalytic reaction, suppressing the formation of the N-acetylated amine 109.  
This reaction strongly favours the formation of six-membered benzolactams over five-membered 
benzolactams, which is the opposite to that observed by Orito.95 
 
Scheme 39:  Rodriguez's sp2 C–H carbonylation of ,-disubstituted phenethylamines98,99 
 
Amine-directed sp2 C–H carbonylation is not only restricted to benzolactam formation, Shi and 
co-workers have shown that benzoate esters could be formed by employing alcohols as external 
nucleophiles.102  Upon treatment of N,N-dimethylbenzylamines such as 110 with carbon 
monoxide and an alcohol nucleophile under palladium catalysis, the corresponding benzoic esters 
111 could be formed selectively at the ortho position in good yields (Scheme 40).  The reaction 
conditions were based on an earlier report of an sp2 C–H ortho-olefination of N,N-
dimethylbenzylamines (section 1.4.3.3).103  Both electron-rich and electron-deficient groups were 
tolerated under the reaction conditions though electron-rich substituents generally gave better 
yields, presumably due to the enhancement of electron density of the phenyl rings.  The authors 
proposed that lithium chloride acts as a ligand and facilitates migratory insertion of carbon 
monoxide into the palladium-carbon bond. 
 
Scheme 40:  Shi's sp2 C–H alkoxycarbonylation of N,N-dimethylbenzylamines102 
 
1.4.3.3  Other sp2 C–H functionalisation of unprotected amines 
 
In 2007, Shi reported the ortho-alkenylation of N,N-dimethylbenzylamines with a range of 
acrylates, acrylamides and substituted alkenes (Scheme 41).103  It is important to note that the aryl 
chloride moiety in 112 was well tolerated under the reaction conditions and the chloride could 
potentially be further functionalised by transition metal-catalysed cross coupling reactions.104  
The authors stated that the acidity of the reaction was important for ensuring good conversion to 
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the ortho-alkenylated products.  This is presumably due to the fine balance between binding too 
strongly which would result in the formation of the catalytically inactive bis-amine complex, or 
binding too weakly i.e. when protonated, and hence unable to direct C–H activation. 
 
Scheme 41:  Shi’s ortho-alkenylation of N,N-dimethylbenzylamines103 
 
Given the utility of trifluoromethyl groups in pharmaceuticals and biologically active 
molecules,105 there has been increasing interests in developing new methods for the installation of 
trifluoromethyl groups onto the aromatic scaffolds of these molecules.106–108  Specifically, 
unprotected amine-directed arene C–H trifluoromethylation would be particularly valuable given 
the amine functionalities could be derivatised after the reaction and thus introducing further 
complexity to the molecules.  To address this need in medicinal chemistry, Yu and co-workers 
have reported a method for ortho-C–H trifluoromethylation of benzylamines utilising an 
electrophilic CF3 reagent (Scheme 42).109  In this reaction, primary and secondary benzylamines 
such as 115 could undergo ortho-C–H trifluoromethylation to generate ortho-trifluoromethyl 
benzylamines such as 117, which are prevalent in medicinal compounds.110,111  The free primary 
amine was protected with a Boc group at the end of the reaction for ease of isolation.  Although 
the reaction was high yielding for simple aryl and alkyl substituted benzylamines, both electron-
rich and electron-deficient groups were poorly tolerated, as was substitution in the -position of 
the amines. 
 
Scheme 42:  Yu's ortho-C–H trifluoromethylation of benzylamines109 
 
Recently, Rodriguez and co-workers reported a synthesis of tetrahydro-3-benzazepines and 
tetrahydroisoquinolines by annulation of phenylethylamines and benzylamines respectively with 
terminal allenes (Scheme 43).112  Similar to their earlier reports on sp2 C–H carbonylation on the 
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same amine system,98,99 the quaternary centre adjacent to the primary amine is crucial for 
reactivity, with the best yields obtained when one of the groups is an ester group. This catalytic 
C–H activation/annulation strategy was proposed to proceed via ring cyclisation of the π-allyl 
intermediates such as 122, formed after the preceding carbopalladation step from the six-
membered palladacycle 121. 
 
Scheme 43:  Rodriguez's C–H annulation of phenylethylamines and benzylamines with allenes112 
 
1.4.3.4  sp3 C–H functionalisation of unprotected amines 
 
Compared to the research on sp2 C–H bond activation, examples of unprotected aliphatic amine-
directed sp3 C–H functionalisation have been extremely rare.  Seminal work by Gaunt and co-
workers in 2014 showed for the first time that unprotected aliphatic secondary amines could 
undergo sp3 C–H cyclopalladation to form novel four-membered-ring cyclopalladation 
complexes such as 126, which could then be functionalised to give strained nitrogen heterocycles 
(Scheme 44).113  It was hypothesised that the use of amines such as 2,2,6,6-tetramethylpiperidine 
(TMP) 123 would increase the steric bulk around the nitrogen atom and the increased steric 
demand would render the bis-amine complex thermodynamically unstable, promoting 
dissociation of one of the amine molecule to provide the vacant coordination site required for C–
H activation.  Moreover, the two quaternary centres adjacent to the nitrogen atom prevents -
hydride elimination from occurring.   
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Scheme 44:  Gaunt's strategy for the sp3 C–H activation of aliphatic amines to form novel four-membered 
palladacycles 
 
Treatment of palladacycle 126 with carbon monoxide furnished -lactam 127 through a 
palladium(II)/(0) pathway.  Subsequent development of catalytic conditions revealed that amine 
123 could undergo carbonylation with 10 mol% of palladium acetate, under an atmosphere of 
carbon monoxide/air and copper acetate as a co-oxidant, to afford -lactam 127 in an excellent 
87% yield (Scheme 45).  Commercial or readily available piperidine derivatives, as well as other 
heterocycles were also well tolerated under the reaction conditions to yield a variety of -lactams 
(128 to 131) in good yields. 
 
Scheme 45:  Gaunt's C–H carbonylation of hindered aliphatic amines113 
 
Replacing carbon monoxide with a mild oxidant, hypervalent iodine reagent PhI(OAc)2, resulted 
in an acetoxylation reaction to give acetoxylated amine 133, proceeding via the putative 
palladium(IV) intermediate 134 (Scheme 46a).  Interestingly, subjecting morpholinone derivative 
135 to the same reaction conditions resulted in an azidiridination reaction to give aziridine 136 
(Scheme 46b), suggesting that the carbonyl group might have played a subtle controlling role in 
this switch in reactivity.  Further computational studies within the group has shown that the 
reason for this switch in reactivity lies behind the difference in energy between the C–O and C–N 
bond reductive elimination pathways.114   
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Scheme 46:  C–H acetoxylation (a) and aziridination (b) of hindered aliphatic amines113 
 
The aziridination reaction was found to be general with a broad range of substituted 
morpholinones, giving the desired aziridines in good to excellent yields.  Aziridine 137 could be 
opened with nucleophiles such as pyrazole to give highly functionalised quaternary -amino 
acids such as 139, after oxidative cleavage of the cyclic framework (Scheme 47). 
 
Scheme 47:  Access to highly functionalised -amino acids 
 
Recently, the Gaunt group has demonstrated that this methodology could be applied to C–H 
arylation using the same four-membered-ring cyclopalladation pathway aforementioned (Scheme 
48).115  Crucial to the success of this reaction is the employment of mono-protected amino acids 
as ligands for the palladium catalyst.  The use of these amino acids as enabling ligands in 
palladium-catalysed C–H functionalisation has recently been introduced by Yu and co-
workers.82,116,117  A range of hindered secondary amines and arylboronic esters were compatible 
with this process. 
 
Scheme 48:  C–H arylation of hindered aliphatic amines115 
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Inspired by these initial reports, the group has recently devised a new strategy for the 
functionalisation of simple primary amino alcohols by transiently converting these substrates into 
bulky secondary amines to facilitate C–H activation.118  A simple ketone acts as a tether to bridge 
the nitrogen and oxygen atoms of the amino alcohols, generating a hindered N,O-ketal which 
facilitates C–H activation.  After the functionalisation event, the removal of the tether group 
reveals the structurally complex amino alcohols, which have broad synthetic applications as well 
as being prevalent in pharmaceuticals (Scheme 49). 
 
Scheme 49:  Aliphatic C–H functionalisation of amino alcohols via a sterically promoted approach118 
 
The hindered N,O-ketal 142 was found to undergo a facile C–H activation to form five-
membered-ring cyclopalladation complex 143, where a broad range of C–H transformations have 
shown to be amenable to this C–H activation strategy (Scheme 50).  
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Scheme 50:  Summary of C–H functionalisations of amino alcohol derivatives118 
 
C–H acetoxylation and arylation are believed to proceed via a palladium(II)/(IV) pathway whilst 
the palladium(II)/(0) pathway is likely for C–H carbonylation and alkenylation, demonstrating 
the flexibility of the palladacycle intermediate 143. 
 
Mechanistically, it was predicted that the secondary amine 149 would bind to the palladium 
catalyst in such a way that the complexation would be accompanied by the formation of a 
hydrogen bond between the acetate ligand on the palladium and the free N–H of the amine in 150 
(Scheme 51).  This hydrogen bonding interaction is believed to play two important roles in the 
reaction: 1) to orientate the amine substituents in the bis-amine palladium(II) complex 151 in 
such a way that interactions between the aliphatic groups would be intensified, enabling the 
equilibrium to shift towards the mono-amine complex 150; 2) to lock the conformation of the 
amine with respect to the palladium centre (in 150), thereby projecting the targeted C–H bond 
into an optimal trajectory for activation, forming a kinetically favoured five-membered 
cyclopalladation complex 152.  Functionalisation of the palladium-carbon bonds in 152 with 
external agents would furnish functionalised products 153. 
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Scheme 51: Hypothesis for C–H activation strategy for the functionalisation of amino alcohols 
 
The hypothesis for the C–H activation event is supported by computational studies conducted 
within the group.  Calculations performed on the basis of the proposed pathway supported the 
presence of the hydrogen bond between the palladium-bound amine N–H and acetate ligands, but 
also identified that the putative mono-amine palladium(II) complex 154 was 1.2 kcal mol-1 
(G298) lower in energy than the corresponding bis-amine palladium(II)-complex 155 (Scheme 
52).  This is in agreement with our hypothesis that the hindered nature of the amine means that 
154 is thermodynamically and kinetically favoured over 155 and therefore leads to facile C–H 
activation.  
 
Scheme 52:  Molecular calculations of the mono- and bis-amine palladium(II) complexes, 154 and 155118 
 
The nature of the tethering ketone was also chosen carefully.  First, we reasoned that the 
cyclohexyl group should provide the requisite bulk to facilitate the amine dissociation step when 
bound to the palladium centre.  Second, the methylene C–H bonds in the cyclohexyl motif are 
less likely to undergo C–H activation than groups with terminal C–H bonds. 
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2 Palladium(II)-Catalysed sp3 C–H Carbonylation of Hindered 
Amines 
 
2.1 Background 
 
As mentioned in the previous section, recent research within our group has focused on C–H 
functionalisation of hindered secondary aliphatic amines, via both the four-membered- and five-
membered- ring cyclopalladation pathways (Scheme 53).113,115,118   
 
Scheme 53:  Palladium(II)-catalysed C–H functionalisation of secondary aliphatic amines developed 
within in our group113,115,118 
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Key to the success of this C–H activation strategy is the steric hindrance around the secondary 
amine motif.  We believe these interactions promote the formation of the putative mono-amine 
palladium(II) complex as a result of destabilising the traditionally more favourable bis-amine 
palladium(II) complex (Scheme 54).  
 
Scheme 54:  Mono-amine palladium(II) complex favoured by sterically hindered amines 
 
Given the success of our sterically promoted C–H activation approach to functionalise 
unprotected amines, we wondered if aliphatic C–H bonds of other useful classes of molecules 
could be functionalised in a similar fashion. 
 
2.2 Project aims 
 
We envisaged that the sterically promoted C–H activation approach could be utilised to 
functionalise the -position of ketones, which are important functional motifs in organic 
chemistry.  We proposed that ketones could be temporarily masked as hindered secondary amines 
capable of undergoing sterically promoted palladium-catalysed C–H functionalisation (Scheme 
55).  Subsequent removal of the tether group would reveal the -functionalised ketones.  
 
Scheme 55:  Proposed aliphatic C–H functionalisation of ketones via a sterically promoted approach 
 
This approach offers an attractive alternative to the traditional conjugate addition of soft 
nucleophiles into α,β-unsaturated ketones in synthesising -functionalised ketones, given the 
wide commercial availability of ketones compared to enones (Scheme 56).  
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Scheme 56:  Traditional conjugate addition approach to -functionalised ketones 
 
In 2013, Macmillan and co-workers reported a general catalytic platform for direct -
functionalisation of ketones and aldehydes, via merger of photocatalysis and organocatalysis 
(Scheme 57).119,120  Central to the success of this approach was the transient generation of 5-
electron -enaminyl radicals such as 168 from ketones and aldehydes that rapidly coupled with 
cyano-substituted aryl rings119 or aryl ketones120 at the carbonyl -position.  However, this 
catalytic reaction was only applicable to cyclic ketones and not acyclic ketones. 
 
Scheme 57:  Direct -functionalisation of ketones via merger of photocatalysis and organocatalysis119,120 
 
Very recently, Dong and co-workers reported a palladium(II)-catalysed direct -arylation of 
ketones with diaryliodonium salts.121  Cyclic ketones with different ring-sizes were arylated in 
good yields.  Moreover, the arylation reactions were shown to be amenable to acyclic ketones, 
albeit lower yields of arylated products were obtained (Scheme 58).   
 
Scheme 58:  Dong’s palladium(II)-catalysed direct -arylation of ketones with diaryliodonium salts121 
 
Up until the recent report by Dong, ketones were known to be ineffective directing groups in 
palladium-catalysed reactions because of their poor coordinating ability to palladium.122,123 To 
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overcome this challenge, Sanford and co-workers developed a palladium(II)-catalysed -
acetoxylation of O-acetyloximes, which masked the ketones as more coordinating oxime 
derivatives during C–H functionalisation before removing it to reveal the ketone functionality 
(Scheme 59).124  This transformation enabled -hydroxylation of ketones and this strategy has 
been successful in constructing the C–O linkage but hasn’t yet been reported for C–C linkage. 
 
Scheme 59:  Sanford's palladium(II)-catalysed -acetoxylation of O-acetyloximes124 
 
In this investigation, we aimed to broaden the scope of aliphatic -C–H functionalisation of 
ketones, through the use of our steric tethering strategy.  In order for our tethering approach to 
become a general protocol for -functionalisation of aliphatic ketones, two key criteria have to be 
met: 1) the tethering group must be easily installed and removed; 2) the tethering group must be 
sufficiently robust to tolerate the catalytic reaction conditions.  Our previous work has shown that 
N,O-ketals can be easily hydrolysed under acidic conditions, for example, in the last step of the 
synthesis of a pharmaceutical agent, GilenyaTM (fingolimod) 176 (Scheme 60).118 
 
Scheme 60:  Hydrolysis of N,O-ketal 175 in the synthesis of GilenyaTM 
 
We chose to begin this investigation with a C–H carbonylation process.  We anticipated that, 
upon treatment of a hindered N,O-ketal 177 with a palladium(II) source, the reaction would 
proceed through the formation of kinetically favourable five-membered ring palladacycle 
complex 178 (Scheme 61).  Insertion of carbon monoxide followed by reductive amination would 
yield -lactam 179.  Subsequent hydrolysis of the N,O-ketal moiety would reveal -keto 
carboxylic acid 180.  These 1,4-dicarbonyls are useful synthetic building blocks in heterocycle 
syntheses as well as being widespread in biologically important natural products.125,126  This C–H 
carbonylation strategy represents an overall -carboxylation of ketones. 
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Scheme 61:  Overall -carboxylation of ketones via a steric-tethering strategy 
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2.3 Results and discussion 
 
2.3.1 Preliminary stoichiometric studies 
 
To test our hypothesis, N,O-ketal 183, prepared from commercially available amino acid 181 in 
two synthetic steps, was chosen as the representative substrate for the preliminary stoichiometric 
studies (Scheme 62).  The cyclohexyl group should provide the steric bulk to favour the 
formation of the mono-amine complex, facilitating C–H activation.  Furthermore, the methylene 
C–H bonds in the cyclohexyl motif should be less likely to undergo to C–H activation than 
terminal C–H bonds. 
 
Scheme 62:  Preparation of N,O-ketal 183 
 
Our initial studies focused on the formation of palladacycle with N,O-ketal 183.  Upon treatment 
with 1.5 equivalents of palladium(II) acetate at room temperature in chloroform, a 
cyclopalladated complex was formed and subsequently identified as a trinuclear complex, whose 
structure was confirmed by X-ray crystallography following recrystallisation.  Exposing the 
palladacycle complex 184 to an atmosphere of carbon monoxide in toluene at 50 ºC furnished the 
desired -lactam 185 in 57% yield (Scheme 63). 
 
Scheme 63:  Cyclopalladation and carbonylation of 183 
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This promising result gave us the proof of concept and we set about investigating the 
development of a catalytic procedure for the conversion of N,O-ketal 183 into -lactam 185. 
 
2.3.2 Optimisation studies for catalytic reaction conditions 
 
Our initial attempts at a catalytic process for N,O-ketal 183 were focused on the reaction 
conditions employed in carbonylation of the structurally similar N,O-ketal 142 (see Scheme 53) 
that was previously developed by Dr Daniel Pla, a former postdoctoral associate within the 
group.118  Under those reaction conditions, the desired -lactam 185 was obtained in 20% yield, 
as well as the unsaturated -lactam 186, which was isolated in 5% yield (Scheme 64).   
 
Scheme 64:  Carbonylation of N,O-ketal 183 using previously developed catalytic conditions by Dr Pla 
 
Our previous studies showed that unsaturated -lactam 189 was most likely originated from sp2 
C–H activation of an allylic amine derivative 188, formed from -hydride elimination of the 
cyclopalladation complex 187 (Scheme 65).118  The intermediacy of the allylic amine was 
confirmed by selective carbonylation of the sp2 C–H bond (in 188) to give the unsaturated -
lactam 189 in excellent yields.  We believe unsaturated -lactam 186 could be formed via a 
similar pathway. 
 
Scheme 65:  Proposed mechanism and experimental evidence for formation of unsaturated -lactam 189118 
Palladium(II)-Catalysed sp3 C–H Carbonylation of Hindered Amines 
48| 
Encouraged by these initial findings, an extensive investigation was carried out into a range of 
reaction parameters including CO source, nature and loadings of oxidants, additives, reaction 
times, concentration and solvents.  As a starting point, an alternative CO source was sought given 
specialist equipment was required in achieving the 2 bar pressure of 6.25% of CO/air mixture.  
To our delight, switching the CO source to a balloon of 100% CO at approximately 1 bar i.e. 
atmospheric pressure gave a sharp increase in the yield of -lactam 185 to 56%, with 5% of the 
oxidized -lactam also obtained (Scheme 66).  Use of Mo(CO)6 as a source of carbon monoxide 
was also explored but gave a number of unidentifiable products. 
 
Scheme 66:  Replacement of 6.25% CO (2 bar) with 100% CO (~1 bar) in the catalytic carbonylation of 
N,O-ketal 183 
 
Reaction times and temperature were next investigated, with the findings summarised in Table 1.  
Increasing the temperature to 120 ºC improved the conversion of starting material to the desired 
product, with the highest yield obtained after heating for 16 hours (84%, entry 5), as determined 
by 1H NMR analysis using 1,1,2,2-tetrachloroethane as an internal standard.  Prolonged stirring 
at 120 oC did not lead to an improvement in yield (entry 6). There was a significant drop off in 
yield if the temperature was increased to 140 ºC (entries 7 and 8), with no starting material 
observed at the end of the reactions. 
 
Table 1:  Optimisation studies on the carbonylation of N,O-ketal 183 - effect of 
reaction temperature and time 
 
Entry Temperature Reaction time Yield 185 [%]a,b 
1 100 8 35 
2 100 16 62 
3 120 4 40 
4 120 8 73 
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5 120 16 84 
6 120 20 84 
7 140 4 25 
8 140 8 0 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard; 
reactions performed on a 0.1 mmol scale in a sealed microwave vial attached with a balloon of 
carbon monoxide. bTraces of unsaturated -lactam 186 were observed in reactions where yields of -
lactam 185 were above 40%. 
 
The effect of terminal oxidant and additives on the carbonylation reaction was assessed and the 
findings from the optimisation screen are summarised in Table 2.  Copper(II) acetate showed 
moderate reactivity, whilst 1,4-benzoquinone and oxygen showed poor reactivity, with the 
remaining mass balance being starting material (entries 1 to 3).  Potassium persulfate yielded no 
product nor starting material, suggesting decomposition of the starting material and/or product 
(entry 4).  Apart from silver(I) acetate, other silver salts such as silver(I) oxide and silver(I) 
carbonate showed much poorer reactivity (entries 5 and 6).  This may highlight a very important 
role of silver(I) acetate in the catalytic cycle, beyond just being a terminal oxidant.  Addition of 
basic additives was detrimental to the yields of the reaction (entries 8 to 10).  Whilst silver(I) 
acetate has shown to be an effective terminal oxidant, we speculated whether addition of a second 
oxidant would further improve the yield of the reaction.  The use of ‘mixed oxidant’ system has 
shown to be more effective than ‘mono oxidant’ system in various palladium(II)-catalysed 
transformations which utilise the palladium(II)/(0) catalytic cycle.48 Unfortunately, lower yields 
were observed when 1,4-benzoquinone or TEMPO or Cu(OAc)2 were added as a second oxidant 
(entries 11 to 13).  Finally, increasing the loading of silver(I) acetate gave poorer yields (entries 
14 and 15), though the reason for that is unclear. 
 
Table 2:  Optimisation studies on the carbonylation of N,O-ketal 183 - effect of 
terminal oxidant and additives 
 
Entry Oxidant  Additive  Yield 185 [%]a,b 
1 Cu(OAc)2 (2.0 equiv) - 39 
2 BQ (2.0 equiv) - 13 
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3 O2c - 5 
4 K2S2O8 (2.0 equiv) - 0 
5 Ag2O (2.0 equiv) - 7 
6 Ag2CO3 (2.0 equiv) - 17 
7 AgOAc (2.0 equiv) - 84 
8 AgOAc (2.0 equiv) NaOAc (5.0 equiv) 63 
9 AgOAc (2.0 equiv) K2CO3 (5.0 equiv) 54 
10 AgOAc (2.0 equiv) K3PO4 (5.0 equiv) 32 
11 AgOAc (2.0 equiv) TEMPO (2.0 equiv) 60 
12 AgOAc (2.0 equiv) BQ (1.0 equiv) 40 
13 AgOAc (2.0 equiv) Cu(OAc)2 (1.0 equiv) 43 
14 AgOAc (2.5 equiv)  - 70 
15 AgOAc (3.5 equiv) - 68 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard; 
reactions performed on a 0.1 mmol scale in 5 mL vials sealed with a Teflon cap and attached with a 
balloon of carbon monoxide.  bTraces of unsaturated -lactam 186 were observed in reactions where 
yields of -lactam 185 were above 40%.  cA balloon of oxygen was attached. 
 
Variation of the reaction solvent had a pronounced effect on the reactivity (Table 3).  Toluene as 
solvent gave the best yield (84%, entry 1), whilst other non-polar or polar aprotic solvents gave 
only moderate yields (entries 2 to 6).  Polar protic solvent, such as n-propanol, showed no 
reactivity, with only decomposition observed (entry 7).  An increase in concentration led to a 
reduction in the yield of -lactam 185, while a lower concentration had little effect (entries 8 and 
9). 
 
Table 3:  Optimisation studies on the carbonylation of N,O-ketal 183 - effect of 
reaction solvent and concentration 
 
Entry Solvent Concentration Yield 185 [%]a,b 
1 PhMe 0.05 M 84 
2 Xylene 0.05 M 49 
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3 1,4-Dioxane 0.05 M 32 
4 PhCl 0.05 M 52 
5 PhCF3 0.05 M 50 
6 DMF 0.05 M 44 
7 n-PrOH 0.05 M 0 
8 PhMe 0.1 M 74 
9 PhMe 0.002 83 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard; 
reactions performed on a 0.1 mmol scale in a sealed microwave vial attached with a balloon of 
carbon monoxide. bTraces of unsaturated -lactam 186 were observed in reactions where yields of -
lactam 185 were above 40%. 
 
Gratifyingly, the optimised reaction conditions could be transferred from a sealed vial system to a 
round bottom flask – condenser set-up.  On 0.8 mmol scale, the reaction yielded -lactam 185 and 
the unsaturated -lactam 186 in 77% and 6%, respectively (Scheme 67). 
 
Scheme 67:  Carbonylation of N,O-ketal 183 with a round bottom flask – condenser set-up 
 
We were pleased to find that the carbonylation was tolerant to changes in the 4-position of the 
N,O-ketal.  Replacement of cyclohexyl with a gem-dimethyl group gave the desired 
carbonylation product 192 in 76% isolated yield on 0.5 mmol scale (Scheme 68).  This 
modification is attractive because gem-dimethyl amino alcohol 190 is readily available 
commercially. 
 
Scheme 68:  Carbonylation of gem-dimethyl N,O-ketal 191 
 
The carbonylation is likely to proceed via a palladium(II)/(0) catalytic cycle and a proposed 
mechanism for the palladium(II)-catalysed carbonylation is outlined in Scheme 69. 
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Scheme 69:  Proposed mechanism for the palladium(II)-catalysed carbonylation of hindered N,O-ketals 
 
The proposed catalytic cycle begins with the binding of the palladium(II) centre by the amine 
substrate to form the mono-amine palladium complex 193.  The empty coordination site allows 
sp3 C–H activation to occur to form the five-membered palladacycle 194.  Binding of a carbon 
monoxide ligand is likely to form monomeric palladacycle 195, which undergoes 1,1-migratory 
insertion to form a six-membered palladacycle 196.  Reductive elimination and deprotonation 
provide -lactam 197 and releases palladium(0) into the catalytic cycle; a terminal oxidant is then 
required to regenerate the catalytically active palladium(II) species. 
 
2.3.3 Substrate scope 
 
With the optimised set of reaction conditions in hand, the focus was switched to investigating the 
reaction scope with respect to functional groups and structural features at the 2-position of the 
N,O-ketal, for both the gem-dimethyl and the cyclohexyl analogues. 
 
 
 
Palladium(II)-Catalysed sp3 C–H Carbonylation of Hindered Amines 
53| 
2.3.3.1  Substrates with simple alkyl substituents 
 
The initial scope was focused on preparation of substrates with simple alkyl substituents.  They 
were prepared from condensation of commercially available ketones with 1,2-amino alcohols 182 
or 190 under Dean-Stark conditions (Scheme 70). 
 
Scheme 70:  Preparation of N,O-ketal substrates for carbonylation 
 
Unfortunately, N,O-ketal 201a and 201b could not be obtained under the standard Dean-Stark 
conditions.  After surveying a variety of reaction conditions, N,O-ketal 201a and 201b were 
synthesised, albeit still with very poor yields, when cyclohexylethyl ketone 203 was employed as 
a solvent as well as present in excess (Scheme 71). 
 
Scheme 71:  Preparation of N,O-ketal 201a and 201b using cyclohexylethyl ketone as solvent 
 
The substrates were then subjected to the optimised C–H carbonylation conditions and the results 
are summarised in Scheme 72.  This initial substrate scope revealed that simple alkyl groups are 
well tolerated, except in the case of 206b, where the yield was much lower than 206a, the 
cyclohexyl counterpart.  It is unclear why that is the case, although more side products were 
observed under the carbonylation conditions with substrate 200b.  With the isopropyl substituent 
where diastereoisomeric mixture could be formed, 205a and 205b were formed with moderate 
diastereoselectivity.  The reaction was incompatible with mono-substituted N,O-ketal in the 2-
position (208a).  In this case, we observed an absence of a proton signal in the region of  4–5 
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ppm where the hydrogen in the -position was expected, suggesting -hydride elimination of 
202a to give possibly oxazoline 202c (Scheme 73).  It should be noted that all substrates showed 
exclusive regioselectivity for the terminal position of the ethyl C–H. 
 
 
 
Scheme 72:  Initial substrate scope for the palladium(II)-catalysed sp3 C–H carbonylation 
 
 
Scheme 73:  Possible -hydride elimination pathway for 202a 
 
2.3.3.2  Substrates with various functional groups 
 
Substrates which bear various different functionalities were next assessed for their reactivity and 
tolerability.  With these substrates, the precursor ketones had to be prepared, most of which 
required multi-step syntheses.  The synthetic routes to these functionalised ketones are shown in 
Scheme 74. 
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Scheme 74:  Access to functionalised ketones  
 
The ketones were then subjected to the condensation conditions described earlier to yield the 
various functionalised N,O-ketals (Scheme 75). 
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Scheme 75:  Preparation of more functionalised N,O-ketal substrates for sp3 C–H carbonylation 
 
These N,O-ketals were then subjected to the optimised C–H carbonylation conditions and the 
results are summarised in Scheme 76.  
 
 
Scheme 76:  Extended substrate scope for the palladium(II)-catalysed sp3 C–H carbonylation 
 
Gratifyingly, a range of functional groups were well-tolerated under the carbonylation conditions 
(for both cyclohexyl and gem-dimethyl analogues), with two notable exceptions.  In the presence 
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of an unprotected alcohol, the desired carbonylation product was only obtained in 19% yield 
(242a), with the remaining mass balance being the starting material N,O-ketal 235a.  This is 
attributed to the coordination of the OH group to palladium(II) which might have partially 
poisoned the catalyst, reducing its catalytic efficiency.  Also, the steric impediment caused by the 
gem-dimethyl group might have reduced the likelihood of the initial coordination of the nitrogen 
to palladium(II). This steric hindrance also explains why no sign of carbonylation on the other 
terminal methyls was observed.  With substrate containing a terminal olefin, no desired product 
nor starting material were detected (0%, 244b).  The disappearance of the diagnostic terminal 
olefin 1H chemical shifts suggests possible coordination of the olefin to palladium(II) followed 
by possibly intramolecular nucleophilic attack by the amine nitrogen atom (5-exo-trig or 6-endo-
trig), leading to mixture of side products.   
 
Although the presence of ester functionality was well tolerated under the carbonylation reaction 
conditions, as exemplified by the formation of lactam 241a and 241b in 77% and 78% 
respectively, it was found that the reaction completely ceased if the ester group was closer to the 
N,O-ketal nitrogen atom.  N,O-ketals 246a and 246b, which were prepared by a double conjugate 
addition of alkyne 245 with the corresponding 1,2-amino alcohols, showed no reactivity under 
the carbonylation reaction conditions, even at elevated temperature with xylene as the solvent or 
with increased palladium catalyst loadings (Scheme 77).   
 
Scheme 77:  Synthesis and attempted sp3 C–H carbonylation of N,O-ketals 246a and 246b 
 
This was a rather surprising result given 246a/b is only one methylene unit less than 234a/b 
between the ester group and the N,O-ketal nitrogen atom.  One possible explanation for this could 
be the formation of a six-membered ring intramolecular hydrogen bonding network between the 
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N–H and the ester carbonyl group, and hence preventing the molecule from adopting the required 
conformation for C–H activation (Figure 1). 
 
Figure 1:  Possible intramolecular hydrogen bonding network in 246a and 246b 
 
In the presence of a trifluoromethyl group in close proximity to the N,O-ketal nitrogen atom, no 
carbonylation took place, with only starting material recovered (Scheme 78).  This is presumably 
as a result of reduced nucleophilicity of the amine caused by the electron-withdrawing effect of 
the trifluoromethyl group. 
 
Scheme 78:  Synthesis and attempted sp3 C–H carbonylation of N,O-ketal 248 
 
2.3.3.3  Substrates with potentially competing C–H activation pathway 
 
We next sought to explore substrates with possible sp2 and sp3 C–H activation pathways.  When 
the phenyl group is directly attached to the N,O-ketal (251), the inherently more facile sp2 C–H 
carbonylation became the predominant pathway under the carbonylation reaction conditions, 
generating -lactam 252 exclusively and in excellent yields (Scheme 79).  It should be noted that 
activation of the phenyl ortho sp2 C–H also proceeds through a kinetically favoured five-
membered cyclopalladated complex. 
 
Scheme 79:  Synthesis and sp2 C–H carbonylation of N,O-ketal 251 
 
We then investigated if the presence of electron withdrawing group on the phenyl ring would 
disfavor sp2 C–H activation by reducing the coordinating ability of the phenyl -system and 
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hence would ‘switch’ the reactivity back to the desired sp3 C–H activation.  To test this 
hypothesis, N,O-ketal 256, prepared in three synthetic steps from the commercially available acid 
chloride 253, was subjected to the carbonylation reaction conditions (Scheme 80).  Whilst the 
presence of the nitro group did prevent sp2 C–H carbonylation, it did not lead to the desired sp3 
C–H carbonylation, presumably due to the reduced nucleophilicity at the nitrogen atom, 
preventing the initial coordination of the amine to the palladium(II) centre. 
 
Scheme 80:  Synthesis and attempted C–H carbonylation of N,O-ketal 256 
 
Next, N,O-ketals 258a and 258b were prepared to investigate the selectivity between terminal 
ethyl and benzylic methylene sp3 C–Hs given the latter position is known to be highly activated 
for C–H insertion by palladium.127  In this case, exclusive selectivity for the terminal ethyl sp3 C–
H was observed, for both the cyclohexyl and gem-dimethyl analogues (Scheme 81). 
 
 
Scheme 81:  Selectivity between terminal ethyl and benzylic sp3 C–H in palladium(II)-catalysed 
carbonylation 
 
We were also interested to see if the cyclopropyl group could be activated in this system.  N,O-
ketal 263 was prepared via standard protocol and subjected to the carbonylation reaction 
conditions (Scheme 82).  Interestingly, this reaction yielded a mixture of two products: 
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spirocyclopropyl -lactam 265 (57% - major product), originating from activation of the methine 
C–H of the cyclopropyl unit, and the expected -lactam 264 (28% - minor product).  Although 
methine C–H functionalisation is known under palladium catalysis, it is still relatively rare 
compared to the methyl and methylene counterparts.128,129  This methodology represents a rare 
example of methine C–H being activated preferentially over methyl C–H. 
 
Scheme 82:  Preparation and carbonylation of cyclopropyl substrate 263 
 
Surprisingly, subjecting the corresponding gem-dimethyl analogue 267 to the optimised reaction 
conditions gave no signs of either 268 or 269, with no starting material remaining at the end of 
the reaction (Scheme 83). 
 
Scheme 83:  Failed carbonylation of cyclopropyl substrate 267 
 
2.3.4 Removal of steric tether: access to -keto carboxylic acids 
 
Having established a protocol for carbonylation which tolerates a wide range of functionalities, 
we next investigated the deprotection/hydrolysis step which would yield the corresponding -keto 
carboxylic acids (Scheme 84). 
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Scheme 84:  Hydrolysis of fused-N,O-ketal-lactam allows access to -keto carboxylic acid 
 
After a brief survey of hydrolysis conditions, it was found that on treatment of -lactam 185 with 
3 N HCl:THF (1:1) at reflux for 4 hours, the desired carboxylic acid 268 was obtained in 93% 
yield (Scheme 85). 
 
Scheme 85:  Hydrolysis of -lactam 185 to give carboxylic acid 268 
 
To demonstrate the practicality of this transformation as a route to access-keto carboxylic acids, 
a range of -lactams were subjected to the acidic ring-opening conditions to obtain the desired -
keto carboxylic acids in excellent yields, ranging from 89% to 92% (Scheme 86). 
 
 
Scheme 86:  Hydrolysis of -lactams 207a, 238b and 239b 
 
Considering the wide scope of substrates that are compatible with the C–H carbonylation 
reaction, coupled with the ease in which the 1,4-dicarbonyl functionality could be revealed, we 
believe this methodology offers a complimentary method to access these important classes of 
building blocks.  
 
2.3.5 Attempted derivitisation of the bicyclic lactam core 
 
In addition to performing deprotection of the bicyclic lactams to enable entry to -keto carboxylic 
acids, we also looked to explore the intrinsic functionality of these molecules to gain access to 
other structurally diverse amine products.  We were pleased to find that enolate methylation of 
185 at the α-position to the carbonyl proceeded smoothly to give 272 in good yield and 
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diastereoselectivity, with the structure of the major diastereoisomer confirmed by nOe analysis 
(Scheme 87). 
 
Scheme 87:  -Methylation of 185 
 
Meyers has shown that chiral bicyclic lactams such as 273 can undergo a Lewis acid-assisted 
cleavage of cyclic N,O-ketal, followed by trapping of the resulting N-acyliminium ion with allyl 
silane as an external nucleophile, yielding 2,2-disubstituted pyrrolidinone 274 (Scheme 88).130   
 
Scheme 88:  Meyers’ Lewis acid-assisted cyclic N,O-ketal ring opening of chiral bicyclic lactams130 
 
We envisaged that this process should be applicable to our lactam scaffold although it was 
anticipated that there would be additional steric hindrance in our system given the carbon atom in 
the -position to the nitrogen is disubstituted.  Subsequent cleavage of the C–N linkage would 
enable access to 2,2-disubstituted pyrrolidinones, or further reduced to 2,2,-disubstituted 
pyrrolidines (Scheme 89). 
 
Scheme 89:  Proposed Lewis acid-assisted ring opening of -lactams to 2,2-disubstituted pyrrolidinones 
and pyrrolidines 
 
We began our investigation using 185 and allyl silane (Scheme 90).  Disappointingly, employing 
the conditions reported by Meyers gave no reaction, with only starting material recovered.  
Replacement of dichloromethane with a higher boiling 1,2-dichloroethane and heating the 
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reaction mixture to 80 oC resulted in 54% of starting material being recovered, but encouragingly, 
amide 276 was also formed in 18% yield.  This product is presumed to be formed from 
nucleophilic attack of the desired transient N-acyliminium species by advantageous water.  
Although no desired product was observed, this finding at least showed that nucleophile attack is 
possible on the hindered electrophile.   
 
Scheme 90:  Attempted ring-opening of 185 with allyl silane 
 
We next attempted the same reaction using boron trifluoride etherate complex as the Lewis acid 
(Scheme 91).  Again, no reactivity was observed at room temperature.  However, when the 
reaction mixture was heated to 80 oC, ,-unsaturated lactam 277 was formed in 52% yield, 
along with 28% of starting material recovered.  This compound is likely to have been formed via 
tautomerisation of the transient N-acyliminium species. 
 
Scheme 91:  Attempted ring-opening of 185 using BF3 as Lewis acid and proposed mechanism for 
formation of 277 
 
With these encouraging findings thus far, we next screened a broad range of Lewis and protic 
acids for their reactivities and the results are summarised in Table 4.  Unfortunately, none of the 
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Lewis or protic acids had yielded any positive results, with only starting material recovered in 
majority of the cases (entries 1 to 6).  With zinc(II) triflate, 28% of 277 was also observed (entry 
3).  Use of triflic acid only resulted in a complex mixture which was difficult to analyse (entry 7).   
 
Table 4:  Screening of Lewis and protic acids for ring-opening of 185 
 
Entry Lewis acids Temperature Resulta 
1 TIPSOTf rt to 80 oC 95% SM 
2 AgTFA rt to 80 oC 92% SM 
3 Zn(OTf)2 rt to 80 oC 67% SM, 28% 277 
4 Sc(OTf)3 rt to 80 oC 92% SM 
5 AlCl3 rt to 80 oC 85% SM 
6 HCl (in dioxane) rt to 80 oC 96% SM 
7 TfOH 0 oC to RT Complex mixture 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an 
internal standard 
 
We next sought to explore different carbon nucleophiles (Table 5).  Silyl ketals such as 278 and 
279 were investigated but showed no desired reactivity under a number of Lewis and protic 
acidic conditions (entries 1 to 7).  Adding an additional activator to generate a more reactive 
enolate failed to improve the reaction (entries 6 and 7).  Diketone 280 also showed no reactivity. 
 
Table 5:  Screening of carbon nucleophiles and Lewis/protic acids for ring-
opening of 185 
 
Entry Nu Lewis acids Resulta 
1 278 TiCl4 Only SM 
2 278 BF3 71% SM and 16% 277 
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3 278 TIPSOTf Only SM 
4 278 HNTf2 Only SM 
5 279 Sn(NTf2)4.7DMSOb Only SM 
6 279 MeLi, then Sn(NTf2)4.7DMSOb Only SM 
7 279 KF, Sn(NTf2)4.7DMSOb  Only SM 
8 280 HNTf2  Only SM 
9 280 Sn(NTf2)4.7DMSO Only SM 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard. 
bReaction performed using acetonitrile as the solvent instead of DCE. 
 
We also tested -lactam 192 to see if replacement of the cyclohexyl group with gem-dimethyl 
would lead to better reactivity (Scheme 92). Unfortunately, repeating the different conditions 
aforementioned on 185 did not lead to any successful outcome. 
 
Scheme 92:  Survey of nucleophiles and Lewis/protic acids for ring-opening of 192 
 
Given no success had been achieved thus far with a range of latent carbon nucleophiles, it was 
decided to explore organometallics as nucleophiles as we hoped the increased nucleophilicity 
would lead to better reactivity (Table 6).  The methyl group was chosen as the transferring group 
for this study due to its small size and hence would provide the least steric impediment. Whilst 
methyllithium appeared to be too reactive and gave a complex mixture with no recovery of 
starting material (entry 1), all the other organometallics investigated had shown no reactivity 
(entries 2 to 8).  Given this investigation had yielded very little success, it wasn’t pursued further 
at this point. 
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Table 6:  Screening of Lewis and protic acids for ring-opening of 185 
 
Entry Me–M Lewis acids solvent Temperature Result 
1 MeLi - THF 0 oC to rt Complex mixture 
2 MeMgBr - THF 0 oC to 60 oC Only SM 
3 MeMgBr TiCl4 DCE 0 oC to 60 oC Only SM 
4 MeMgBr BF3 THF 0 oC to 60 oC Only SM 
5 AlMe3 - DCE rt to 80 oC Only SM 
6 AlMe3 TiCl4 DCE rt to 80 oC Only SM 
7 Me2CuLia TiCl4 THF 0 oC to 60 oC Only SM 
8 Me2CuLia BF3 THF 0 oC to 60 oC Only SM 
aPrepared from 2 equivalents of methyllithium and 1 equivalent of copper(I) iodide in THF. 
 
2.3.6 Palladium(II)-catalysed sp3 C–H alkenylation – Dr Jonas Calleja 
 
To broaden the scope of this methodology, different transformations were explored with this 
N,O-ketal scaffold.  Dr Jonas Calleja, a postdoctoral research associate within the group, has 
discovered and optimised a Pd(II)-catalysed sp3 C–H alkenylation on N,O-ketal 185 (Scheme 93). 
 
Scheme 93:  Palladium(II)-catalysed sp3 C–H alkenylation on 185 - discovered and optimised by Dr 
Calleja 
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Treatment of 185 under the optimised reaction conditions with hexafluoroisopropyl acrylate 282 
generated initially the alkenylated alkene 283, which underwent a facile 1,4-conjuate addition to 
yield fused-pyrrolidine 284 in 75% yield, and as a single diastereoisomer.  He also found that the 
reaction was influenced by the electronic properties of the alkene, whereby the yields of the 
reaction increase with the electron-withdrawing ability of the alkenes (Scheme 94).  This trend is 
consistent for other substituents at the 2-position of the N,O-ketal.  
 
Scheme 94:  Influence of electronic properties of alkenes on the C–H alkenylation – Dr Calleja 
 
This reaction is likely to proceed via a palladium(II)/(0) pathway, in an analogous fashion to the 
carbonylation.  The proposed mechanism for the palladium(II)-catalysed alkenylation is shown in 
Scheme 95.  The proposed catalytic cycle begins with the binding of the palladium(II) centre by 
amine 185 to form a mono-amine complex which undergoes C–H activation to form a five-
membered palladacycle 194.  Binding of acrylate 282 ligand is likely to form a monomeric 
palladacycle 285, which undergoes carbopalladation to form a seven-membered palladacycle 
286.  -hydride elimination provides alkenylated amine 283 and simultaneously cyclises via a 
1,4-conjugate addition to generate fused-pyrrolidine 284.  The -hydride elimination step releases 
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palladium(0) into the catalytic cycle and a terminal oxidant is then required to regenerate the 
catalytically active palladium(II) species. 
 
 
Scheme 95:  Proposed mechanism for palladium(II)-catalysed sp3 C–H alkenylation (substituents 
abbreviated as R or R1 for clarity) 
 
2.3.7 Summary 
 
Chapter 2 described the development of a palladium(II)-catalysed sp3 C–H carbonylation of 
hindered N,O-ketals which was shown to have a broad substrate scope, leading to a range of -
lactams in good yields (Scheme 96).  Most substrates showed exclusive regioselectivity for the 
terminal ethyl sp3 C–H (section 2.3.3.1 and 2.3.3.2).  With substrates which have potentially 
competing C–H activation pathways, structurally attractive products such as 252 and 265 were 
obtained (section 2.3.3.3).  The carbonylation is believed to proceed through a palladium(II)/(0) 
catalytic cycle. 
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Scheme 96:  Overall substrate scope of the palladium(II)-catalysed carbonylation 
 
Upon ring opening of the -lactams, a range of -keto carboxylic acids could be obtained, thus 
providing an alternative entry to these important classes of building blocks.  The palladium(II)-
catalysed carbonylation served as the key step in allowing an overall -carboxylation of ethyl 
ketones (Scheme 97). 
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Scheme 97:  Overall -carboxylation of ethyl ketones 
 
Early studies by Dr Calleja showed that the N,O-acetals could undergo C–H alkenylation to yield 
structurally complex fused pyrrolidines as single diastereoisomers (section 2.3.6). 
 
The manuscript for this work is in preparation. 
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3 Design and Synthesis of Functionalised Astemizole Analogues 
via sp3 C–H Functionalisation of Hindered Amines 
 
3.1 Background  
 
Astemizole, marketed under the brand name Hismanal, is a second-generation antihistamine drug 
originally developed by Janssen Pharmaceutica in 1977 and was approved for the treatment of 
allergic diseases.131  It is a non-sedative, potent, long-lasting and selective H1-antagonist.  
However, it has been withdrawn from the market in most countries because of the cardiac 
arrhythmia side effect that is attributed to inhibition of the hERG channel. 
 
Human ether-a-go-go related gene (hERG) potassium (K+) channels play a critical role in cardiac 
action potential repolarisation.  Inhibition of the hERG channel causes QT interval prolongation 
resulting in potentially fatal ventricular tachyarrhythmia called Torsade de Pointes.  This 
potentially fatal side effect is a major pharmacological safety concern for the pharmaceutical 
industry and the health regulatory authorities.132  As a result, a number of blockbuster drugs have 
been withdrawn from the market because of reports of sudden cardiac death and several others 
were forced to carry “black box” warning labels.133  The hERG channel is unusually susceptible 
to blockage by drugs in comparison with other potassium channels, suggesting that it has a 
unique binding site.  Site-directed mutagenesis studies into hERG channels identified two 
aromatic amino acid residues, Tyr 652 and Phe 656, located in the S6 domain and predicted to 
face the central cavity of the channel that are critical for high affinity binding of drugs containing 
tertiary amines (Figure 2a).134  Further mutagenesis identified potent blockage of hERG channel 
by terfenadine required an aromatic residue in position 652, suggesting the possible importance 
of a cation-π interaction between the positively charged nitrogen atom of the drug and the π-
electrons of Tyr 652 (Figure 2b).135 A strongly hydrophobic attraction with Phe656 was also 
identified for the same drug. 
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Figure 2:  a) Model of the hERG drug-binding site, and b) binding mode of terfenadine to the hERG 
channel134,135 
 
Early detection of compounds with this undesirable side effect is consequently an important 
objective in assessing preclinical risks of new drug candidates.  As a result, in silico approaches 
are now widely used to predict hERG channel blockade.  These computational models are based 
on the now generally accepted hERG pharmacophore model for what molecular features are 
likely to give rise to hERG inhibition. The most important features are found to be the presence 
of a basic nitrogen atom, attaching to hydrophobic groups in at least two of the three vectors 
(Figure 3a).133,136  Examples of known hERG inhibitors are shown in Figure 3b. 
 
Figure 3:  a) hERG pharmacophore model, and b) known hERG inhibitors 
 
One of the commonly employed strategies in medicinal chemistry to reduce hERG inhibition is to 
reduce the basicity i.e. pKa of the amine.  This is often achieved by incorporation of 
electronegative atoms in close proximity to the basic nitrogen atom (Scheme 98).137,138  
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Scheme 98:  Reducing pKa of amine nitrogen improves hERG profile137,138 
 
3.2 Project aims 
 
As mentioned in the introduction (see section 1.4.3.4), we have recently developed a 
palladium(II)-catalysed C–H activation strategy for functionalisation of hindered aliphatic amines 
via a novel four-membered ring cyclopalladation pathway (Scheme 99).113  This approach has 
enabled entry to previously inaccessible amines.  
 
Scheme 99:  C–H functionalisation of hindered aliphatic amines via a novel four-membered 
cyclopalladation pathway113 
 
We envisaged that we could exploit this C–H activation strategy to access analogues of 
astemizole which have the potential to reduce the level of hERG inhibition (Scheme 100).  Our 
hypothesis was that by increasing the steric bulk around the piperidine nitrogen atom, we could 
reduce the basicity of the nitrogen by virtue of steric hindrance and therefore reduce hERG 
binding.  Although the additional methyl groups would bring an undesirable increase in the logP 
value in such derivative (287), it could be compensated by the introduction of polar groups (288 
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and 289).  Moreover, the newly installed polar functional handles could offer opportunities for 
further derivitisation to fine-tune the physicochemical properties of these derivatives.  
 
Scheme 100:  Synthetically-driven design of astemizole analogues 
 
The initial aim of the project was to establish the synthetic route for the synthesis of TMP-
astemizole 287 and to subsequently employ the C–H functionalisation chemistry to further obtain 
the OH and COOH derivatives (288 and 289) in order to test their hERG activities. 
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3.3 Results and discussion 
 
3.3.1 Synthesis of ‘TMP-astemizole’ 
 
The original discovery synthesis of astemizole by Janssen Pharmaceutica,131 outlined in Scheme 
101, was completed in six linear synthetic steps, starting from ethyl, 4-aminopiperidine 
carboxylate 290.    
 
Scheme 101:  Discovery synthesis of astemizole by Janssen Pharmaceutica131 
 
In this synthesis, treatment of ethyl, 4-aminopiperidine carboxylate 290 with ortho-
nitrophenylisothiocyanate 291 afforded thiourea 292.  Catalytic hydrogenation of nitro to amino 
group furnished aniline 293 which underwent cyclodesulfurisation in the presence of mercury(II) 
oxide and sulfur powder to yield benzimidazole 294.  Subsequent N-alkylation of the 
benzimidazole followed by carbamate deprotection gave piperidine 296, which after N-alkylation 
with 4-methoxyphenylethyl bromide, furnished astemizole, with a 6% yield over six steps. 
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Sandoval-Ramirez and coworkers139 later reported an improved synthesis of astemizole, which 
allowed a more convergent synthesis via a nucleophilic aromatic substitution (SNAr) reaction of 
ethyl, 4-aminopiperidine carboxylate 290 with 2-chloro-1-(4-fluorobenzyl)benzimidazole 297, 
which required two steps to synthesise though it is now commercially available (Scheme 102).  
The subsequent steps were identical to the original synthesis and an overall 20% yield was 
achieved. 
 
Scheme 102: Improved synthesis of astemizole by Sandoval-Ramirez139 
 
3.3.1.1  Original route 
 
Based on the established synthetic route to astemizole, it was proposed that TMP-astemizole 287 
could be synthesised in a similar fashion, starting from 2,2,6,6-tetramethylpiperidin-4-amine 298 
(Scheme 103).  It was anticipated that the N-heteroarylation reaction could be carried out without 
the need to protect the TMP nitrogen atom as it is sterically hindered and hence rendering it 
unreactive. Although this route is short, we anticipated that the subsequent N-alkylation on 
piperidine 299 could give rise to regioselectivity issues with two free amines in the molecule 
(highlighted in purple).  This route was investigated nevertheless given the brevity of the 
synthetic route. 
 
Scheme 103:  Proposed synthetic route to TMP-astemizole 287 
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The N-heteroarylation reaction proceeded efficiently between 2,2,6,6-tetramethylpiperidin-4-
amine 298 and 2-chloro-1-(4-fluorobenzyl)benzimidaole 297, yielding the desired amine 299 in 
77% yield.  However, the subsequent alkylation with 4-methoxyphenylethyl bromide 300 gave 
exclusively the undesired regioisomer 301, in 34% yield (Scheme 104).  The regiochemistry was 
confirmed by nOe analysis. 
 
Scheme 104:  Initial attempts to synthesize TMP-astemizole 287 
 
Given the pKa of the amino-benzimidazole NH is likely to be lower than that of the TMP NH, a 
double deprotonation strategy was attempted (Scheme 105).  Unfortunately, treatment of amine 
299 with 2 equivalents of sodium hydride, followed by addition of bromide 300, gave no desired 
product 287 and only trace amount of the undesired regioisomer 301 was observed by 1H NMR 
and LCMS analyses. 
 
Scheme 105:  Double deprotonation strategy 
 
The next approach attempted was protection of the more reactive amino-benzimidazole nitrogen 
atom followed by alkylation.  The Boc-protected amino-benzimidazole 302 and Ts-protected 
amino-benzimidazole 304 were prepared and subjected to the N-alkylation conditions, this time 
with the more reactive alkylating agent 4-methoxyphenylethyl iodide 303 (Scheme 106).  
Unfortunately, the protecting groups were proved too labile and the N-alkylation again took place 
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on the amino-benzimidazole nitrogen atom.  As this synthetic route was met with little success, 
different strategies were sought. 
Scheme 106:  Blocking the amino-benzimidazole NH with protecting groups 
 
3.3.1.2  Phthalimide route 
 
It was thought the order of the N-heteroarylation and N-alkylation steps could be reversed as this 
would avoid the regioselectivity issue encountered with the first route.  To this end, amine 305 
was prepared from 2,2,6,6-tetramethylpiperidin-4-amine 298 and a brief survey of alkylation 
conditions were carried out (Scheme 107).  The alkylations were found to be sluggish, with 
mainly starting amine recovered as well as methoxy-styrene resulting from elimination of halides 
300 and 303.  Nevertheless, the desired product 306 could be obtained on treatment of amine 305 
with potassium carbonate as base in neat 4-methoxyphenylethyl bromide 300 at 120 oC, albeit in 
only a poor 12% isolated yield (entry 2).  Weak organic bases such as triethylamine and strong 
bases such as sodium hydride resulted in no conversion (entries 3 and 5).  Alkylation with 
microwave irradiation, as well as using the more reactive iodide 303, showed similar conversion 
to that obtained from the neat reaction (entries 4 and 6). 
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Scheme 107:  Preparation and attempted alkylation of amine 305 
 
The next step was removal of the phthalimide group, which proceeded smoothly to give primary 
amine 307 in quantitative yield (Scheme 108).  Unfortunately, the subsequent N-heteroarylation 
reaction was unsuccessful under a number of reaction conditions investigated, with only starting 
material observed at the end of the reaction. 
 
Scheme 108:  Removal of phthalimide group and attempted N-heteroarylation reaction on 307 
 
Another precedented approach to install the benzimidazole unit to 4-aminopiperidine is the 
Buchwald-Hartwig amination.140  However, due to the irreproducible and unreliable N-alkylation 
step, it was found to be rather problematic to produce an appreciable quantity of amine 307 using 
the current route.  At this point, we investigated making a test substrate which would hopefully 
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allow quick access to an analogue of amine 307 to trial the amination.  To this end, amine 309 
was prepared, which bore a heptyl unit on the hindered nitrogen atom instead of the 4-
methoxyphenylethyl group (Scheme 109).  The alkylation with heptyl iodide proved to be more 
robust, giving the alkylated amine 308 in a moderate 43% yield.  Subsequent removal of the 
phthalimide group furnished amine 309, an analogue of amine 307, in 97% yield. 
 
Scheme 109:  Preparation of test substrate 309 
 
Gratifying, the Buchwald-Hartwig amination with amine 309 and 2-chloro-1-(4-
fluorobenzyl)benzimidaole 297 proceeded smoothly under the reported amination conditions,140 
yielding the desired compound 310 in 64% yield (Scheme 110). 
 
Scheme 110:  Buchwald-Hartwig amination on test substrate 309 
 
With the method to the install the benzimidazole unit established, the focus was switched to an 
alternative approach to synthesise amine 307, the precursor to TMP-astemizole 287. 
 
3.3.1.3  Dioxolane route 
 
We next sought to attempt alkylation on acetal-protected tetramethylpiperidine-4-one 132 and 
proposed an alternative route to synthesise amine 307 starting from 132 (Scheme 111).  
Alkylation would be followed by an acetal deprotection. Reductive amination of the resulting 
ketone would install the primary amine functionality. Starting the synthesis with 132 would also 
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be ideal as the palladium-catalysed functionalisation has been shown to work effectively on this 
exact system.113 
 
Scheme 111:  Proposed synthetic route starting from dioxolane 132 
 
It was anticipated that alkylation with 4-methoxyphenylethyl bromide 300 would be poor.  
Therefore, as with the phthalimide route, it was decided to trial this route using a test substrate 
(Scheme 112).  To this end, primary amine 309 was prepared, starting from ketone 313.  
Protection of 313 with ethylene glycol gave dioxolane 132 in 54% yield.  N-alkylation with 
heptyl iodide proceeded to give 43% of tertiary amine 314. Subsequent acetal deprotection under 
acidic conditions furnished ketone 315 in 63% yield.  Two different reductive amination 
conditions were attempted and it was found that treatment of 315 with 7 N ammonia in methanol 
and titanium(IV) isopropoxide, followed by reduction of the transient hemiaminal species with 
sodium borohydride, gave the best yield of the desired primary amine 309, in 71% yield.  The 
two step reduction via oxime returned 309 in a marginally lower 65% yield.   
 
Scheme 112:  Preparation of test substrate 309 via the dioxolane route 
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With the synthetic route and conditions established, attempts were made to synthesise TMP-
astemizole 287 (Scheme 113).  N-alkylation of 132 with 4-methoxyphenylethyl bromide 300 or 
iodide 303 was found to be a more reliable reaction, affording 36% of the desired tertiary amine 
311 with bromide 300.  Ketone 312 was obtained in 61% yield following an acidic acetal 
deprotection.  Subsequent reductive amination, following the conditions established for ketone 
315, enabled primary amine 307 to be obtained in 77% yield. 
 
Scheme 113:  Preparation of 307 via the dioxolane route 
 
Finally, subjecting 307 to the validated Buchwald-Hartwig amination conditions furnished the 
desired TMP-astemizole 287 in 61% yield (Scheme 114). 
 
Scheme 114:  Access to TMP-astemizole 287 via Buchwald-Hartwig amination 
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3.3.2 Proposed synthetic routes to functionalised astemizole analogues 
 
Having established a synthetic route for synthesis of TMP-astemizole, we next set out to 
synthesise astemizole analogues 288 and 289, based on the palladium-catalysed acetoxylation 
and carbonylation, respectively, starting from 132 (Scheme 115).  
 
Scheme 115:  Palladium-catalysed functionalisation approach to 288 and 289 
 
The proposed synthesis to 288, starting from 133, is shown in Scheme 116.  Protection of the 
newly installed hydroxyl group was deemed necessary to avoid regioselective issues in the 
subsequent displacement reaction.  However, it was envisaged that the installed acetyl group 
would be too labile to carry through the synthetic sequence.  As such, the acetyl group would first 
be removed and replaced with a more robust protecting group, such as benzyl.  Displacement 
with 4-methoxybenzyl bromide, followed by acetal deprotection would yield ketone 319.  The 
primary amine group could subsequently be introduced via reductive amination to yield a mixture 
of diastereoisomers 320.  If possible, the diastereoisomers would be separated before the 
subsequent Buchwald-Hartwig amination and benzyl deprotection, yielding functionalised 
astemizole analogue 288. 
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Scheme 116:  Proposed synthetic route to functionalised astemizole analogue 288  
 
The proposed synthesis of 289, starting from 128, is shown in Scheme 117.  We envisaged ring-
opening of the -lactam ring with a bulky alcohol group such as iso-propanol would enhance the 
stability of the resulting ester from re-formation of the -lactam ring in the subsequent alkylation.  
At this point, selective deprotection of acetal 323 to ketone 324 in the presence of the ester 
functionality would be explored.  Should the ester group hydrolysed during acetal deprotection, it 
should be easily reinstalled via a Fisher esterification.  The ensuing reductive amination followed 
by Buchwald-Hartwig amination steps would yield ester 326.  Final hydrolysis of ester 326 (and 
the other diastereoisomer) would furnish functionalised astemizole analogue 289. 
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Scheme 117:  Proposed synthetic route to functionalised astemizole analogue 289  
 
3.3.3 Introduction of polar functionality: palladium(II)-catalysed acetoxylation and 
carbonylation 
 
3.3.3.1  Palladium(II)-catalysed acetoxylation 
 
We began our synthesis of 288 with the precedented palladium-catalysed acetoxylation of 132 
(Scheme 118).113  Subjecting 132 to the acetoxylation condition yielded the acetoxylated amine 
133 in 38% yield after purification.  The subsequent acetate hydrolysis proceeded without note 
and delivered alcohol 316 in 78% yield.   
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Scheme 118:  Palladium(II)-catalysed acetoxylation followed by hydrolysis 
 
Due to difficult and time-consuming purification of 133, we attempted telescoping the crude 
material of 133 directly into the acetate hydrolysis step (Scheme 119).  Gratifyingly, this 
telescoped process proved more efficient both in terms of time and yield of 316 as the 
chromatographic purification was significantly easier.  Overall, 48% yield was achieved over 2 
steps. 
 
Scheme 119:  Telescoped palladium-catalysed acetoxylation/hydrolysis sequence 
 
3.3.3.2  Palladium(II)-catalysed carbonylation 
 
In an analogous fashion, we began our synthesis of 289 with the precedented palladium-catalysed 
carbonylation of 132, which proceeded smoothly to give 128 in 62% yield (Scheme 120).113   
 
Scheme 120:  Palladium(II)-catalysed carbonylation of 132 
 
We next investigated ring opening of the -lactam ring with the intention of forming -amino 
ester 327 or 328 (Table 7).  Ring-opening of 128 with different metal isopropoxides showed no 
conversion to the desired amino ester 327 whilst using the smaller methoxide nucleophile gave 
no reaction either (entries 1 to 4).  Under protic or Lewis acidic conditions, the reaction gave 
complex mixtures with no sign of 327 or 329 observed (entries 7 and 8).  
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Table 7:  Screening of -lactam ring-opening conditions 
 
Entry Reaction conditions Result 
1 LiOiPr (5.0 equiv), IPA, reflux, 16 h Only SM 
2 NaOiPr (5.0 equiv), IPA, reflux, 16 h SM and an unknown compound 
3 KOiPr (5.0 equiv), IPA, reflux, 16 h SM and an unknown compound 
4 NaOMe (5.0 equiv), MeOH, reflux 16 h Only SM 
5 4 N HCl in dioxane (2.0 equiv), IPA, reflux, 2 h No SM, complex mixture 
6 3 N HCl, IPA, reflux, 2 h No SM, complex mixture 
7 BF3 (2.0 equiv),  IPA, reflux, 2 h No SM, complex mixture 
8 TMSCl (2.0 equiv), IPA, reflux, 2 h No SM, complex mixture 
 
Given the lack of success in the ring-opening to give -amino ester directly, we next explored a 
two-step procedure involving hydrolysis then esterification (Table 8).  Treatment of 128 with 
metal hydroxides succeeded in producing the desired -amino acid 331, but the conversion was 
very poor, despite prolonged heating (entries 1 and 2).  Acidic ring-opening condition again gave 
a complex reaction mixture (entry 3). 
Table 8:  Screening of -lactam ring-opening conditions 
 
Entry Reaction conditions Yielda 
1 KOH (10 equiv), THF/water(1:1), reflux, 5 days 22% 331; 20% SM 
2 LiOH (10 equiv), THF/water(1:1), reflux, 5 days 7% 331; 85% SM 
3 3 N HCl, THF/water, reflux, 3 h No SM, complex mixture 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard 
Whilst -lactam ring-opening with oxygen nucleophiles was met with little success, we 
questioned whether using stronger nucleophiles would improve the ring-opening reaction.  We 
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were pleased to find that, on treatment with the stronger nucleophile lithium aluminium hydride, 
reduction of -lactam 128 proceeded efficiently to give amino alcohol 333 in 69% yield, along 
with 11% of azetidine 334 (Scheme 121). 
 
Scheme 121:  Reduction of 128 to -amino alcohol 333 
 
We envisaged that that amino alcohol 333 could lead to astemizole analogue 335 by following a 
synthetic route similar to that proposed for the synthesis of 288 (Scheme 122). 
 
Scheme 122: Proposed synthesis of 335 - homologated analogue of 288 
 
3.3.4 Installation of the 4-methoxyphenylethyl unit 
 
With the successful introduction of polar OH groups via palladium-catalysed acetoxylation and 
carbonylation, the focus was switched to the incorporation of the 4-methoxyphenylethyl unit onto 
the hindered nitrogen.  Alcohols 316 and 333 were first protected with benzyl groups (Scheme 
123). 
 
Scheme 123:  Benzylation of alcohols 316 and 333 
 
The alkylation reaction of 317 and 336 with 4-methoxyphenylethyl bromide/iodides were next 
explored (Table 9).  
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Table 9:  Screening of alkylation conditions on 317 and 336 
 
Entry n Reaction conditions Yielda 
1 1 
Bromide (7.0 equiv), K2CO3 (3.0 equiv), 
120 oC, 16 h 
7% (3%)b 
2 1 
Bromide (7.0 equiv), K3PO4 (3.0 equiv), 
120 oC, 16 h 
Traces of product (<5%) 
3 1 
Iodide (7.0 equiv), K2CO3 (3.0 equiv), 
120 oC, 16 h 
Traces of product (<5%) 
4 1 
NaH (2.0 equiv), bromide (3.0 equiv), 
DMF, rt to 100 oC, 16 h 
0% 
5 1 
Bromide (3.0 equiv), K2CO3 (3.0 equiv), 
CH3CN, 150 oC, MW, 4 h 
0% 
6 2 
Bromide (7.0 equiv), K2CO3 (3.0 equiv), 
120 oC, 16 h 
Traces of product (<5%) 
7 2 
NaH (2.0 equiv), bromide (3.0 equiv), 
DMF, rt to 100 oC, 16 h 
0% 
8 2 
Bromide (3.0 equiv), K2CO3 (3.0 equiv), 
CH3CN, 150 oC, MW, 4 h 
6% 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard.   
 
Poor conversion was observed when potassium carbonate was employed as base and gave a mere 
3% isolated yield of 317, with mostly starting material remaining (entry 1).  Stronger bases, such 
as tribasic potassium phosphate and sodium hydride did not lead to any improvements (entries 2, 
4 and 7).  Employing the more reactive iodide 303 gave only traces of product whilst stirring 
under microwave irradiation at 150 oC gave no conversion (entries 3 and 5).  The low reactivity 
of 316 in alkylation could be attributed to the reduced nucleophilicity of the nitrogen atom due to 
the -heteroatom effect.  It was also speculated that the possible formation of a stable 
intramolecular hydrogen bonding network might also diminish the nucleophilicity of the nitrogen 
atom (Figure 4). 
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Figure 4:  Possible intramolecular hydrogen bonding network in 316 and 333  
 
As the displacement reactions with 316 and 333 were met with little success, different approaches 
to install the 4-methoxyphenylethyl unit were examined.  A summary of the alternative strategies 
investigated is shown in Scheme 124. 
 
Scheme 124:  Summary of the alternative strategies attempted to install the 4-methoxyphenylethyl group 
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Reductive amination (Scheme 124a): 
 
A number of standard reductive amination procedures were attempted using phenyl acetaldehyde 
as the model aldehyde.  Disappointingly, none led to formation of the desired product 337, with 
only starting material and alcohol stemming from reduction of the aldehyde recovered (Table 10).  
Attempts to isolate the enamine that would be formed after the initial condensation also failed, 
presumably owing the poor reactivity of the sterically hindered amine. 
 
Table 10:  Screening of reductive amination conditions. 
 
Entry Reaction conditions Result 
1 
Aldehyde (2.0 equiv), AcOH (~0.1 equiv), rt to 
50 oC; then NaBH(OAc)3 (2.0 equiv), 50 oC,16 h Only SM and reduction of aldehyde 
2 
Aldehyde (2.0 equiv), Ti(OiPr)4 (2.0 equiv), 
MeOH, rt, 6h; then NaBH4 (2.0 equiv), rt, 10 h Only SM and reduction of aldehyde 
3 
Aldehyde (2.0 equiv), Ti(OiPr)4 (5.0 equiv), rt, 
16h; then NaBH4 (4.0 equiv), rt, 6 h 
Only SM and reduction of aldehyde 
 
Acylation/reduction (Scheme 124b): 
 
Pleasingly, acylation of 132 proceeded efficiently to give amide 338 in 67% yield.  However, the 
ensuing amide reduction proved more challenging.  Standard hydride reducing agents such as 
lithium aluminium hydride and borane gave no desired product with only alcohol 343 observed 
by 1H NMR (Scheme 125).  Alcohol 343 was presumably formed from cleavage of the 
hemiaminal intermediate 344 followed by reduction of the resulting aldehyde.  Attempts to 
activate the amide with triflic anhydride followed by reduction with sodium borohydride was also 
unsuccessful, with either product or starting material recovered after the reaction.  We next 
explored the possibility of using silanes as reducing agents under transition-metal catalysis.141–145  
Unfortunately, this approach was also met with little success and so it was not pursued further. 
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Scheme 125:  Failed reduction of 338 with standard hydride reducing agents 
 
Electrophilic amination (Scheme 124c): 
 
Electrophilic amination involves the formation of a carbon–nitrogen bond through the reaction of 
a nucleophilic carbanion with an electrophilic source of nitrogen.  In 2004, Johnson reported a 
mild method for the preparation of various tertiary amines through the copper-catalysed 
electrophilic amination of organozinc reagents with O-benzoylhydroxylamines.146  Lalic later 
developed a protocol for hindered aniline synthesis via copper-catalysed electrophilic amination 
of aryl boronic esters (Scheme 126).147  The use of neopentyl glycol boronic ester is important for 
high yields, owing to a faster transmetallation compared to the corresponding ethylene glycol or 
pinacol boronic esters.  
  
Scheme 126:  Lalic's hindered aniline synthesis via copper-catalysed electrophilic amination of aryl 
boronic esters147 
 
Encouraged by these literature precedents, we began our initial studies based on Johnson’s 
conditions, using 339 as our model amine electrophile (Scheme 127).  Unfortunately, subjecting 
339 to the reaction condition gave only unreacted starting material, even when the temperature 
was increased to 60 oC, indicating no copper insertion has taken place. 
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Scheme 127:  Attempted electrophilic amination using Johnson's conditions 
 
We next investigated Lalic’s reaction conditions using styrenyl boronic ester 347.  
Disappointingly, after a brief survey of additives, solvents and temperature, only starting material 
could be recovered from the reactions (Scheme 128).  Preformed copper(I) tert-
butoxide/Xantphos complex was also tested in the reaction, but again, only starting material was 
recovered. 
 
Scheme 128:  Attempted electrophilic amination using Lalic's conditions 
 
Anti-Markovnikov hydroamination of vinyl arenes (Scheme 124d): 
 
Hydroamination of vinyl arenes with a range of amines are known under both rhodium-148 and 
ruthenium-catalysed149 conditions.  We investigated this approach using 132 as the model amine 
substrate and 4-methoxystyrene 349 as the alkene partner.  Unfortunately, subjecting 132 to both 
the reported rhodium- and ruthenium-catalysed conditions resulted only in recovery of the 
starting material, even at elevated temperature (Scheme 129).  
 
Scheme 129:  Attempted anti-Markovnikov hydroamination of 4-methoxystyrene with 349 
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Mannich (Scheme 124d): 
 
Ku et. al. reported an efficient synthesis of -arylethylamines via an in situ formation of iminium 
ions, and this method was shown to be amenable to sterically hindered amines.150  Encouraged by 
this report, we began investigation using 132 as the model substrate.  Disappointingly, after a 
brief survey of Lewis/protic acids, equivalents of paraformaldehyde, solvent, temperature and 
reaction time, no conversion of the starting material to the desired product was observed (Scheme 
130).  The poor reactivity could be attributed to the poor conversion of the hindered amine to the 
transient iminium ion 350.  Given the lack of success of this approach, it was not pursued further. 
 
Scheme 130:  Attempted Mannich reactions 
 
C–H borylation/Suzuki (Scheme 124e): 
 
Whilst exploring other disconnection pathway to incorporate the 4-methophenylethyl unit, we 
became aware of an iridium-catalysed borylation of sterically hindered sp3 C–H bonds reported 
by Suginome (Scheme 131).151  The installed boronic ester could then be converted to an aryl 
group via a traditional Suzuki cross coupling reaction. 
 
Scheme 131:  Suginome’s iridium-catalysed borylation of sterically hindered sp3 C–H bonds151 
 
This approach was tested using 341 (Scheme 132). The iridium-catalysed borylation procedure 
had to be modified from the reported conditions because 341 was a solid, as opposed to liquids in 
all the reported examples by Suginome.  Thus, a small quantity of dioxane was added (made up 
to 1 M concentration) to ensure efficient mixing.  Also, the stoichiometry was reversed so that 
Design and Synthesis of Functionalised Astemizole Analogues  
95| 
341 became the limiting reagent.  Disappointingly, this modified reaction conditions resulted in a 
complex mixture where neither desired boronic ester 342 or starting material 341 were recovered. 
 
Scheme 132:  Preparation and attempted iridium-catalysed sp3C–H borylation of 341 
 
Owing to the lack of the success of the aforementioned investigations, we next revisited the N-
alkylation approach and focused on 317 for optimisation.  We questioned whether replacing 
dioxolane in the 4-position of the piperidine ring with a less electron-withdrawing 
triisopropylsilyl-protected alcohol would enhance the nucleophilicity of the nitrogen atom and 
hence improve the reactivity (Scheme 133). 
 
Scheme 133:  Proposed hypothesis of enhancing nucleophilicity of the nitrogen atom 
 
To test this hypothesis, 353 was prepared from 317 via three simple functional group 
manipulations (Scheme 134).  
 
Scheme 134:  Preparation of 356 
 
The alkylation of 356 was then explored and the results are summarised in Table 11. 
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Table 11:  Screening of N-alkylation conditions on 356  
 
Entry Conditions Yielda 
1 Bromide (7.0 equiv), K2CO3 (3.0 equiv), 120 oC, 16 h 15% 
2 Bromide (7.0 equiv), K3PO4 (3.0 equiv), 120 oC, 16 h 11% 
3 Bromide (7.0 equiv), K2CO3 (3.0 equiv), 18-crown-6, 120 oC, 16 h 14% 
4 Iodide (7.0 equiv), K2CO3 (3.0 equiv), 120 oC, 16 h 13% 
5 NaH (2.0.equiv), bromide (3.0 equiv), DMF, rt to 100 oC, 16 h 0% 
6 Bromide (3.0 equiv), K2CO3 (3.0 equiv), CH3CN, 150 oC, MW, 4 h 24% 
aYields determined by 1H NMR spectroscopy using 1,1,2,2-tetrachloroethane as an internal standard.   
 
The majority of the reaction conditions attempted did show a quantifiable amount of product and 
using superheated acetonitrile in the microwave at 150 oC over 4 hours gave the best 1H NMR 
yield of 24% (entry 6).  However, isolation proved to be extremely difficult, especially as the 
product was present as a mixture of diastereoisomers.  We envisaged purification could be made 
simpler if it was carried out after the subsequent triisopropylsilyl group removal, followed by an 
oxidation to ketone 319 to avoid the diastereoisomeric mixture isolation issue. 
 
To this end, the reaction mixture after the alkylation step was carried straight into the 
deprotection step after a simple filtration and a solvent switch to ethanol.  After an aqueous work 
up, the crude alcohol 358 was taken directly to the oxidation step, which was performed using 
tetrapropylammonium perruthenate.  Subsequent purification by flash chromatography delivered 
ketone 319 in a mere 8% yield, as well as recovery of 80% of 354 (Scheme 135).   
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Scheme 135:  Preparation of ketone 319 via an alkylation/deprotection/oxidation sequence 
 
This sequence was also employed for the synthesis of astemizole analogue 289, delivering ketone 
363 in 10% yield as well as 76% of recovered 359 (Scheme 136). 
 
Scheme 136:  Synthesis of ketone 363 via the optimised process 
 
3.3.5 Installation of primary amine via reductive amination 
 
With ketones 319 and 363 in hand, the next step in the synthesis was to install the primary amine 
unit, via reductive amination.  We decided to focus on 319 and proceed through the subsequent 
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steps to the final compound 288.  Reductive amination via formation of oxime followed by 
reduction with lithium aluminium hydride did give 68% of the desired amine 320, as a 1.4:1 
mixture of diastereoisomers.  However, 1H NMR analysis showed there were other minor 
aliphatic impurities which could not be removed, despite attempting the chromatography using 
Florisil® or basic alumina as absorbents (Scheme 137).  Buchwald-Hartwig amination was also 
attempted on this material with the hope of better separation after the amination step, but that also 
proved unsuccessful.  Replacing lithium aluminum hydride with the milder reducing agent 
lithium borohydride gave a much lower recovery (~62%) after aqueous workup as well as a more 
complex reaction profile. 
 
 
Scheme 137:  Reductive amination of 319 via oxime 
 
The next conditions attempted were the previously validated one-pot titanium isoproxide-
mediated reductive amination procedure (section 3.3.1.3).  We were pleased to find that this 
procedure successfully delivered pure amine 320, as a 2:1 mixture of diastereoisomers, in 52% 
yield after purification by silica gel flash chromatography (Scheme 138).  The structure of the 
major diastereoisomer could not be definitively determined given the complex nature of the 1H 
NMR. 
 
Scheme 138:  One-pot titanium isopropoxide-mediated reductive amination of 319 
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3.3.6 Buchwald-Hartwig amination and deprotection end-game 
 
The diastereoisomeric mixture of amine 320 was next subjected to the established Buchwald-
Hartwig conditions employed previously.  However, only starting material could be observed by 
LCMS at the end of the reaction.  Pleasingly, it was found that increasing the reaction 
temperature from 85 oC to 120 oC resulted in conversion to the desired product 321, as indicated 
by LCMS.  Chromatographic separation succeeded in isolation of only one of the 
diastereoisomers, in 48% yield, with the structure of the diastereoisomer confirmed by 1D nOe 
analysis (Scheme 139).  LCMS and 1H NMR analyses showed that the other diastereoisomer was 
present, but it could not be isolated cleanly 
 
Scheme 139:  Buchwald-Hartwig amination of 320 
 
With the framework of the functionalised astemizole complete, the final step in the synthesis was 
the removal of the benzyl group appended to the alcohol.  Trial hydrogenation of the benzyl 
group with palladium on carbon in methanol at reflux showed no conversion.  Replacement of 
palladium on carbon with the more reactive palladium hydroxide on carbon (Pearlman’s catalyst) 
gave no success either (Scheme 140). 
 
Scheme 140: Trial benzyl deprotection conditions 
 
Gratifyingly, transfer hydrogenation conditions proved to be more successful. With ammonium 
formate as the hydrogen source and heating at reflux in methanol, desired alcohol 288 was 
obtained in 50% yield (Scheme 141). 
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Scheme 141:  Transfer-hydrogenation conditions for benzyl deprotection of 321 
 
Regrettably, synthesis of the other astemizole analogue 335 and hERG binding assay of 288 
could not be completed in time. 
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3.3.7 Summary 
 
In summary, the synthesis of functionalised astemizole analogue 288 was completed in 13 steps, 
with an overall yield of 0.07%, from 2,2,6,6-tetramethylpiperidin-4-one 132 (Scheme 142).  The 
key challenge of the synthesis was the installation of the 4-methoxyphenylethyl group onto the 
hindered nitrogen.  In the end, a three-step telescoped procedure enabled access to ketone 
intermediate 319, albeit in very low yield.  Alternative strategies to incorporate this unit was 
investigated but proved unsuccessful.  Regrettably, the hERG profile of this compound could not 
be established in time.  The installed hydroxyl group nevertheless provides opportunities for 
further derivitisation to gain access to further analogues of 288.   
 
Scheme 142:  Summary of the synthesis of 288 
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4 Conclusions and Outlook 
 
The first part of this thesis described the development and application of a sterically promoted C–
H carbonylation strategy, enabling access to a diverse range of -keto carboxylic acids.  Key to 
this strategy was the temporary conversion of simple ketones into hindered secondary amines that 
facilitated a sterically promoted palladium-catalysed C–H activation (Scheme 143).  Directed by 
the nitrogen atom of the hindered N,O-acetals, C–H activation occurred readily to form the 
kinetically favoured five-membered palladacycle.  Subsequent carbonylation and removal of the 
steric tether furnished a variety of -keto carboxylic acids, which are important building blocks in 
the synthesis of medicinally relevant heterocycles.   
 
Scheme 143:  Sterically promoted palladium(II)-catalysed -C–H carbonylation of ketones 
 
Given the stability of the palladacycle, it can be envisaged that other transformations on this 
palladacycle may be possible; therefore future work could involve broadening the scope of 
transformations using this hindered N,O-acetal scaffold.  Early studies by Dr Calleja 
demonstrated that the N,O-acetals could undergo C–H alkenylation to yield structurally complex 
fused pyrrolidines as single diastereoisomers (section 2.3.6).  A second key area of investigation 
could be functionalisation of the more challenging methylene sp3 C–H.  As well as being a 
logical and desirable extension to the methodology, it would also offer a unique opportunity to 
investigate the development of asymmetric C–H functionalisation, most likely through the use of 
chiral ligands.  The use of mono-protected amino acids as ligands to induce chirality in C–H 
arylation of 2,2,6,6-tetramethylpiperidine has been the subject of investigation within the group 
and early results have been promising.115 
 
The second part of this thesis described the application of palladium-catalysed C–H 
functionalisations to the synthesis of astemizole analogues, with the intention of reducing hERG 
inhibition through increasing the steric bulk of the tertiary amine.  Proceeding through four-
membered palladacycles, palladium-catalysed acetoxylation and carbonylation of the 2,2,6,6-
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tetramethylpiperidine core served as the key step in introduction of polar functionalities in close 
proximity to the nitrogen atom.  Functionalised astemizole analogue 288 was synthesised in 13 
linear steps, with the key C–H functionalisation being the second step of the synthesis (Scheme 
144).  The synthesis of 288 was an excellent example of the potential offered by novel C–H 
functionalisation for incorporation of functional handles into inert positions of complex 
molecules. 
 
Scheme 144:  Synthesis of 288 completed in 13 steps starting from 313 
 
To improve the utility of this methodology, a late stage functionalisation of the 2,2,6,6-
tetramethylpiperidine moiety would be ideal because 1) it eliminates the need for protecting 
groups as the reactive functionalities are added at the end of the synthesis, and 2) it streamlines 
syntheses of analogues through rapid diversification of the piperidine core at a late stage.  Also, it 
can be envisaged that iterative sp3 C–H functionalisation of the piperidine core could be possible 
to generate analogues with even more complexity.  For example, an iterative C–H 
acetoxylation/carbonylation sequence could allow access to astemizole analogues such as 364 
(Scheme 145). 
 
Scheme 145:  Potential iterative C–H functionalisation strategy 
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This methodology can potentially be applied to synthesise analogues of other known hERG 
channel blockers (Scheme 146).  
 
Scheme 146:  Potential analogues of other known hERG channel blockers 
 
Given the difficulty encountered with installation of the 4-methoxyphenylethyl unit, another area 
for further research could be to improve on existing methods to functionalise hindered amines, 
which remains a long-standing challenge in synthetic chemistry. 
 
Palladium catalysis remains a focus of research within our group and we have shown recently 
that sp3 C–H carbonylation can carried out on less hindered amines, thereby broadening the range 
of amines that can be functionalised.  This advancement offers further opportunities to synthesise 
analogues of amine-containing drugs with different steric properties around the amine 
functionality.  This would be of great benefits to medicinal chemists in expanding chemical space 
or to fine-tune the pharmaceutical properties of active substances. 
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5 Experimental  
 
5.1 General Information: 
 
Data Collection: 1H NMR spectra were recorded at 400 or 500 MHz on a Bruker DPX-400 or 500 
spectrometer. 13C NMR spectra were recorded at 100 or 125 MHz on the same spectrometers.  19F NMR 
spectra were recorded at 376 MHz on a Bruker DPX 400 spectrometer.  Chemical shifts (δ) are reported 
in parts per million (ppm) relative to the residual solvent (CDCl3 - δH = 7.26 ppm, δC = 77.0 ppm; MeOD 
- δH = 3.31 ppm, δC = 49.1 ppm; δC = 1.39 ppm), and are measured to the centre of the signal except in the 
case of multiplets which are quoted as a range to the nearest 0.01 ppm.  Coupling constants (J) are quoted 
in Hertz (Hz) to the nearest 0.1 Hz.  DEPT-135 and 2-dimensional experiments (COSY, HMBC, HMQC) 
were used where appropriate to assign structures.  Splitting patterns are abbreviated as follows: singlet (s), 
doublet (d), triplet (t), quartet (q), pentet (p) and multiplet (m).  
Equipment: High Resolution Mass Spectrometry (HRMS) samples were sent to the EPSRC mass 
spectrometry service at Swansea for analysis.  Infrared (IR) spectra were recorded on a Perkin Elmer 
Spectrum One FT-IR spectrometer with automatic background subtraction.  Samples were prepared as 
neat films or run as solids, with absorptions reported in wavenumbers (cm-1).  Melting points (m.p.) were 
recorded on a Gallenkamp melting point apparatus and are reported uncorrected.  Liquid 
Chromatography-Mass Spectrometry (LCMS) was performed on a Shimadzu UFLC-XR/LCMS 2020 
system using a Shim-pack XR-ODS column (C18, 2.2μm, 3.0 mm x 50 mm). The LCMS acetonitrile 
(Rathburn) was pre-treated with water (5% vol) and formic acid (12.5 mM) and the LCMS water 
(Rathburn) was pre-treated with formic acid (25 mM) and ammonium acetate (10 mM). Gas 
Chromatography-Mass Spectrometry (GCMS) was performed on a Shimadzu MDGC/GCMS-2010 
system. Microwave experiments were performed in a Biotage® Initiator+ System. 
Chromatography: Flash chromatography was carried out on silica gel 60 (200-400 mesh) and activated 
basic alumina (~150 mesh).  Thin layer chromatography (TLC) was carried out on Kieselgel 60 PF254 
(Merck) 0.2 mm plates.  Plates were visualised using ultraviolet light (λ = 254 nm) and by chemical 
staining with acidic potassium permanganate/ ceric ammonium molybdate solutions followed by heating. 
Solvents: All anhydrous solvents were dried by standard techniques and freshly distilled before use. 
Diethyl ether and tetrahydrofuran (THF) were distilled from lithium aluminium hydride; acetonitrile, 
dichloromethane and toluene from calcium hydride; and triethylamine from potassium hydroxide. 1,2-
Dichloroethane (DCE) and 1,4-dioxane were purchased in anhydrous form from Acros Organics.  
Petroleum ether is 40–60 b.p. unless otherwise stated. 
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Reagents:  All reagents were purchased at the highest commercial quality and used without further 
purification. All reactions were monitored by TLC and or 1H NMR spectra taken from reaction samples, 
with NMR yields determined by 1H NMR with reference to 1,1,2,2-tetrachloroethane as an internal 
standard.  Reactions were carried out under atmosphere of N2 unless otherwise stated.  All reagents were 
used as supplied without further purification unless otherwise stated. 
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5.2 C–H carbonylation:  Synthesis of N,O-ketals 
 
General Procedure A for the formation of N,O-ketals 
 
 
 
To a dry round bottom flask, equipped with a stir bar, was charged the noted amount of amino alcohol 
and ketone in toluene (1 M), followed by addition of para-toluenesulfonic acid (0.1 equiv).  The flask was 
equipped with a Dean-Stark apparatus and the solution was heated under reflux for 16 hours.  The 
solution was then allowed to cool to room temperature and solvent removed under reduced pressure.  The 
crude was further purified by either bulb-to-bulb distillation or flash chromatography on silica gel to 
afford the desired N,O-ketal. 
 
General Procedure B for the formation of N,O-ketals 
 
 
 
To a sealed tube was charged the noted amount of amino alcohol and ketone as the solvent, followed by 
addition of para-toluenesulfonic acid (0.1 equiv) and 4Å molecular sieve (~10 mg/ mmol).  The tube was 
sealed and heated at 120 °C for 16 hours.  The solution was then allowed to cool to room temperature and 
solvent removed under reduced pressure.  The crude was further purified by flash chromatography on 
silica gel to afford the desired N,O-ketal. 
 
General Procedure C for the formation of N,O-ketals 
 
 
 
To a sealed tube was charged the noted amount of amino alcohol and ketone in toluene (3 M), followed 
by addition of para-toluenesulfonic acid (0.1 equiv) and 4Å molecular sieve (~10 mg/ mmol).  The tube 
was sealed and heated at 120 °C for 16 hours.  The solution was then allowed to cool to room temperature 
and solvent removed under reduced pressure.  The crude was further purified by flash chromatography on 
silica gel to afford the desired N,O-ketal. 
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(1-Aminocyclohexyl)methanol (182) 
 
To a solution of 1-aminocyclohexanecarboxylic acid (2.00g, 14.0 mmol, 1.0 equiv) in dry 
tetrahydrofuran (30 mL) was added lithium aluminium hydride (1M in tetrahydrofuran, 28ml, 28.0 mmol, 
2.0 equiv).  The reaction mixture was stirred at room temperature for 6 hours and then cooled to 0 oC in 
an ice bath.  To the cooled mixture was added water (1.1 mL) dropwise, followed by 1 N NaOH (3.3 mL) 
and then water (1.1 mL).  To the resulting slurry was added magnesium sulfate and the mixture was 
warmed to room temperature for 20 minutes.  The mixture was then filtered and the filter cake was 
washed with diethyl ether.  The filtrate was then concentrated in vacuo to yield the title compound as a 
colourless oil (1.46 g, 10.1 mmol, 72%).  The crude material was used in the subsequent condensation 
without further purification. IR max/cm
-1 (film): 3320, 3210 3305 (br), 3210, 2980, 1562, 1409, 1203, 
1142, 987, 857, 831; 1H NMR (500 MHz, CDCl3) δ 3.31 (s, 2H, H-1), 1.64 – 1.26 (m, 10H, H-3, H-4 and 
H-5); 13C NMR (126 MHz, CDCl3) δ 70.3, 52.0, 35.5, 26.1, 21.9.  The physical data were identical in all 
respect to that previously reported.152 
 
 
2,2-Diethyl-3-oxa-1-azaspiro[4.5]decane (183) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (3.13 g, 24.2 mmol, 
1.0 equiv) and 3-pentanone (3.13 g, 36.3 mmol, 1.5 equiv); purification by bulb-to-bulb distillation 
afforded the title compound as a colourless oil (3.44 g, 17.44 mmol, 72%); IR max/cm
-1 (film): 2965, 
2929, 2854, 1450, 1350, 1196, 1055, 920, 815, 759, 668; 1H NMR (500 MHz, CDCl3) δ 3.63 (s, 2H, H-
4), 1.88 – 1.18 (m, 14H, H-2, H-6, H-7 and H-8), 0.91 (t, J = 7.5 Hz, 6H, H-1); 13C NMR (126 MHz, 
CDCl3) δ 98.8, 74.5, 62.0, 38.1, 30.5, 25.4, 24.0, 8.7; m/z HRMS (ESI) found [M+H]
+ 198.1852, 
C12H24NO requires 198.1852. 
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Trinuclear N,O-ketal palladacycle (184) 
            
Resolved NMR spectra were obtained by treating the trinuclear N,O-ketal palladacycle with deuterated 
pyridine (2 drops added to 15 mg of palladacycle in chloroform) to generate the corresponding N,O-ketal 
palladacycle pyridine complex.  IR max/cm
-1 (film): 2971, 2292, 1738, 1566, 1366, 1217, 1045, 661.1H 
NMR (500 MHz, CDCl3) δ 3.63 (s, 2H, H-4), 1.88 – 1.18 (m, 14H, H-2, H-6, H-7 and H-8), 0.91 (t, J = 
7.5 Hz, 6H, H-1).  13C NMR (126 MHz, CDCl3) δ 98.8, 74.5, 62.0, 38.1, 30.5, 25.4, 24.0, 8.7.   
 
 
2,2-Diethyl-4,4-dimethyloxazolidine (191) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (5.60 g, 62.8 mmol, 1.0 
equiv) and 3-pentanone (8.12 g, 94.0 mmol, 1.5 equiv); purification by a silica plug, eluting with 0 to 
50% diethyl ether in petroleum ether afforded the title compound as a colourless oil (4.90 g, 31.2 mmol, 
56%); IR max/cm
-1 (film): 2967, 2939, 2879, 1460, 1381, 1364, 1198, 1056, 999, 918, 825, 757; 1H 
To a solution of 2,2-diethyl-3-oxa-1-azaspiro[4.5]decane 183 (500 mg, 2.54 mmol, 1.0 equiv) in 
chloroform (25 mL) was added palladium(II) acetate (853 mg, 3.81 mmol, 1.5 equiv) and the resulting 
brown solution was stirred at room temperature for 16 hours.  The solution was filtered through a pad of 
Celite®, eluting with chloroform and the solvent was then removed under vacuum.  The residue was 
redissolved in the minimum amount of toluene, and the toluene solution was added dropwise to 50 mL of 
petroleum ether.  A solid crashed out and was filtered off, rinsed with petroleum ether and dried under 
vacuum to afford the palladacycle (1.79 g, 1.82 mmol, 72%) as a green solid.  Crystals were grown by 
slow diffusion of acetone in a chloroform solution of the palladacycle at 0 °C.  X-Ray crystal structure is 
deposited in the Cambridge Crystallographic Data Centre CCDC 997660.    
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NMR (500 MHz, CDCl3) δ 3.58 (s, 2H, H-4), 1.64 (q, 4H, J = 7.5 Hz, H-2), 1.26 (s, 6H, H-6), 0.92 (t, J = 
7.5 Hz, 6H, H-1); 13C NMR (126 MHz, CDCl3) δ 99.7, 76.8, 58.8, 30.4, 28.5, 8.7.  The physical data 
were identical in all respect to that previously reported.153 
 
 
2,2-Diethyl-3-oxa-1-azaspiro[4.5]decane (198a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (4.50 g, 34.9 mmol, 
1.0 equiv) and 2-butanone (3.77 g, 52.2 mmol, 1.5 equiv); purification by bulb-to-bulb distillation 
afforded the title compound as a colourless oil (3.9 g, 21.3 mmol, 61%); IR max/cm
-1 (film): 2972, 2929, 
2854, 1450, 1371, 1283, 1209, 1114, 1086, 866, 810, 748; 1H NMR (500 MHz, CDCl3) δ 3.66 (d, J = 8.3 
Hz, 1H, H-5), 3.58 (d, J = 8.3 Hz, 1H, H-5), 1.73 – 1.40 (m, 10H, H-2, H-7 and H-8), 1.38 – 1.29 (m, 2H, 
H-9), 1.30 (s, 3H, H-4), 0.93 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 96.6, 74.4, 62.2, 
38.1, 37.8, 33.9, 25.9, 25.4, 24.0, 23.9, 9.0; m/z HRMS (ESI) found [M+H]+ 184.1693, C11H21NO 
requires 184.1696. 
 
 
2-Ethyl-2,4,4-trimethyloxazolidine (198b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (4.50 g, 50.5 mmol, 1.0 
equiv) and 2-butanone (5.46 g, 76.0 mmol, 1.5 equiv); purification by a silica plug, eluting with 0 to 50% 
diethyl ether in petroleum ether afforded the title compound as a colourless oil (3.90 g, 27.2 mmol, 54%); 
IR max/cm
-1 (film): 2967, 2931, 1463, 1372, 1201, 1057, 804; 1H NMR (500 MHz, CDCl3) δ 3.61 (d, J = 
8.1 Hz, 1H, H-5), 3.53 (d, J = 8.1 Hz, 1H, H-5), 1.61 (apparent septet, J = 6.3 Hz, 2H, H-2), 1.32 (s, 3H, 
H-4), 1.26 (s, 3H, H-8), 1.23 (s, 3H, H-8), 0.94 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 
97.5, 76.9, 59.1, 34.0, 28.4, 28.1, 25.7, 9.0; m/z HRMS (ESI) found [M+H]+ 144.1380, C8H17NO requires 
144.1383. 
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2-Isopropyl-2-methyl-3-oxa-1-azaspiro[4.5]decane (199a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (2.90 g, 22.5 mmol, 
1.0 equiv) and 3-methylbutan-2-one (2.90 g, 33.7 mmol, 1.5 equiv); purification by bulb-to-bulb 
distillation afforded the title compound as a colourless oil (3.90 g, 19.8 mmol, 88%); IR max/cm
-1 (film): 
2971, 2929, 2853, 1739, 1448, 1366, 1229, 1217, 1055, 891, 860, 806, 784; 1H NMR (500 MHz, CDCl3) 
δ 3.66 (d, J = 8.3 Hz, 1H, H-5), 3.57 (d, J = 8.3 Hz, 1H, H-5), 1.76 (septet, J = 7.0 Hz 1H, H-2), 1.72 – 
1.25 (m, 10H, H-7, H-8 and H-9), 1.22 (s, 3H, H-4), 0.95 (d, J = 7.0 Hz, 3H, H-1), 0.93 (d, J = 7.0 Hz, 
3H, H-1); 13C NMR (126 MHz, CDCl3) δ 98.9, 74.3, 62.1, 38.2, 37.8, 37.8, 25.4, 24.1, 23.9, 22.1, 18.1, 
18.0; m/z HRMS (ESI) found [M+H]+ 198.1851, C12H23NO requires 198.1852. 
 
 
2-Isopropyl-2,4,4-trimethyloxazolidine(199b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (5.00 g, 56.1 mmol, 1.0 
equiv) and 3-methylbutan-2-one (7.25 g, 84.0 mmol, 2.0 equiv); purification by a silica plug, eluting with 
0 to 50% diethyl ether in petroleum ether afforded the title compound as a colourless oil (3.80 g, 24.2 
mmol, 43%); IR max/cm
-1 (film): 2962, 2872, 1466, 1371, 1194, 1056, 907, 856, 789; 1H NMR (500 
MHz, CDCl3) δ 3.62 (d, J = 8.0 Hz, 1H, H-5), 3.51 (d, J = 8.0 Hz, 1H, H-5), 1.82 (septet, J = 6.8 Hz, 1H, 
H-2), 1.27 (s, 3H, H-4), 1.24 (s, 3H, H-8), 1.22 (s, 3H, H-8), 0.96 (d, J = 6.8 Hz, 3H, H-1), 0.94 (d, J = 
6.9 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 99.8, 76.9, 59.0, 37.9, 28.5, 28.2, 21.9, 18.1, 18.0; m/z 
HRMS (ESI) found [M+H]+ 158.1536, C9H19NO requires 158.1539. 
 
 
2-Ethyl-2-propyl-3-oxa-1-azaspiro[4.5]decane (200a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (1.00 g, 7.74 mmol, 
1.0 equiv) and 3-hexanone (1.16 g, 11.6 mmol, 1.5 equiv); purification by flash chromatography on silica 
Experimental 
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gel, eluting with 0 to 10% ethyl acetate in petroleum ether, afforded the title compound as a pale yellow 
oil (533 mg, 2.51 mmol, 33%); Rf (ethyl acetate in petroleum ether, 20%): 0.21; IR max/cm
-1 (film): 
2929, 2854, 1450, 1376, 1251, 1192, 1175, 1055, 947, 930, 899, 817, 739; 1H NMR (500 MHz, CDCl3) δ 
3.61 (d, J = 8.4 Hz, 1H), 3.60 (d, J = 8.4 Hz, 1H), 1.72 – 1.41 (m, 11H, H-2, H-4, H-10, H-11 and H-12), 
1.40 – 1.24 (m, 5H, H-5, H-10 and H-11), 0.91 (t, J = 7.3 Hz, 3H, H-6), 0.88 (t, J = 7.5 Hz, 3H, H-1); 13C 
NMR (126 MHz, CDCl3) δ 98.5, 74.4, 62.0, 40.5, 38.1, 38.1, 31.1, 25.4, 24.0, 24.0, 17.7, 14.5, 8.8; m/z 
HRMS (ESI) found [M+H]+ 212.2007, C13H26NO requires 212.2007. 
 
 
2-Ethyl-2-propyl-3-oxa-1-azaspiro[4.5]decane (200b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (500 mg, 5.61 mmol, 1.0 
equiv) and 3-hexanone (843 mg, 8.41 mmol, 1.5 equiv); purification by a silica plug, eluting with 0 to 
50% diethyl ether in petroleum ether afforded the title compound as a colourless oil (461 mg, 2.69 mmol, 
48%); Rf (ethyl acetate in petroleum ether, 20%): 0.21; IR max/cm
-1 (film): 2936, 2925, 2858, 1428, 
1364, 1198, 1127, 1056, 1001, 918, 825; 1H NMR (400 MHz, CDCl3) δ 3.54 (s, 2H, H-7), 1.67 – 1.48 
(m, 4H, H-2 and H-4), 1.34 (apparent sextet, J = 7.5 Hz, 2H, H-5), 1.23 (s, 3H, H-10), 1.21 (s, 3H, H-10), 
0.91 (t, J = 7.3 Hz, 3H, H-6), 0.89 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (101 MHz, CDCl3) δ 99.8, 77.2, 
59.2, 40.7, 31.4, 28.9, 28.9, 18.1, 14.9, 9.2; m/z HRMS (ESI) found [M+H]+ 172.1625, C10H22NO 
requires 172.1623. 
 
 
2-Cyclohexyl-2-ethyl-3-oxa-1-azaspiro[4.5]decane (201a) 
 
Prepared according to General Procedure B using (1-aminocyclohexyl)methanol 182 (800 mg, 6.19 mmol, 
1.0 equiv) and 1-cyclohexylpropan-1-one (2.87 mL, 18.6 mmol, 3.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil (250 mg, 0.99 mmol, 17%); Rf (ethyl acetate in petroleum ether, 20%): 
0.31; IR max/cm
-1 (film): 2923, 2851, 1450, 1319, 1116, 1058, 951, 891, 825; 1H NMR (500 MHz, 
CDCl3) δ 3.62 (d, J = 8.1 Hz, 1H, H-8), 3.57 (d, J = 8.1 Hz, 1H, H-8), 1.86 – 1.72 (m, 4H, c-hexyl CHs), 
Experimental 
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1.70 – 1.47 (m, 10H, H-4, H-2, c-hexyl CHs), 1.37 – 0.93 (m, 9H, c-hexyl CHs), 0.86 (t, J = 7.5 Hz, 3H, 
H-1); 13C NMR (126 MHz, CDCl3) δ 100.3, 74.8, 61.7, 44.2, 38.4, 38.0, 28.4, 27.8, 27.5, 26.8, 26.7, 26.5, 
25.4, 24.2, 24.0, 8.3; m/z HRMS (ESI) found [M+H]+ 252.2324, C16H30NO requires 252.2322. 
 
 
2-Cyclohexyl-2-ethyl-4,4-dimethyloxazolidine (201b) 
 
Prepared according to General Procedure B using 2-amino-2-methylpropan-1-ol (1.0 g, 11.2 mmol, 1.0 
equiv) and 1-cyclohexylpropan-1-one (5.19 mL, 33.7 mmol, 3.0 equiv): purification by flash 
chromatography on silica gel, eluting with 0 to 30% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil (261 mg, 1.23 mmol, 11%); Rf (ethyl acetate in petroleum ether, 20%): 
0.21; IR max/cm
-1 (film): 2963, 2924, 2852, 1975 1451, 1381, 1364, 1191, 1057, 890, 826, 757, 672; 1H 
NMR (500 MHz, CDCl3) δ 3.59 (d, J = 7.9 Hz, 1H, H-8), 3.52 (d, J = 7.9 Hz, 1H, H-8), 1.90 – 1.73 (m, 
4H, H-5 and H-6), 1.73 – 1.57 (m, 4H, H-2, H-4 and H-6), 1.26 (s, 3H, H-11), 1.24 (s, 3H, H-11), 1.23 – 
1.09 (m, 3H, H-5 and H-6), 1.02 (apparent pentet, J = 7.2 Hz, 2H, H-7), 0.88 (t, J = 7.5 Hz, 3H, H-1); 13C 
NMR (126 MHz, CDCl3) δ 101.3, 77.0, 58.6, 44.2, 28.9, 28.6, 28.4, 27.8, 27.4, 26.8, 26.6, 26.5, 8.3; m/z 
HRMS (ESI) found [M+H]+ 212.2010, C11H18NO2 requires 212.2009. 
 
 
2-(Tert-butyl)-3-oxa-1-azaspiro[4.5]decane (202a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (1.20 g, 9.30 mmol, 
1.0 equiv) and trimethylacetaldehyde (1.20 g, 14.0 mmol, 1.5 equiv); purification by bulb-to-bulb 
distillation afforded the title compound as a colourless oil (1.39 g, 7.07 mmol, 76%); IR max/cm
-1 (film): 
2971, 2929, 2855, 1739, 1481, 1449, 1366, 1229, 1217, 1110, 1033, 910, 820, 663; 1H NMR (500 MHz, 
CDCl3) δ 4.21 (s, 1H, H-3), 3.61 (d, J = 7.7 Hz, 1H, H-4), 3.27 (d, J = 7.7 Hz, 1H, H-4), 1.98 – 1.13 (m, 
10H, H-6, H-7 and H-8), 0.92 (s, 9H, H-1); 13C NMR (126 MHz, CDCl3) δ 97.6, 75.0, 62.0, 36.7, 35.0, 
33.4, 25.7, 25.2, 24.2, 23.0; m/z HRMS (ESI) ) found [M+H]+ 198.1850, C12H23NO requires 198.1852. 
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6-Chlorohexan-3-one (210) 
 
To a solution of 4-chlorobutanoyl chloride (5.00 g, 35.5 mmol, 1.0 equiv) in dry tetrahydrofuran (120 
mL) at 0 ºC was added ethyl magnesium bromide (1 M in tetrahydrofuran; 35.5 mL, 35.5 mmol, 1.0 
equiv) dropwise.  The reaction mixture was slowly warmed to room temperature and stirred for 4 hours 
and then slowly quenched with saturated ammonium chloride.  The layers were separated and the aqueous 
layer was extracted with ethyl acetate.  The combined organic extracts were washed with brine, dried and 
concentrated in vacuo to afford the title compound as a yellow oil (4.1 g, 30.5 mmol, 86%) which was 
used in the next step without further purification; IR max/cm
-1 (film): 2970, 1819, 1710, 1412, 1376, 
1309, 1115, 1036, 979, 867, 787, 729; 1H NMR (400 MHz, CDCl3) δ 3.57 (t, J = 6.3 Hz, 1H), 2.61 (t, J = 
7.0 Hz, 2H, H-6), 2.45 (q, J = 7.3 Hz, 2H, H-2), 2.12 – 1.99 (m, 2H, H-5), 1.07 (t, J = 7.3 Hz, 3H, H-1); 
13C NMR (101 MHz, CDCl3) δ 210.3, 44.5, 38.8, 36.0, 26.3, 7.8.  The physical data were identical in all 
respect to that previously reported.154 
 
 
2-(4-Oxohexyl)isoindoline-1,3-dione (211) 
 
To a solution of 6-chlohexan-3-one 210 (4.1 g, 30.5 mmol, 1.0 equiv) in N,N-dimethylformamide (61 
mL) was added potassium phthalimide (6.77 g, 36.6 mmol, 1.2 equiv).  The reaction mixture was stirred 
at room temperature for 8 hours.  The reaction mixture was partitioned between diethyl ether (60 mL) and 
water (40 mL).  The aqueous layer was extracted with diethyl ether.  The combined organic extracts were 
washed with water, dried and concentrated in vacuo.  The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, affording the title 
compound as a yellow oil (4.1 g, 16.7 mmol, 55%); Rf (ethyl acetate in petroleum ether, 25%): 0.38; IR 
max/cm
-1 (film):  2939, 1772, 1705, 1467, 1438, 1395, 1362, 1188, 1112, 1055, 1000, 888, 795, 719; 1H 
NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 5.4, 3.0 Hz, 2H, H-9), 7.70 (dd, J = 5.4, 3.0 Hz, 2H, H-10), 3.70 
(t, J = 6.9 Hz, 2H, H-6), 2.46 (t, J = 7.2 Hz, 2H, H-4), 2.41 (q, J = 7.3 Hz, 2H, H-2), 1.96 (quint, J = 6.9 
Hz, 2H, H-5), 1.02 (t, J = 7.3 Hz, 3H, H-1); 13C NMR (101 MHz, CDCl3) δ 210.1, 168.4, 133.9, 132.1, 
123.2, 39.2, 37.3, 35.9, 22.7, 7.8; m/z HRMS (ESI) found [M+H]+ 246.1125, C14H16NO3 requires 
246.1125. 
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2-{3-(2-Ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propyl}isoindoline-1,3-dione (231a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 183 (316 mg, 2.45 mmol, 
1.2 equiv) and 2-(4-oxohexyl)isoindoline-1,3-dione 211 (500 mg, 2.04 mmol, 1.0 equiv); purification by 
flash chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, afforded the 
title compound as a colourless oil (356 mg, 1.00 mmol, 49%); Rf (ethyl acetate in petroleum ether, 25%): 
0.36  IR max/cm
-1 (film): 2975, 2932, 1776, 1707, 1463, 1401, 1370, 1062, 885, 721; 1H NMR (500 
MHz, CDCl3) δ 7.84 (dd, J = 5.4, 3.0 Hz, 2H, H-9), 7.70 (dd, J = 5.4, 3.0 Hz, 2H, H-10), 3.72 (apparent t, 
J = 6.8 Hz, 2H, H-6), 3.61 (d, J = 8.2 Hz, 1H, H-11), 3.57 (d, J = 8.2 Hz, 1H, H-11), 1.83 – 1.67 (m, 2H, 
H-2 and H-5), 1.67 – 1.37 (m, 11H, H-2, H-4, H-5, H-14 and H-15), 1.36 – 1.23 (m, 3H, H-15 and H-16), 
0.87 (t, J = 7.5 Hz, 3H); 13C NMR (126 MHz, CDCl3) δ 168.4(x2), 133.9, 132.1, 123.2, 98.1, 74.7, 62.0, 
38.2, 38.2, 38.0, 35.2, 31.1, 25.4, 24.0, 23.9, 23.8, 8.6; m/z HRMS (ESI) found [M+H]+ 357.2172, 
C21H29N2O3 requires 357.2173. 
 
 
2-{3-(2-Ethyl-4,4-dimethyloxazolidin-2-yl)propyl}isoindoline-1,3-dione (231b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (273 mg, 3.06 mmol, 1.5 
equiv) and 2-(4-oxohexyl)isoindoline-1,3-dione 211 (500 mg, 2.04 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil (380 mg, 1.20 mmol, 59%); Rf (ethyl acetate in petroleum ether, 25%): 
0.28; IR max/cm
-1 (film): 2966, 2769, 1709, 1617, 1396, 1361, 1260, 1189, 1056, 913, 796, 720; 1H 
NMR (500 MHz, CDCl3) δ 7.84 (dd, J = 5.4, 3.0 Hz, 2H, H-9), 7.71 (dd, J = 5.4, 3.0 Hz, 2H, H-10), 3.71 
(t, J = 6.5 Hz, 2H, H-6), 3.57 (d, J = 8.1 Hz, 1H, H-11), 3.53 (d, J = 8.1 Hz, 1H, H-11), 1.80 – 1.71 (m, 
2H, H-5), 1.68 – 1.56 (m, 4H, H-4 and H-2), 1.23 (s, 3H, H-14), 1.23 (s, 3H, H-14), 0.88 (t, J = 7.5 Hz, 
3H, H-1); 13C NMR (126 MHz, CDCl3) δ 168.4, 133.9, 132.1, 123.2, 99.0, 76.8, 58.9, 38.2, 35.1, 30.9, 
28.5, 28.4, 23.8, 8.7; m/z HRMS (ESI) found [M+H]+ 317.1863, C18H25N2O3 requires 317.1865. 
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2-(Benzyloxy)-N-methoxy-N-methylacetamide (213) 
 
To a solution of 2-(benzyloxy)acetic acid (2.00 g, 12.04 mmol, 1.0 equiv) and triethylamine (3.69 mL, 
26.5 mmol, 2.2 equiv) in dry dichloromethane (32 mL) was added N,N-carbonyl diimidazole (2.54 g, 15.7 
mmol, 1.3 equiv).  The reaction mixture was stirred at room temperature for 2 hours, followed by addition 
of N,O-dimethylhydroxylamine hydrochloride (1.41 g, 14.4 mmol).  The reaction mixture was stirred at 
this temperature for another 4 hours.  Saturated ammonium chloride was added to the mixture and the 
layers separated.  The aqueous layer was extracted with dichloromethane.  The combined organic extracts 
were washed with brine, dried and concentrated in vacuo.  The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, affording the title 
compound as a yellow oil (2.20 g, 10.5 mmol, 87%); Rf (ethyl acetate in petroleum ether, 20%): 0.28; IR 
max/cm
-1 (film):. 2938, 2899, 1676, 1454, 1392, 1328, 1177, 1138, 1086, 991, 916, 739, 699; 1H NMR 
(500 MHz, CDCl3) δ 7.53 – 7.27 (m, 5H, Ar-H), 4.67 (s, 2H, H-5), 4.28 (s, 2H, H-6), 3.63 (s, 3H, H-8), 
3.19 (s, 3H, H-9); 13C NMR (126 MHz, CDCl3) δ 171.0, 137.5, 128.4, 128.1, 127.8, 73.3, 67.1, 61.4, 
32.3.  The physical data were identical in all respect to that previously reported.155   
 
 
1-(Benzyloxy)butan-2-one (214) 
 
To a solution of 2-(benzyloxy)-N-methoxy-N-methylacetamide 213 (2.20 g, 10.5 mmol, 1.0 equiv) in dry 
tetrahydrofuran (60 mL) at 0 ºC was added ethyl magnesium bromide (1 M in tetrahydrofuran; 26.3 mL, 
26.3 mmol, 2.5 equiv) dropwise.  The reaction mixture was slowly warmed to room temperature and 
stirred for 4 hours and then slowly quenched with saturated ammonium chloride.  The layers were 
separated and the aqueous layer was extracted with ethyl acetate.  The combined organic extracts were 
washed with brine, dried and concentrated in vacuo to afford the title compound as a yellow oil (1.6 g, 
9.00 mmol, 85%) which was used in the next step without further purification; IR max/cm
-1 (film): 2977, 
2881, 1717, 1455, 1340, 1103, 1028, 96, 737, 697; 1H NMR (500 MHz, CDCl3) δ 7.42 – 7.28 (m, 5H, 
Ar-H), 4.59 (s, 2H, H-5), 4.07 (s, 2H, H-4), 2.50 (q, J = 7.3 Hz, 2H, H-2), 1.07 (t, J = 7.3 Hz, 3H, H-1); 
13C NMR (126 MHz, CDCl3) δ 209.37, 137.25, 128.52, 128.00, 127.88, 74.80, 73.36, 32.27, 7.22.  The 
physical data were identical in all respect to that previously reported.156 
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2-((Benzyloxy)methyl)-2-ethyl-3-oxa-1-azaspiro[4.5]decane (232a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (435 mg, 3.37 mmol, 
1.2 equiv) and 1-(benzyloxy)butan-2-one 214 (2.87 mL, 18.6 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 10% ethyl acetate in petroleum ether, afforded the title 
compound as a pale yellow oil (530 mg, 1.83 mmol, 65%); Rf (ethyl acetate in petroleum ether, 20%): 
0.28; IR max/cm
-1 (film): 2968, 2869, 1454, 1382, 1363, 1253, 1201, 1099, 1055, 914, 824, 734, 697; 1H 
NMR (500 MHz, CDCl3) δ 7.36 – 7.31 (m, 4H, Ar-H), 7.30 – 7.25 (m, 1H, Ar-H), 4.61 (d, J = 12.2 Hz, 
1H, H-5), 4.58 (d, J = 12.2 Hz, 1H, H-5), 3.65 (d, J = 8.1 Hz, 1H, H-10), 3.62 (d, J = 8.1 Hz, 1H, H-10), 
3.43 (d, J = 10.1 Hz, 1H, H-4), 3.38 (d, J = 10.1 Hz, 1H, H-4), 1.70 (q, J = 7.5 Hz, 2H, H-2), 1.68 – 1.26 
(m, 10H, H-13, H-14 and H-15), 0.88 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 138.3, 
128.3, 127.6, 127.5, 97.6, 75.2, 73.4, 73.0, 62.1, 37.7, 37.6, 30.3, 28.4, 25.5, 23.9, 8.5; m/z HRMS (ESI) 
found [M+H]+ 290.2113, C18H28NO2 requires 290.2115. 
 
 
2-{(Benzyloxy)methyl}-2-ethyl-4,4-dimethyloxazolidine (232b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (1.50 g, 16.8 mmol, 1.5 
equiv) and 1-(benzyloxy)butan-2-one 214 (2.00 g, 11.2 mmol, 1.0 equiv): purification by flash 
chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, afforded the title 
compound as a pale yellow oil (1.00 g, 4.01 mmol, 36%); Rf (ethyl acetate in petroleum ether, 20%): 
0.35; IR max/cm
-1 (film): 2968, 2869, 1454, 1382, 1363, 1253, 1201, 1099, 1055, 914, 824, 734, 697; 1H 
NMR (500 MHz, CDCl3) δ 7.37 – 7.26 (m, 5H, Ar-H), 4.62 (d, J = 12.2 Hz, 1H, H-5), 4.57 (d, J = 12.2 
Hz, 1H, H-5), 3.60 (d, J = 7.8 Hz, 1H, H-10), 3.58 (d, J = 7.8 Hz, 1H, H-10), 3.45 (d, J = 10.1 Hz, 1H, H-
4), 3.42 (d, J = 10.1 Hz, 1H, H-4), 1.72 (qd, J = 7.5, 1.4 Hz, 2H, H-2), 1.25 (s, 3H, H-13), 1.23 (s, 3H, H-
13), 0.89 (t, J = 7.6 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 138.3, 128.3, 127.6, 127.5, 98.4, 77.5, 
73.4, 72.9, 59.0, 30.4, 28.3, 27.8, 8.6; m/z HRMS (ESI) found [M+H]+ 250.1796, C15H23NO2 requires 
250.1801. 
 
Experimental 
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N-Methoxy-N-methyl-4-(1-tosylpiperidin-4-yl)butanamide (216) 
 
To a solution of 4-(piperidin-4-yl)butanoic acid hydrochloride (5.00 g, 24.1 mmol, 1.0 equiv) in 
acetonitrile (100 mL) was added triethylamine (13.4 mL, 96.4 mmol, 4.0 equiv) and para-toluenesulfonyl 
chloride (6.9 g, 36.3 mmol, 1.5 equiv).  The reaction mixture was stirred at room temperature for 16 
hours.  Solvent was removed under reduced pressure and partitioned between 3 N HCl and ethyl acetate.  
The aqueous layer was extracted with ethyl acetate.  The combined organic extracts were washed with 
brine, dried and concentrated in vacuo to yield 4.1 g of the crude acid which was taken on crude for the 
next step. 
 
To a solution of the crude acid (4.1 g, 12.6 mmol, 1.0 equiv) and triethylamine (3.52 mL, 25.2 mmol, 2.0 
equiv) in dry dichloromethane (70 mL) was added N,N-carbonyl diimidazole (2.04 g, 12.6 mmol, 1.0 
equiv).  The reaction mixture was stirred at room temperature for 2 hours, followed by addition of N,O-
dimethylhydroxylamine hydrochloride (1.84 g, 18.9 mmol, 1.5 equiv).  The reaction mixture was stirred 
at this temperature for another 4 hours.  Saturated ammonium chloride was added to the mixture and 
layers separated.  The aqueous layer was extracted with dichloromethane.  The combined organic extracts 
were washed with brine, dried and concentrated in vacuo. The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 50% ethyl acetate in petroleum ether, affording the title 
compound as a yellow solid (2.20 g, 10.5 mmol, 44% over 2 steps); M.p.: 117–119 ºC; Rf (ethyl acetate 
in petroleum ether, 50%): 0.39; IR max/cm
-1 (film): 2935, 1663, 1417, 1385, 1334, 1306, 1248, 1157, 
1095, 1048, 989, 928, 854, 817, 724; 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.3 Hz, 2H, H-11), 7.31 
(d, J = 7.9 Hz, 2H, H-12), 3.75 (d, J = 11.7 Hz, 2H, H-9), 3.65 (s, 3H, H-2), 3.15 (s, 3H, H-1), 2.43 (s, 
3H, H-14), 2.37 (t, J = 7.4 Hz, 2H, H-4), 2.20 (td, J = 11.8, 2.4 Hz, 2H, H-9), 1.73 (dd, J = 12.8, 1.9 Hz, 
2H, H-8), 1.66 – 1.51 (m, 2H, H-5), 1.40 – 1.21 (m, 4H, H-6 and H-8), 1.19 – 1.05 (m, 1H, H-7); 13C 
NMR (126 MHz, CDCl3) δ 174.4, 143.3, 133.2, 129.5, 127.7, 61.2, 46.4, 35.8, 35.1, 32.1, 31.8, 31.5, 
21.7, 21.5; m/z HRMS (ESI) found [M+H]+ 369.1848, C18H29N2O4S requires 369.1843. 
 
 
 
 
 
 
 
Experimental 
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6-(1-Tosylpiperidin-4-yl)hexan-3-one (217) 
 
To a solution of N-methoxy-N-methyl-4-(1-tosylpiperidin-4-yl)butanamide 216 (1.60 g, 4.35 mmol, 
1.0 equiv) in dry tetrahydrofuran (40 mL) at 0 ºC was added ethyl magnesium bromide (1 M in 
tetrahydrofuran; 8.7 mL, 8.70 mmol, 2.0 equiv) dropwise.  The reaction mixture was slowly warmed to 
room temperature and stirred for 2 hours and then slowly quenched with saturated ammonium chloride.  
The layers were separated and the aqueous layer was extracted with diethyl ether.  The combined organic 
extracts were washed with brine, dried and concentrated in vacuo.  The crude product was purified by 
flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, affording the 
title compound as a white solid (1.1 g, 3.26 mmol, 79%); M.p.: 81–83 ºC; Rf (ethyl acetate in petroleum 
ether, 20%): 0.30; IR max/cm
-1 (film): 2922, 2852, 1714, 1597, 1465, 1338, 1305, 1247, 1161, 1108, 
1087, 1046, 975, 928, 849, 814, 728; 1H NMR (500 MHz, CDCl3) δ 7.63 (d, J = 8.3 Hz, 2H, H-11), 7.31 
(dd, J = 8.3 Hz, 2H, H-12), 3.75 (d, J = 11.6 Hz, 2H, H-9), 2.43 (s, 3H, H-14), 2.38 (q, J = 7.3 Hz, 2H, H-
2), 2.35 (t, J = 7.3 Hz, 2H, H-4), 2.19 (td, J = 11.8, 2.4 Hz, 2H, H-9), 1.71 (ddd, J = 14.3, 11.8, 3.1 Hz, 
2H, H-8), 1.57 – 1.48 (m, 2H, H-5), 1.27 (ddd, J = 14.3, 12.4, 4.0 Hz, 2H, H-8), 1.21 – 1.08 (m, 3H, H-6 
and H-7), 1.03 (t, J = 7.3 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 211.5, 143.3, 133.2, 129.5, 127.7, 
46.4, 42.3, 35.9, 35.6, 35.1, 31.4, 21.5, 20.9, 7.8; m/z HRMS (ESI) found [M+H]+ 338.1787, C18H28NO3S 
requires 338.1789. 
 
 
2-Ethyl-2-(3-[1-tosylpiperidin-4-yl]propyl)-3-oxa-1-azaspiro[4.5]decane (233a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (138 mg, 1.07 mmol, 
1.2 equiv) and 6-(1-tosylpiperidin-4-yl)hexan-3-one 217 (300 mg, 0.89 mmol, 1.0 equiv); purification by 
flash chromatography on silica gel, eluting with 0 to 30% ethyl acetate in petroleum ether, afforded the 
title compound as a pale yellow oil (232 mg, 0.52 mmol, 59%); Rf (ethyl acetate in petroleum ether, 
50%): 0.43; IR max/cm
-1 (film): 2925, 2850, 1598, 1449, 1339, 1251, 1163, 1094, 1049, 931, 815, 724; 
1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.2 Hz, 2H, H-11), 7.31 (d, J = 8.2 Hz, 2H, H-12), 3.75 (d, J = 
11.6 Hz, 2H, H-9), 3.60 (d, J = 8.3 Hz, 1H, H-15), 3.57 (d, J = 8.3 Hz, 1H, H-15), 2.43 (s, 3H, H-14), 
2.28 – 2.13 (m, 2H, H-9), 1.77 – 1.40 (m, 12H, H-2, H-3, H-8, H-18 and H-19), 1.39 – 1.11 (m, 11H, H-5, 
Experimental 
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H-6, H-7, H-8, H-18 and H-19), 0.86 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 143.3, 
133.2, 129.5, 127.7, 98.4, 74.5, 62.0, 46.5, 38.2, 38.2, 38.1, 36.4, 35.1, 31.5, 31.5, 31.0, 25.4, 24.0, 21.5, 
21.5, 8.7. m/z HRMS (ESI) found [M+H]+ 449.2822, C25H41N2O3S requires 449.2819. 
 
 
2-Ethyl-4,4-dimethyl-2-(3-[1-tosylpiperidin-4-yl]propyl)oxazolidine (233b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (119 mg, 1.34 mmol, 1.5 
equiv) and 6-(1-tosylpiperidin-4-yl)hexan-3-one 217 (300 mg, 0.89 mmol, 1.0 equiv); purification by 
flash chromatography on silica gel, eluting with 0 to 40% ethyl acetate in petroleum ether, afforded the 
title compound as a pale yellow oil (260 mg, 0.63 mmol, 72%); Rf (ethyl acetate in petroleum ether, 
50%): 0.33; IR max/cm
-1 (film): 2935, 2848, 1598, 1461, 1339, 1163, 1094, 1050, 931, 816, 725; 1H 
NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.2 Hz, 2H, H-11), 7.31 (d, J = 8.1 Hz, 2H, H-12), 3.75 (d, J = 
11.6 Hz, 2H, H-9), 3.55 (d, J = 8.1 Hz, 1H, H-15), 3.52 (d, J = 8.1 Hz, 1H, H-15), 2.43 (s, 3H, H-14), 
2.19 (d, J = 11.6, 2H, H-9), 1.71 (d, J = 10.8 Hz, 2H, H-8), 1.64 – 1.47 (m, 4H, H-2 and H-4), 1.36 – 1.05 
(m, 7H, H-5, H-6, H-7 and H-8), 1.23 (s, 3H, H-18), 1.22 (s, 3H, H-18), 0.87 (t, J = 7.5 Hz, 3H).; 13C 
NMR (126 MHz, CDCl3) δ 143.3, 133.2, 129.5, 127.7, 99.3, 76.7, 58.8, 46.5, 38.1, 36.4, 35.2, 31.5, 30.8, 
28.6, 28.4, 21.5, 21.5, 8.8; m/z HRMS (ESI) found [M+H]+ 409.2512, C22H37N2O3S requires 409.2514. 
 
 
2-(2-Ethyl-1,3-dithian-2-yl)propan-2-ol (219) 
 
To a solution of 2-ethyl-1,3-dithiane (2.92 mL, 20.2 mmol, 1.0 equiv) in dry tetrahydrofuran (50 mL) at -
78 ºC was added n-butyllithium (1.6 M in hexane; 15.1 mL, 24.2 mmol, 1.2 equiv) and stirred at this 
temperature for 15 mins.  Acetone (2.93 mL, 40.4 mL, 2.0 equiv) was added and the reaction mixture was 
warmed to room temperature and stirred for 16 hours.  The reaction mixture was quenched with saturated 
ammonium chloride and layers separated.  The aqueous layer was extracted with diethyl ether.  The 
combined organic extracts were washed with brine, dried and concentrated in vacuo.  The crude product 
was purified by flash chromatography on silica gel, eluting with 0 to 5% ethyl acetate in petroleum ether, 
affording the title compound as a colourless oil (3.2 g, 15.5 mmol, 76%); Rf (ethyl acetate in petroleum 
ether, 10%): 0.33; IR max/cm
-1 (film): 3463 (br), 2978, 2932, 1452, 1365, 1278, 1240, 1177, 1131, 998, 
Experimental 
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959, 907, 861, 816, 798; 1H NMR (400 MHz, CDCl3) δ 2.99 – 2.87 (m, 2H, H-7), 2.86 – 2.73 (m, 2H, H-
7), 2.52 (s, 1H, OH), 2.01 – 1.86 (m, 4H, H-2 and H-8), 1.41 (s, 6H, H-5), 1.18 (t, J = 7.3 Hz, 3H, H-1); 
13C NMR (101 MHz, CDCl3) δ 78.8, 64.7, 30.8, 27.1, 26.2, 23.6, 11.3; m/z HRMS (ESI) found 
[M+NH4]
+ 224.1132, C9H22NOS2 requires 224.1129. 
 
 
2-Hydroxy-2-methylpentan-3-one (220) 
 
To a solution of 2-(2-Ethyl-1,3-dithian-2-yl)propan-2-ol 219 (500 mg, 2.43 mmol, 1.0 equiv) in 
dichloromethane (6 mL) was added water (0.09 mL) and bismuth(III) nitrate pentahydrate (588 mg, 1.21 
mmol, 1.2 equiv). [Caution: slight exotherm detected.] The reaction was vigorously stirred at room 
temperature for 4 hours.  The solvent was removed under reduced pressure and the crude product was 
purified by bulb-to-bulb distillation, affording the title compound as a colourless oil (210 mg, 1.81 mmol, 
74%).  IR max/cm
-1 (film): 3469 (br), 2925, 2855, 1718, 1458, 1230, 1090, 968, 863, 735; 1H NMR (400 
MHz, CDCl3) δ 2.60 (q, J = 7.3 Hz, 2H, H-2), 2.42 (s, 1H, OH), 1.41 (s, 6H, H-5), 1.14 (t, J = 7.3 Hz, 3H, 
H-1).  13C NMR (400 MHz, CDCl3) δ 215.0, 28.7, 26.6, 26.4, 7.9.  The physical data were identical in all 
respect to that previously reported.157 
 
 
2-(2-Ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propan-2-ol (235a) 
 
Prepared according to General Procedure B using (1-aminocyclohexyl)methanol 182 (500 mg, 10.7 mmol, 
1.0 equiv) and 3-hydroxy-3-methylbutan-2-one 220 (3 mL, 28.5 mmol, 2.7 equiv); purification by 
flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, afforded the 
title compound as a pale brown oil (175 mg, 0.77 mmol, 7%); Rf (ethyl acetate in petroleum ether, 20%): 
0.23; IR max/cm
-1 (film): 3469 (br), 2928, 2855, 1450, 1367, 1164, 1049, 946, 843, 703; 1H NMR (500 
MHz, CDCl3) δ 3.76 (d, J = 8.1 Hz, 1H, H-6), 3.69 (d, J = 8.1 Hz, 1H, H-6), 1.77 – 1.50 (m, 8H, H-2, H-
9, H-10), 1.47 – 1.29 (m, 4H, H-10 and H-11), 1.27 (s, 3H, H-5), 1.17 (s, 3H, H-5), 0.97 (t, J = 7.6 Hz, 
3H, H-1); 13C NMR (126 MHz, CDCl3) δ 102.0, 74.3, 61.9, 38.4, 37.9, 28.6, 26.4, 26.1, 25.3, 24.6, 24.1, 
24.0, 9.6; m/z HRMS (ESI) found [M+H]+ 228.1956, C13H26NO2 requires 228.1958. 
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Methyl 4-nitrohexanoate (222) 
 
To a solution of methyl acrylate (6.65 g, 77.0 mmol, 5.1 equiv) in 1 N sodium hydroxide (31 mL) was 
added 1-nitropropane (15.2g, 15.2 mmol, 1.0 equiv).  The reaction mixture was stirred at RT for 20 hours.  
Brine was added to the mixture and extracted with diethyl ether.  The combined organic extracts were 
dried and concentrated in vacuo.  The crude product was purified by bulb-to-bulb distillation, affording 
the title compound as a colourless oil (8.50 g, 48.5 mmol, 63%); IR max/cm
-1 (film): 2943, 2157, 1736, 
1546, 1438, 1369, 1326, 1254, 1201, 1174, 993, 864, 815; 1H NMR (500 MHz, CDCl3) δ 4.54 – 4.41 (m, 
1H, H-3), 3.68 (s, 3H, H-7), 2.44 – 2.26 (m, 2H, H-5), 2.26 – 2.15 (m, 1H, H-4), 2.14 – 2.04 (m, 1H, H-
4), 2.03 – 1.91 (m, 1H, H-2), 1.87 – 1.74 (m, 1H, H-2), 0.96 (t, J = 7.4 Hz, 3H, H-1); 13C NMR (101 
MHz, CDCl3) δ 172.4, 89.1, 51.9, 29.9, 28.3, 27.2, 10.1; The physical data were identical in all respect to 
that previously reported.158 
 
 
Methyl 4-oxohexanoate (223) 
 
To a solution of methyl 4-nitrohexanoate 222 (1.00 g, 5.71 mmol, 1.0 equiv) in acetonitrile (23 mL) was 
added 1,8-diazabicycloundec-7-ene (1.72 mL, 11.4 mmol, 2.0 equiv).  The resulting mixture was heated 
at 60 ºC for 72 hours.  The reaction mixture was cooled and partitioned between 3 N HCl and diethyl 
ether.  The aqueous layer was extracted with diethyl ether.  The combined organic extracts were washed 
with brine, dried and concentrated in vacuo.  The crude product was purified by flash chromatography on 
silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, affording the title compound as a yellow 
oil (200 mg, 1.39 mmol, 24%); Rf (ethyl acetate in petroleum ether, 20%): 0.31; IR max/cm
-1 (film): 
1915, 1736, 1714, 1550, 1438, 1359, 1263, 1206, 1170, 1115, 842, 785; 1H NMR (500 MHz, CDCl3) δ 
3.67 (s, 3H, H-7), 2.72 (t, J = 6.5 Hz, 2H, H-4), 2.59 (t, J = 6.6 Hz, 2H, H-5), 2.48 (q, J = 7.3 Hz, 2H, H-
2), 1.07 (t, J = 7.3 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 209.4, 173.3, 51.8, 36.6, 35.9, 27.8, 7.8.  
The physical data were identical in all respect to that previously reported.159 
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Methyl 3-(2-ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propanoate (234a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (161 mg, 1.25 mmol, 
1.2 equiv) and methyl 4-oxohexanoate 223 (150 mg, 1.04 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 10% ethyl acetate in petroleum ether, afforded the title 
compound as a pale yellow oil (102 mg, 0.40 mmol, 38%); Rf (ethyl acetate in petroleum ether, 20%): 
0.24; IR max/cm
-1 (film): 2929, 2859, 1737, 1437, 1258, 1168, 1101, 1053, 923, 815, 715; 1H NMR (500 
MHz, CDCl3) δ 3.67 (s, 3H, H-7), 3.63 (d, J = 8.3 Hz, 1H, H-8), 3.59 (d, J = 8.3 Hz, 1H, H-8), 2.41 – 
2.33 (m, 2H, H-5), 1.96 – 1.88 (m, 2H, H-4), 1.70 – 1.27 (m, 12H, H-2, H-11, H-12 and H-13), 0.91 (t, J 
= 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 174.3, 97.6, 74.8, 62.0, 51.6, 38.1, 38.1, 32.9, 31.1, 
29.7, 25.4, 24.0, 23.8, 8.5; m/z HRMS (ESI) found [M+H]+ 256.1910, C14H26NO3 requires 256.1907. 
 
 
Methyl 3-(2-ethyl-4,4-dimethyloxazolidin-2-yl)propanoate (234b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (185 mg, 2.08 mmol, 1.5 
equiv) and methyl 4-oxohexanoate 223 (200 mg, 1.39 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 40% ethyl acetate in petroleum ether, afforded the title 
compound as a pale yellow oil (102 mg, 0.47 mmol, 34%); Rf (ethyl acetate in petroleum ether, 25%): 
0.21; IR max/cm
-1 (film): 2964, 2866, 1736, 1437, 1365, 1258, 1195, 1167, 1053, 992, 904, 834; 1H 
NMR (500 MHz, CDCl3) δ 3.67 (s, 3H, H-7), 3.59 (d, J = 8.1 Hz, 1H, H-8), 3.54 (d, J = 8.1 Hz, 1H, H-
8), 2.42 – 2.33 (m, 2H, H-5), 2.00 – 1.87 (m, 2H, H-4), 1.65 – 1.55 (q, J = 7.5 Hz, 2H, H-2), 1.25 (s, 3H, 
H-11), 1.24 (s, 3H, H-11), 0.92 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 174.3, 98.5, 
76.8, 58.9, 51.6, 32.7, 31.0, 29.7, 28.5, 28.5, 8.6; m/z HRMS (ESI) found [M+H]+ 216.1593, 
C11H22NO3 requires 216.1594. 
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(E)-2-(Butan-2-ylidene)-1,1-dimethylhydrazine (225) 
 
To a solution of butanone (10.0 mL, 112 mmol, 1.0 equiv) in ethanol (30 mL) was added N,N-
dimethylhydrazine (10 mL, 132 mmol, 1.2 equiv).  The reaction mixture was heated at reflux for 8 hours 
and cooled to room temperature.  The reaction was concentrated in vacuo.  The crude product was 
purified by distillation to yield the title compound (as a mixture of isomers) as a colourless oil (12.1 g, 
106 mmol, 95%); IR max/cm
-1 (film):  2974, 2951, 2854, 2817, 1638, 1466, 1359, 1196, 1155, 1074, 
1022, 975, 947, 848, 731; 1H NMR (400 MHz, CDCl3) δ 2.47 (q, J = 7.7 Hz, 2H, H-3; minor), 2.44 (s, 
6H, H-5; major), 2.42 (s, 6H, H-5; minor), 2.22 (q, J = 7.6 Hz, 2H, H-3; major), 1.95 (s, 3H, H-1; major), 
1.92 (s, 3H, H-1; minor), 1.10 (t, J = 7.7 Hz, 3H, H-4; minor), 1.09 (t, J = 7.6 Hz, 3H, H-4; major); 13C 
NMR (101 MHz, CDCl3) δ 170.8 (minor), 169.2 (major), 48.0 (minor), 47.4 (major), 32.6 (major), 24.9 
(minor), 22.5 (minor), 16.4 (major), 11.9 (major), 11.4 (minor).  The physical data were identical in all 
aspect to that previously reported.160 
 
 
(E)-6-Bromohex-2-ene (227) 
 
To a solution of (E)-hex-4-en-1-ol (5.00 g, 50.0 mmol, 1.0 equiv) and pyridine (0.50 mL) in dry diethyl 
ether (50 mL) at 0 ºC was added phosphorous tribromide (1.83 mL, 19.3 mmol, 0.4 equiv).  The reaction 
mixture was warmed to room temperature and stirred for 3 hours.  The reaction was quenched with 
saturated ammonium chloride and layers separated.  The organic layer was washed with brine, dried and 
concentrated in vacuo to yield the title compound as a pale brown oil (3.08 g, 19.0 mmol, 76%) which 
was used in the next step without further purification; IR max/cm
-1 (film): 2920, 2851, 1739, 1464, 1375, 
1242, 1017, 803; 1H NMR (400 MHz, CDCl3) δ 5.59 – 5.42 (m, 1H, H-2), 5.42 – 5.30 (m, 1H, H-3), 3.40 
(t, J = 6.8 Hz, 2H, H-6), 2.17 – 2.09 (m, 2H, H-4), 1.90 (quint, J = 7.0 Hz, 2H, H-5), 1.65 (ddd, J = 6.3, 
2.6, 1.2 Hz, 3H, H-1); 13C NMR (101 MHz, CDCl3) δ 129.2, 126.5, 33.3, 32.5, 30.9, 17.9.  The physical 
data were identical in all respect to that previously reported.161   
 
 
(E)-Dec-8-en-3-one (228) 
 
Experimental 
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To a solution of (E)-2-(butan-2-ylidene)-1,1-dimethylhydrazine 225 (3.00 g, 18.5 mmol, 1.0 equiv) in dry 
tetrahydrofuran (60 mL) at -78 ºC was added n-butyllithium (1.6 M in hexane; 13.9 mL, 22.2 mmol, 1.2 
equiv) and the mixture was stirred at this temperature for 1 hour.  (E)-6-Bromohex-2-ene 227 (3.60 g, 
22.2 mmol, 1.2 equiv) was then added and the reaction mixture allowed to warm to room temperature and 
stirred for 6 hours.  The reaction was quenched with saturated ammonium chloride and layers separated.  
The aqueous layer was extracted with ethyl acetate.  The combined organic extracts were washed with 
brine, dried and concentrated in vacuo.  The crude product was purified by flash chromatography on silica 
gel, eluting with 0 to 10% ethyl acetate in petroleum ether, affording the title compound as a colourless 
oil (2.17 g, 14.1 mmol, 76%); Rf (ethyl acetate in petroleum ether, 20%): 0.32; IR max/cm
-1 (film):  2935, 
2856, 1714, 1454, 1413, 1376, 1111, 965, 732; 1H NMR (500 MHz, CDCl3) δ 5.49 – 5.30 (m, 2H, H-2 
and H-3), 2.44 – 2.36 (m, 4H, H-7 and H-9), 2.02 – 1.94 (m, 2H, H-4), 1.65 – 1.62 (m, 3H, H-1), 1.61 – 
1.52 (m, 2H, H-6), 1.39 – 1.27 (m, 2H, H-5), 1.04 (t, J = 7.3 Hz, 3H, H-10); 13C NMR (126 MHz, CDCl3) 
δ 211.9, 131.0, 125.1, 42.3, 35.9, 32.3, 29.2, 23.4, 17.9, 7.8; Elemental analysis: Anal. Calcd. For 
C10H18O: C, 77.87; H, 11.76.  Found: C, 77.84; H, 11.77. 
 
 
(E)-2-Ethyl-2-(hept-5-en-1-yl)-3-oxa-1-azaspiro[4.5]decane (236a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (314 mg, 2.43 mmol, 
1.5 equiv) and (E)-dec-8-en-3-one 228 (250 mg, 1.62 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil (277 mg, 1.05 mmol, 65%); Rf (ethyl acetate in petroleum ether, 25%): 
0.41; IR max/cm
-1 (film): 2928, 2853, 2191, 1450, 1195, 1114, 1055, 965, 813, 738; 1H NMR (500 MHz, 
CDCl3) δ 5.44 – 5.37 (m, 2H, H-8 and H-9), 3.62 (d, J = 8.4 Hz, 1H, H-11), 3.60 (d, J = 8.4 Hz, 1H, H-
11), 2.01 – 1.95 (m, 2H, H-7), 1.71 – 1.43 (m, 15H, H-2, H-4, H-14 and H-15), 1.39 – 1.26 (m, 6H, H-5, 
H-6 and H-16), 0.89 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 131.4, 124.8, 98.6, 74.4, 
62.0, 38.1, 38.1, 37.9, 32.5, 31.0, 30.0, 25.4, 24.1, 24.0, 23.9, 17.9, 8.8; m/z HRMS (ESI) found [M+H]+ 
266.2475, C17H32NO requires 266.2478. 
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(E)-2-Ethyl-2-(hept-5-en-1-yl)-4,4-dimethyloxazolidine (236b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (217 mg, 2.43 mmol, 1.5 
equiv) and (E)-dec-8-en-3-one 228 (250 mg, 1.62 mmol, 1.0 equiv); purification by flash chromatography 
on silica gel, eluting with 0 to 25% ethyl acetate in petroleum ether, afforded the title compound as a 
colourless oil (252 mg, 1.12 mmol, 69%); Rf (ethyl acetate in petroleum ether, 25%): 0.31; IR max/cm
-1 
(film): 2963, 2933, 2856, 1460, 1381, 1364, 1199, 1056, 964, 827, 769; 1H NMR (500 MHz, CDCl3) δ 
5.48 – 5.32 (m, 2H, H-8 and H-9), 3.56 (d, J = 8.3 Hz, 1H, H-11), 3.54 (d, J = 8.3 Hz, 1H, H-11), 2.05 – 
1.92 (m, 2H, H-7), 1.65 – 1.51 (m, 7H, H-2, H-4 and H-10), 1.40 – 1.27 (m, 4H, H-5 and H-6), 1.24 (s, 
3H, H-14), 1.24 (s, 3H, H-14), 0.89 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 131.3, 124.8, 
99.5, 76.8, 58.8, 37.8, 32.5, 30.9, 29.9, 28.5, 28.4, 23.9, 17.9, 8.8; m/z HRMS (ESI) found [M+H]+ 
226.2162, C14H28NO requires 226.2165. 
 
 
Hept-6-en-3-one (230) 
 
To a solution of hept-6-en-ol (1.00 g, 8.76 mmol, 1.0 equiv) in dichloromethane (18 mL) was added N-
methylmorpholine N-oxide (1.54 g, 13.1 mmol, 1.5 equiv) and 4Å molecular sieve (~4 g), followed by 
tetrapropylammonium perruthenate (154 mg, 0.44 mmol, 0.05 equiv).  [Note of caution: delayed 
exotherm observed after addition of the oxidant].  The mixture was stirred at room temperature for 2 
hours and then filtered through a short plug of silica, eluting with dichloromethane.  The filtrate was 
concentrated in vacuo.  The crude product was purified by flash chromatography on silica gel, eluting 
with 0 to 10% ethyl acetate in petroleum ether, affording the title compound as a colourless oil (501 mg, 
4.47 mmol, 51%); Rf (ethyl acetate in petroleum ether, 10%): 0.29; IR max/cm
-1 (film): 2971, 1936, 1716, 
1658, 1407, 1272, 1177, 1114, 773; 1H NMR (500 MHz, CDCl3) δ 5.80 (ddt, J = 17.1, 10.2, 6.5 Hz, 1H, 
H-7), 5.02 (apparent dq, J = 17.1, 1.7 Hz, 1H, H-9), 4.97 (apparent ddd, J = 10.2, 2.9, 1.7 Hz, 1H, H-10), 
2.50 (t, J = 7.4 Hz, 2H, H-4), 2.42 (q, J = 7.3 Hz, 2H, H-2), 2.35 – 2.29 (m, 2H, H-5), 1.05 (t, J = 7.3 Hz, 
3H, H-1); 13C NMR (126 MHz, CDCl3) δ 210.8, 137.2, 115.1, 41.4, 36.0, 27.8, 7.8.  The physical data 
were identical in all respect to that previously reported.162 
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2-(But-3-en-1-yl)-2-ethyl-4,4-dimethyloxazolidine (237b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (2.38 g, mmol, 3.0 
equiv) and hept-6-en-3-one 230 (1.00 g, mmol, 1.0 equiv): purification by flash chromatography on silica 
gel, eluting with 0 to 15% ethyl acetate in petroleum ether, afforded the title compound as a pale yellow 
oil (210 mg, 1.15 mmol, 13%); Rf (ethyl acetate in petroleum ether, 20%): 0.32; IR max/cm
-1 (film): 
2966, 2937, 2362, 1641, 1450, 1382, 1365, 1196, 1056, 907, 831, 774; 1H NMR (500 MHz, CDCl3)  δ 
5.84 (ddt, J = 16.8, 10.2, 6.5 Hz, 1H, H-6), 5.03 (apparent dq, J = 16.8, 1.7 Hz, 1H, H-9), 4.95 (apparent 
ddd, J = 10.2, 3.2, 1.7 Hz, 1H, H-8), 3.58 (d, J = 8.1 Hz, 1H, H-10), 3.56 (d, J = 8.1 Hz, 1H, H-10), 2.16 – 
2.05 (m, 2H, H-5), 1.76 – 1.54 (m, 4H, H-4 and H-2), 1.25 (s, 3H, H-13), 1.25 (s, 3H, H-13), 0.91 (t, J = 
7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 138.7, 114.3, 99.2, 76.9, 58.9, 37.0, 31.0, 28.8, 28.5, 
28.5, 8.7; m/z HRMS (ESI) found [M+H]+ 184.1693, C11H21NO requires 184.1696. 
 
 
Ethyl 2-(2-ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)acetate (246a) 
 
To a solution of (1-aminocyclohexyl)methanol 182 (500 mg, 3.87 mmol, 1.0 equiv) in methanol (20 mL) 
was added ethyl pent-2-ynoate (732 mg, 5.80 mmol, 1.5 equiv).  The resulting solution was heated at 
reflux for 10 hours.  The solvent was then removed under vacuum.  The crude product was purified by 
flash chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, affording the 
title compound as a colourless oil (682 mg, 2.67 mmol, 69%); Rf (ethyl acetate in petroleum ether, 20%): 
0.31; IR max/cm
-1 (film): 2929, 2857, 1724, 1450, 1370, 1322, 1210, 1036, 930, 819, 664; 1H NMR (500 
MHz, CDCl3) δ 4.14 (q, J = 7.1 Hz, 1H, H-6), 3.65 (d, J = 8.3 Hz, 1H, H-8), 3.60 (d, J = 8.3 Hz, 1H, H-
8), 2.63 (d, J = 13.9 Hz, 1H, H-4), 2.59 (d, J = 13.9 Hz, 1H, H-4), 1.75 (qd, J = 7.4, 4.0 Hz, 2H, H-2), 
1.69 – 1.29 (m, 10H, H-11, H-12 and H-13), 1.26 (t, J = 7.1 Hz, 3H, H-7), 0.94 (t, J = 7.5 Hz, 3H, H-1).  
13C NMR (126 MHz, CDCl3) δ 170.9, 97.1, 75.2, 62.1, 60.5, 42.6, 38.0, 37.6, 32.9, 25.4, 24.0, 23.9, 14.2, 
8.8;  m/z HRMS (ESI) found [M+H]+ 256.1905, C14H26NO3 requires 256.1907. 
 
 
 
Experimental 
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Ethyl 2-(2-ethyl-4,4-dimethyloxazolidin-2-yl)acetate (246b) 
 
To a solution of 2-amino-2-methylpropan-1-ol (500 mg, 5.61 mmol, 1.0 equiv) in methanol (25 mL) was 
added ethyl pent-2-ynoate (1.06 g, 8.41 mmol, 1.5 equiv).  The resulting solution was heated at reflux for 
10 hours.  The solvent was then removed under vacuum.  The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, affording the title 
compound as a colourless oil (713 mg, 3.31 mmol, 59%); Rf (ethyl acetate in petroleum ether, 20%): 
0.22; IR max/cm
-1 (film): 2970, 2934, 1723, 1464, 1367, 1198, 1096, 1049, 917, 815, 779; 1H NMR (500 
MHz, CDCl3) δ 4.14 (q, J = 7.1 Hz, 2H, H-6), 3.59 (d, J = 8.0 Hz, 1H, H-8), 3.55 (d, J = 8.0 Hz, 1H, H-
8), 2.64 (d, J = 14.0 Hz, 1H, H-4), 2.61 (d, J = 14.0 Hz, 1H, H-4), 1.77 (tt, J = 7.6, 4.0 Hz, 2H, H-2), 1.27 
(s, 3H, H-10), 1.27 (t, J = 7.1 Hz, 3H, H-7), 1.24 (s, 3H, H-10); 13C NMR (126 MHz, CDCl3) δ 170.9, 
97.8, 77.3, 60.6, 59.1, 42.4, 32.9, 28.6, 27.9, 14.2, 8.8; m/z HRMS (ESI) found [M+H]+ 216.1588, 
C11H22NO3 requires 216.1588.  
 
 
2-Ethyl-2-(trifluoromethyl)-3-oxa-1-azaspiro[4.5]decane (248) 
 
Prepared according to General Procedure B using (1-aminocyclohexyl)methanol 182 (100 mg, 0.77 mmol, 
1.0 equiv) and 1,1,1-trifluorobutan-2-one (1 mL, 7.37 mmol, 9.5 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 10% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil (98 mg, 0.41 mmol, 53%); Rf (ethyl acetate in petroleum ether, 25%): 0.24; 
IR max/cm
-1 (film): 2931, 2858, 1453, 1382, 1300, 1153, 1082, 1045, 945, 814, 714; 1H NMR (500 MHz, 
CDCl3) δ 3.92 – 3.76 (m, 2H, H-5), 2.00 – 1.84 (m, 2H, H-2), 1.80 – 1.24 (m, 10H, H-8, H-9 and H-10), 
1.00 (td, J = 7.5, 0.7 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 125.1 (q, J = 289.1 Hz), 95.5 (q, J = 
28.9 Hz), 77.3, 62.3, 38.1, 37.2, 26.1, 25.1, 24.2, 23.8, 6.7; 19F NMR (376 MHz, MeOD) δ -86.15; m/z 
HRMS (ESI) found [M+H]+ 238.1412, C11H19F3NO requires 238.1411. 
 
 
 
 
Experimental 
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2-Ethyl-2-phenyl-3-oxa-1-azaspiro[4.5]decane (251) 
 
Prepared according to general procedure A using (1-aminocyclohexyl)methanol 182 (500 mg, 3.87 mmol, 
1.0 equiv) and propiophenone (1.56 g, 11.6 mmol, 3.0 equiv); purification by flash chromatography on 
silica gel, eluting with toluene, afforded the title compound as a colourless oil (350 mg, 1.43 mmol, 37%); 
Rf (ethyl acetate in petroleum ether, 25%): 0.34; IR max/cm
-1 (film): 2927, 2854, 1602, 1448, 1196, 1173, 
1045, 919, 814, 757, 702; 1H NMR (500 MHz, CDCl3) δ 7.56 – 7.51 (m, 2H, H-5), 7.34 – 7.27 (m, 2H, 
H-6), 7.25 – 7.20 (m, 1H, H-7), 3.66 (d, J = 8.0 Hz, 1H, H-8), 3.46 (d, J = 8.0 Hz, 1H, H-8), 1.92 – 1.75 
(m, 2H, H-2), 1.74 – 1.49 (m, 4H, H-10, H-11), 1.45 – 1.29 (m, 3H, H-11, H-12), 1.24 – 1.04 (m, 3H, H-
10, H-12), 0.81 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (101 MHz, CDCl3) δ 145.17, 127.63, 126.89, 126.43, 
99.24, 75.20, 62.68, 38.16, 36.96, 35.96, 25.45, 24.17, 23.39, 8.56; m/z HRMS (ESI) found [M+H]+ 
246.1846, C16H24NO requires 246.1852. 
 
 
N-Methoxy-N-methyl-4-nitrobenzamide (254) 
 
To a solution of 4-nitrobenzoyl chloride (3.00 g, 16.2 mmol, 1.0 equiv) and triethylamine (4.51 mL, 32.3 
mmol, 2.0 equiv) in dry dichloromethane (32 mL) at 0 ºC was added N,O-dimethylhydroxylamine 
hydrochloride (1.58 g, 16.2 mmol, 1.0 equiv).  The reaction mixture was then warmed to room 
temperature stirred for another 2 hours.  Saturated ammonium chloride was added to the mixture and 
layers separated.  The aqueous layer was extracted with dichloromethane.  The combined organic extracts 
were washed with brine, dried and concentrated in vacuo to yield the title compound as a yellow solid 
(2.82 g, 13.4 mmol, 83%), which was taken on to the next step without further purification; IR max/cm
-1 
(film): 2953, 2854, 1685, 1543, 1390, 1362, 1177, 1071, 991, 914, 756; 1H NMR (400 MHz, 
CDCl3) δ 8.26 (d, J = 8.9 Hz, 2H, H-2), 7.84 (d, J = 8.9 Hz, 2H, H-3), 3.53 (s, 3H, H-7), 3.39 (s, 3H, H-
6); 13C NMR (101 MHz, CDCl3) δ 167.7, 148.9, 140.1, 129.2, 123.2, 61.4, 33.2.  The physical data were 
identical in all respect to that previously reported.163 
 
 
 
Experimental 
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1-(4-Nitrophenyl)propan-1-one (255) 
 
To a solution of ethyl magnesium bromide (1 M in tetrahydrofuran; 5.39 mL, 5.39 mmol, 1.0 equiv) in 
dry tetrahydrofuran (20 mL) at 0 ºC was added zinc(II) chloride (1 M in diethyl ethyl, 4.90 mL, 4.90 
mmol, 1.0 equiv).  The mixture was stirred at this temperature for 10 minutes then warmed to room 
temperature and stirred for a further 20 minutes.  The mixture was then cooled to 0 ºC followed by 
addition of tetrakis(triphenylphosphine)palladium(0) (283 mg, 0.25 mmol, 0.05 equiv) and a solution N-
methoxy-N-methyl-4-nitrobenzamide 254 (1.00 g, 5.39 mmol, 1.0 equiv) in dry tetrahydrofuran (5 
mL).  The reaction mixture was stirred at temperature for 40 minutes and then quenched with 3 N HCl to 
adjust to ~pH=1.  The layers were separated and the aqueous layer was extracted with ethyl acetate.  The 
combined organic extracts were washed with brine, dried and concentrated in vacuo.  The crude product 
was purified by flash chromatography on silica gel, eluting with 0 to 10% ethyl acetate in petroleum 
ether, affording the title compound as a yellow solid (404 mg, 2.25 mmol, 46%); Rf (ethyl acetate in 
petroleum ether, 10%): 0.30; IR max/cm
-1 (film): 2985, 1686, 1602, 1519, 1341, 1320, 1211, 953, 852, 
804, 740, 682; 1H NMR (400 MHz, CDCl3) δ 8.31 (d, J = 9.0 Hz, 2H, H-2), 8.11 (d, J = 9.0 Hz, 1H, H-
3), 3.06 (q, J = 7.2 Hz, 1H, H-6), 1.26 (t, J = 7.2 Hz, 2H, H-7); 13C NMR (101 MHz, CDCl3) δ 199.1, 
150.3, 141.3, 129.0, 123.9, 32.5, 7.9.  The physical data were identical in all respect to that previously 
reported.164  
 
 
2-Ethyl-4,4-dimethyl-2-(4-nitrophenyl)oxazolidine (256) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (120 mg, 362 mmol, 1.0 
equiv) and 1-(4-nitrophenyl)propan-1-one 255 (362 mg, 2.02 mmol, 1.5 equiv) except with the use of 
boron trifluoride etherate (0.02 mL, 0.14 mmol) instead of para-toluenesulfonic acid; purification by flash 
chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, affording the title 
compound as a yellow solid (84 mg, 0.34 mmol, 25%); Rf (ethyl acetate in petroleum ether, 20%): 0.27; 
IR max/cm
-1 (film): 2968, 2212, 2016, 1598, 1521, 1348, 1222, 1046, 922, 854, 754, 703; 1H NMR (500 
MHz, CDCl3) δ 8.17 (d, J = 8.9 Hz, 2H, H-6), 7.73 (d, J = 8.9 Hz, 2H, H-5), 3.59 (d, J = 7.9 Hz, 1H, H-
8), 3.49 (d, J = 7.9 Hz, 1H, H-8), 1.94 – 1.69 (m, 2H, H-2), 1.31 (s, 3H, H-11), 0.85 (s, 3H, H-11), 0.82 (t, 
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J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 159.2, 147.2, 127.6, 123.0, 99.4, 59.7, 35.7, 28.1, 
27.5, 8.3; m/z HRMS (ESI) found [M+H]+ 251.1392, C13H19N2O3 requires 251.1390. 
 
 
2-Ethyl-2-phenethyl-3-oxa-1-azaspiro[4.5]decane (258a) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (478 mg, 3.70 mmol, 
1.2 equiv) and 1-phenylpentan-3-one (500 mg, 3.08 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil (520 mg, 1.90 mmol, 62%); Rf (ethyl acetate in petroleum ether, 20%): 
0.26; IR max/cm
-1 (film): 2928, 2854, 1604, 1496, 1451, 1054, 814, 746, 698; 1H NMR (500 MHz, 
CDCl3) δ 7.28 (t, J = 6.6 Hz, 2H, H-8), 7.22 – 7.14 (m, 2H, H-7 and H-9), 3.67 (d, J = 8.3 Hz, 1H, H-10), 
3.64 (d, J = 8.3 Hz, 1H, H-10), 2.77 – 2.59 (m, 2H, H-5), 1.93 – 1.84 (m, 2H, H-4), 1.74 – 1.26 (m, 13H, 
H-2, H-13, H-14 and H-15), 0.95 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 142.5, 
128.4(x2), 128.3(x2), 125.7, 98.3, 74.7, 62.1, 39.9, 38.2, 38.1, 31.1, 31.0, 25.4, 24.0, 23.9, 8.7; m/z 
HRMS (ESI) found [M+H]+ 274.2161, C18H27NO requires 274.2165. 
 
 
2-Ethyl-4,4-dimethyl-2-phenethyloxazolidine (258b) 
 
Prepared according to General Procedure A using 2-amino-2-methylpropan-1-ol (412 mg, 4.62 mmol, 1.5 
equiv) and 1-phenylpentan-3-one (500 mg, 3.08 mmol, 1.0 equiv): purification by flash chromatography 
on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, afforded the title compound as a pale 
yellow oil (250 mg, 1.07 mmol, 35%); Rf (ethyl acetate in petroleum ether, 25%): 0.23; IR max/cm
-1 
(film): 2964, 2891, 1496, 1455, 1364, 1200, 1054, 900, 841, 746; 1H NMR (500 MHz, CDCl3) δ 7.30 – 
7.26 (m, 2H, H-8), 7.22 – 7.16 (m, 3H, H-7 and H-9), 3.62 (d, J = 8.1 Hz, 1H, H-10), 3.60 (d, J = 8.1 Hz, 
1H, H-10), 2.75 – 2.61 (m, 2H, H-5), 1.91 (dd, J = 12.9, 4.8 Hz, 2H, H-4), 1.78 – 1.65 (m, 2H, H-2), 1.27 
(s, 3H, H-13), 1.26 (s, 3H, H-13), 0.97 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 142.5, 
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128.5, 128.4, 125.9, 99.3, 77.1, 59.1, 39.9, 31.2, 31.1, 28.7, 28.7, 8.9; m/z HRMS (ESI) found [M+H]+ 
234.1846, C15H24NO requires 234.1851. 
 
 
2-Cyclopropyl-N-methoxy-N-methylacetamide (261) 
 
To a solution of 2-cyclopropylacetic acid (5.00 g, 49.9 mmol, 1.0 equiv) and triethylamine (54.9 mL, 109 
mmol, 2.2 equiv) in dry dichloromethane (150 mL) at 0 ºC was added N,N,N′,N′-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexafluorophosphate (20.8 g, 54.9 mmol, 1.1 equiv) and N,O-
dimethylhydroxylamine hydrochloride (5.35 g, 54.9 mmol, 1.1 equiv).  The reaction mixture was warmed 
to room temperature and stirred for 16 hours.  Saturated ammonium chloride was added to the mixture 
and layers separated.  The aqueous layer was extracted with dichloromethane.  The combined organic 
extracts were washed with brine, dried and concentrated in vacuo. The crude product was purified by 
flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, affording the 
title compound as a yellow oil (5.65 g, 39.5 mmol, 79%); Rf (ethyl acetate in petroleum ether, 25%): 0.27; 
IR max/cm
-1 (film): 3003, 2942, 1659, 1463, 1414, 1367, 1176, 1008, 979, 951, 832, 805, 772, 670; 1H 
NMR (400 MHz, CDCl3) δ 3.66 (s, 3H, H-6), 3.19 (s, 3H, H-5), 2.34 (d, J = 6.9 Hz, 2H, H-3), 1.16 – 0.99 
(m, 1H, H-2), 0.60 – 0.49 (m, 2H, H-1), 0.20 – 0.12 (m, 2H, H-1); 13C NMR (101 MHz, CDCl3) δ 182.8, 
61.5, 37.4, 32.2, 6.7, 4.4.  The physical data were identical in all respect to that previously reported.165 
 
 
1-Cyclopropylbutan-2-one (262) 
 
To a solution of 2-cyclopropyl-N-methoxy-N-methylacetamide 261 (4.5 g, 10.5 mmol, 1.0 equiv) in 
dry tetrahydrofuran (120 mL) at 0 ºC was added ethyl magnesium bromide (3 M in diethyl ether; 21.0 
mL, 62.9 mmol, 2.0 equiv) dropwise.  The reaction mixture was slowly warmed to room temperature and 
stirred for 4 hours and then slowly quenched with saturated ammonium chloride.  The layers were 
separated and the aqueous layer was extracted with ethyl acetate.  The combined organic extracts were 
washed with brine, dried and concentrated in vacuo to afford the title compound as a yellow oil (2.0 g, 
17.8 mmol, 57%) which was used in the next step without further purification; IR max/cm
-1 (film):  2965, 
2924, 1714, 1460, 1378, 1259, 1095, 1017, 954, 867, 798; 1H NMR (400 MHz, CDCl3) δ 2.48 (q, J = 7.3 
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Hz, 2H, H-5), 2.28 (d, J = 7.0 Hz, 2H, H-3), 1.06 (t, J = 7.3 Hz, 3H, H-6), 1.03 – 0.93 (m, 1H, H-2), 0.62 
– 0.51 (m, 2H, H-1), 0.16 – 0.07 (m, 2H, H-1); 13C NMR (101 MHz, CDCl3) δ 212.0, 48.1, 35.9, 8.1, 6.9, 
4.9.  The physical data were identical in all respect to that previously reported.166 
 
 
2-(Cyclopropylmethyl)-2-ethyl-3-oxa-1-azaspiro[4.5]decane (263) 
 
Prepared according to General Procedure A using (1-aminocyclohexyl)methanol 182 (276 mg, 2.14 mmol, 
1.2 equiv) and 1-cyclopropylbutan-2-one 262 (200 mg, 1.78 mmol, 1.0 equiv); purification by flash 
chromatography on silica gel, eluting with 0 to 15% ethyl acetate in petroleum ether, afforded the title 
compound as a colourless oil 235 mg, 1.05 mmol, 59%); Rf (ethyl acetate in petroleum ether, 25%): 0.34;  
IR max/cm
-1 (film): 2927, 2853, 1450, 1261, 1176, 1112, 1052, 1017, 936, 822, 765; 1H NMR (500 MHz, 
CDCl3) δ 3.65 (d, J = 8.2 Hz, 1H, H-7), 3.62 (d, J = 8.2 Hz, 1H, H-7), 1.98 (s, 1H, NH), 1.78 – 1.25 (m, 
14H, H-2, H-4, H-10, H-11 and H-12), 0.89 (t, J = 7.5 Hz, 3H, H-1), 0.83 – 0.70 (m, 1H, H-5), 0.55 – 
0.41 (m, 2H, H-6), 0.15 – 0.03 (m, 2H, H-6); 13C NMR (126 MHz, CDCl3) δ 99.1, 74.6, 62.2, 42.2, 38.2, 
38.1, 31.7, 25.4, 24.1, 23.9, 8.9, 6.2, 4.8, 3.9; m/z HRMS (ESI) found [M+H]+ 224.2009, C14H26NO 
requires 224.2009. 
 
 
2-(Cyclopropylmethyl)-2-ethyl-4,4-dimethyloxazolidine (267) 
 
Prepared according to General Procedure C using 2-amino-2-methylpropan-1-ol (954 mg, 10.7 mmol, 1.5 
equiv) and 1-cyclopropylbutan-2-one 262 (800 mg, 7.13 mmol, 1.0 equiv); purification by a silica 
plug, eluting with 0 to 50% diethyl ether in petroleum ether afforded the title compound as a colourless 
oil (549 mg, 3.00 mmol, 42%); IR max/cm
-1 (film): 2966, 2958, 1463, 1364, 1196, 1054, 1040, 987, 824, 
753; 1H NMR (500 MHz, CDCl3) δ 3.60 (d, J = 8.0 Hz, 1H, H-7), 3.57 (d, J = 8.0 Hz, 1H, H-7), 2.08 (s, 
1H, NH), 1.80 – 1.63 (m, 3H, H-2 and H-4), 1.41 (dd, J = 14.4, 7.6 Hz, 1H, H-4), 1.26 (s, 3H, H-10), 1.25 
(s, 3H, H-10), 0.90 (t, J = 7.5 Hz, 3H, H-1), 0.82 – 0.69 (m, 1H, H-5), 0.55 – 0.39 (m, 2H, H-6), 0.16 – 
0.03 (m, 2H, H-6); 13C NMR (126 MHz, CDCl3) δ 100.0, 77.3, 59.0, 42.1, 31.6, 28.6, 28.5, 8.9, 6.2, 4.8, 
3.9; m/z HRMS (ESI) found [M+H]+ 184.1696, C11H22NO requires 184.1696. 
Experimental 
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5.3 C–H carbonylation:  Carbonylation products 
 
General Procedure D for C–H carbonylation. 
 
 
To a flame dried round bottom flask, equipped with a stir bar, was charged the N,O-ketal (0.20 mmol), 
palladium(II) acetate (0.02 mmol, 0.1 equiv), silver(I) acetate (0.40 mmol, 2.0 equiv) and toluene (0.05 
M).  The reaction flask was evacuated and back-filled with carbon monoxide (3-times, balloon).  A 
balloon filled with carbon monoxide was fitted and then the flask was placed in a pre-heated oil bath at 
120 ºC and heated at this temperature for 16 hours under vigorous stirring.  The reaction mixture was then 
cooled to room temperature and filtered through a small pad of Celite®.  The filtrate was concentrated in 
vacuo and purified by flash chromatography on silica gel to afford the desired lactam. 
 
 
7a'-Ethyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one (185) and 
7a'-ethyl-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(7a'H)-one (186) 
              
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 10% ethyl acetate in petroleum ether, provided 7a'-ethyldihydro-2'H-spiro(cyclohexane-1,3'-
pyrrolo[2,1-b]oxazol)-5'(6'H)-one 185 as a pale yellow oil (34 mg, 0.15 mmol, 76%), and 7a'-ethyl-2'H-
spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(7a'H)-one 186 as a colourless oil (2 mg, 0.01 mmol, 
5%). 
 
7a'-Ethyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one (185): 
 
Rf (ethyl acetate in petroleum ether, 25%): 0.22; IR max/cm
-1 (film): 2943, 1683, 1453, 1385, 1263, 131, 
963, 920, 805, 657; 1H NMR (500 MHz, CDCl3) δ 4.24 (d, J = 9.0 Hz, 1H, H-7), 3.95 (dd, J = 9.0, 2.0 
Hz, 1H, H-7), 2.79 – 2.70 (m, 1H, H-9), 2.67 (ddd, J = 17.0, 9.4, 6.1 Hz), 2.50 (ddd, J = 17.0, 9.7, 0.9 Hz, 
1H, H-5), 2.20 (ddd, J = 12.3, 8.1, 0.9 Hz, 1H, H-4), 2.15 – 2.02 (m, 1H, H-9), 1.95 – 1.88 (m, 1H, H-4), 
1.87 – 1.78 (m, 2H, H-2 and H-10), 1.76 – 1.63 (m, 3H, H-2, H-9 and H-11), 1.61 – 1.56 (m, 1H, H-10), 
1.46 (dd, J = 10.4, 2.6 Hz, 1H, H-9), 1.33 – 1.18 (m, 2H, H-10), 1.09 – 1.00 (m, 1H, H-11), 0.96 (t, J = 
Experimental 
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7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 173.0, 102.9, 77.4, 61.4, 36.8, 36.2, 32.0, 30.9, 28.8, 
24.5, 24.5, 23.7, 8.3; m/z HRMS (ESI) found [M+H]+ 224.1644, C13H22NO2 requires 224.1645.   
 
7a'-Ethyl-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(7a'H)-one (186): 
 
Rf (ethyl acetate in petroleum ether, 25%): 0.28; IR max/cm
-1 (film): 2930, 2860, 1973, 1704, 1455, 1332, 
1253, 958, 814, 689; 1H NMR (500 MHz, CDCl3) δ 6.97 (d, J = 5.8 Hz, 1H, H-4), 5.99 (d, J = 5.8 Hz, 
1H, H-5), 4.24 (d, J = 8.9 Hz, 1H, H-7), 4.14 (dd, J = 8.9, 1.7 Hz, 1H, H-9), 2.79 – 2.54 (m, 1H, H-9), 
2.04 – 1.92 (m, 2H, H-2 and H-10), 1.90 – 1.80 (m, 3H, H-2, H-9 and H-10), 1.77 – 1.69 (m, 1H, H-11), 
1.63 – 1.57 (m, 1H, H-10), 1.44 – 1.38 (m, 1H, H-9), 1.32 – 1.23 (m, 2H, H-9 and H-10), 1.17 – 1.05 (m, 
1H, H-11), 0.88 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 174.2, 148.6, 130.9, 104.4, 79.1, 
63.0, 37.6, 30.7, 28.3, 24.7, 24.3, 23.9, 8.4; m/z HRMS (ESI) found [M+H]+ 222.1486, C13H20NO2 
requires 222.1489.   
 
 
7a-Ethyl-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (192) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 15% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (28 mg, 
0.15 mmol, 77%); Rf (ethyl acetate in petroleum ether, 20%): 0.11; IR max/cm
-1 (film): 2972, 2935, 1696, 
1460, 1367, 1268, 1230, 1125, 1043, 1002, 961, 809, 683, 667; 1H NMR (500 MHz, CDCl3) δ 3.99 (d, J 
= 8.8 Hz, 1H, H-7), 3.95 (d, J = 8.8 Hz, 1H, H-7), 2.65 (ddd, J = 17.0, 12.0, 8.2 Hz, 1H, H-5), 2.49 (ddd, 
J = 17.0, 9.7, 0.8 Hz, 1H, H-5), 2.22 (ddd, J = 12.4, 8.1, 0.9 Hz, 1H, H-4), 1.99 – 1.89 (m, 1H, H-4), 1.89 
– 1.80 (m, 1H, H-2), 1.74 – 1.65 (m, 1H, H-2), 1.57 (s, 3H, H-8 or H-9), 1.40 (s, 3H, H-8 or H-9), 0.97 (t, 
J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 173.7, 103.5, 81.5, 57.9, 35.6, 32.0, 28.6, 26.6, 
24.6, 8.3; m/z HRMS (ESI) found [M+H]+ 184.1331, C10H18NO2 requires 184.1332. 
 
 
7a'-Methyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one (204a) 
 
Experimental 
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Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (30 mg, 
0.14 mmol, 72%); Rf (ethyl acetate in petroleum ether, 25%): 0.21; IR max/cm
-1 (film): 2930, 2860, 2163, 
2026, 1695, 1455, 1369, 1250, 1191, 1085, 1030, 993, 899, 841, 809, 690, 667; 1H NMR  (500 MHz, 
CDCl3) δ 4.26 (d, J = 9.0 Hz, 1H, H-6), 4.03 (dd, J = 9.0, 1.9 Hz, 1H, H-6), 2.79 – 2.62 (m, 2H, H-4 and 
H-8), 2.51 (ddd, J = 16.8, 9.0, 0.9 Hz, 1H, H-4), 2.17 – 1.99 (m, 3H, H-3, H-8 and H-9), 1.90 – 1.79 (m, 
1H, H-8), 1.78 – 1.68 (m, 2H, H-3 and H-10), 1.65 – 1.54 (m, 1H, H-9), 1.48 (s, 3H, H-1), 1.46 – 1.43 (m, 
1H, H-8), 1.34 – 1.18 (m, 2H, H-2 and H-9), 1.11 – 0.99 (m, 1H, H-10); 13C NMR (126 MHz, CDCl3) δ 
172.5, 100.6, 77.8, 77.4, 61.5, 36.7, 36.3, 36.2, 31.0, 24.6, 23.8, 23.7; m/z HRMS (ESI) found [M+H]+ 
210.1486, C12H20NO2 requires 210.1489. 
 
 
3,3,7a-Trimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (204b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (25 mg, 
0.15 mmol, 74%); Rf (ethyl acetate in petroleum ether, 25%): 0.15; IR max/cm
-1 (film): 2975, 2876, 1693, 
1457, 1365, 1258, 1201, 1131, 1085, 1036, 1002, 824, 810, 672; 1H NMR (500 MHz, CDCl3) δ 4.05 (dd, 
J = 8.8, 0.5 Hz, 1H, H-6), 3.97 (d, J = 8.8 Hz, 1H, H-6), 2.70 (ddd, J = 16.8, 12.3, 8.0 Hz, 1H, H-4), 2.49 
(ddd, J = 16.8, 8.8, 1.2 Hz, 1H, H-4), 2.15 – 2.00 (m, 2H, H-3), 1.56 (s, 3H, H-1), 1.49 (s, 3H, H-8), 1.41 
(s, 3H, H-8); 13C NMR (126 MHz, CDCl3) δ 173.0, 101.0, 81.7, 57.9, 36.1, 35.6, 26.5, 24.3, 23.4; m/z 
HRMS (ESI) found [M+H]+ 170.1175, C9H16NO2 requires 170.1176.    
 
 
7',7a'-Dimethyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 
(205a) – diastereoisomeric mixture 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a 2.8:1 mixture of 
diastereoisomers (determined by crude NMR analysis) as a pale yellow oil (37 mg, 0.17 mmol, 83%); Rf 
(ethyl acetate in petroleum ether, 25%): 0.21; IR max/cm
-1 (film): 2928, 2860, 1693, 1453, 1368, 1214, 
Experimental 
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1190, 1031, 993, 921, 810, 689; m/z HRMS (ESI) found [M+H]+ 224.1641, C13H22NO2 requires 
224.1645.  Major diastereoisomer: 1H NMR (500 MHz, CDCl3) δ 4.29 – 4.22 (m, 1H, H-7), 4.08 – 4.02 
(m, 1H, H-7), 2.69 – 2.59 (m, 1H, H-9), 2.57 – 2.47 (m, 1H, H-5), 2.40 – 2.25 (m, 2H, H-3 and H-5), 2.17 
– 2.03 (m, 1H, H-9), 1.87 – 1.78 (m, 1H, H-10), 1.77 – 1.68 (m, 2H, H-9 and H-11), 1.59 (ddd, J = 6.2, 
3.3, 1.5 Hz, 1H, H-10), 1.46 – 1.43 (m, 1H, H-9), 1.31 (s, 3H, H-1), 1.30 – 1.18 (m, 2H, H-10), 1.09 – 
1.00 (m, 1H, H-11), 1.05 (d, J = 6.7 Hz, 3H, H-4); 13C NMR (126 MHz, CDCl3) δ 171.3, 101.70, 77.79, 
61.49, 44.07, 42.69, 36.61, 30.87, 24.49, 24.45, 23.74, 18.39, 13.42.  Minor diastereoisomer: 1H NMR 
(500 MHz, CDCl3) δ 4.29 – 4.22 (m, 1H, H-7), 4.08 – 4.02 (m, 1H, H-7), 2.91 (dd, J = 16.6, 6.8 Hz, 1H, 
H-5), 2.69 – 2.59 (m, 1H, H-9), 2.40 – 2.25 (m, 1H, H-3), 2.17 – 2.03 (m, 2H, H-5 and H-9), 1.87 – 1.78 
(m, 1H, H-10), 1.77 – 1.68 (m, 2H, H-9 and H-11), 1.59 (ddd, J = 6.2, 3.3, 1.5 Hz, 1H, H-10), 1.49 (s, 3H, 
H-1), 1.46 – 1.43 (m, 1H, H-9), 1.30 – 1.18 (m, 2H, H-10), 1.09 – 1.00 (m, 1H, H-11), 0.97 (d, J = 7.0 
Hz, 3H, H-4); 13C NMR (126 MHz, CDCl3) δ 171.2, 101.2, 78.2, 60.4, 44.4, 39.3, 36.5, 30.2, 24.3, 24.3, 
23.7, 18.2, 14.8.    
 
 
3,3,7,7a-Tetramethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (205b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 30% ethyl acetate in petroleum ether, provided the title compound as a 3.1:1 mixture of 
diastereoisomers (determined by crude NMR analysis) as a pale yellow oil (31 mg, 0.17 mmol, 87%); Rf 
(ethyl acetate in petroleum ether, 25%): 0.15; IR max/cm
-1 (film): 2972, 2875, 1694, 1458, 1366, 1263, 
1170, 1052, 989, 923, 826, 664, 654; m/z HRMS (ESI) found [M+H]+ 184.1331, C10H18NO2 requires 
184.1332.  Major diastereoisomer: 1H NMR (500 MHz, CDCl3) δ 4.10 – 4.03 (m, 1H, H-7), 3.99 – 3.94 
(m, 1H, H-7), 2.51 (dd, J = 14.5, 6.5 Hz, 1H, H-5), 2.43 – 2.26 (m, 2H, H-3 and H-5), 1.54 (s, 3H, H-9), 
1.41 (s, 3H, H-9), 1.33 (s, 3H, H-1), 1.07 (d, J = 6.5 Hz, 3H, H-4); 13C NMR (126 MHz, CDCl3) δ 172.0, 
102.3, 81.9, 58.1, 43.5, 42.7, 26.4, 24.2, 18.3, 13.5.  Minor diastereoisomer: 1H NMR (500 MHz, CDCl3) 
δ 4.10 – 4.03 (m, 1H, H-7), 3.99 – 3.94 (m, 1H, H-7), 2.90 (dd, J = 16.6, 6.8 Hz, 1H, H-5), 2.43 – 2.26 
(m, 2H, H-3 and H-5), 2.06 (d, J = 16.6 Hz, 1H, H-5), 1.54 (s, 3H, H-9), 1.48 (s, 3H, H-1), 1.42 (s, 3H, H-
9), 0.99 (d, J = 7.0 Hz, 3H, H-4); 13C NMR (126 MHz, CDCl3) δ 171.8, 101.8, 82.3, 57.0, 43.9, 39.5, 
26.5, 24.2, 23.5, 14.8. 
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7a'-Propyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one (206a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 15% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (34 mg, 
0.14 mmol, 73%); Rf (ethyl acetate in petroleum ether, 20%): 0.29; IR max/cm
-1 (film): 2929, 2856, 1698, 
1452, 1377, 1250, 1190, 1136, 1085, 1052, 995, 905, 807, 657; 1H NMR (500 MHz, CDCl3) δ 4.24 (d, J 
= 9.0 Hz, 1H, H-8), 3.97 (dd, J = 9.0, 2.0 Hz, 1H, H-8), 2.79 – 2.69 (m, 1H, H-10), 2.64 (ddd, J = 16.9, 
9.4, 6.1 Hz, 1H, H-6), 2.50 (ddd, J = 16.9, 9.7, 0.8 Hz, 1H, H-6), 2.21 (ddd, J = 12.3, 8.0, 0.8 Hz, 1H, H-
5), 2.14 – 2.06 (m, 1H, H-10), 1.98 – 1.69 (m, 5H, H-5, H-10 and H-11 and H-12), 1.67 – 1.59 (m, 1H, H-
3), 1.51 – 1.16 (m, 6H, H-2, H-10 and H-11), 1.10 – 1.00 (m, 1H, H-12), 0.97 (t, J = 7.4 Hz, 3H, H-1); 
13C NMR (126 MHz, CDCl3) δ 172.9, 102.5, 77.4, 61.4, 38.3, 36.8, 36.1, 32.6, 30.9, 24.6, 24.5, 23.7, 
17.4, 14.4; m/z HRMS (ESI) found [M+H]+ 238.1802, C14H24NO2 requires 238.1802. 
 
 
3,3,7a-Trimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (206b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a colourless oil which 
solidified on standing (14 mg, 0.07 mmol, 35%); Rf (ethyl acetate in petroleum ether, 20%): 0.14; IR 
max/cm
-1 (film): 2952, 2915, 1665, 1459, 1368, 1281, 1232, 1125, 1043, 1014, 961, 809, 683; 1H NMR  
(500 MHz, CDCl3) δ 4.00 (dd, J = 8.8, 0.6 Hz, 1H, H-8), 3.95 (d, J = 8.8 Hz, 1H, H-8), 2.65 (ddd, J = 
17.0, 12.1, 8.1 Hz, 1H, H-6), 2.48 (ddd, J = 12.4, 9.7, 0.9 Hz, 1H, H-6), 2.23 (ddd, J = 12.4, 8.1, 0.9 Hz, 
1H, H-5), 2.00 – 1.90 (m, 1H, H-5), 1.85 – 1.75 (m, 1H, H-3), 1.69 – 1.60 (m, 1H, H-3), 1.56 (s, 3H, H-
10), 1.50 – 1.34 (m, 2H, H-2), 1.41 (s, 3H, H-10), 0.97 (t, J = 7.4 Hz, 3H, H-1); 13C NMR (126 MHz, 
CDCl3) δ 173.6, 103.1, 81.6, 57.9, 38.1, 35.6, 32.7, 26.7, 24.6, 17.4, 14.3; m/z HRMS (ESI) found 
[M+H]+ 198.1490, C11H20NO2 requires 198.1494. 
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7a'-Cyclohexyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one (207a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (43 mg, 
0.16 mmol, 78%); Rf (ethyl acetate in petroleum ether, 20%): 0.24; IR max/cm
-1 (film): 2927, 2855, 1693, 
1454, 1383, 1357, 1184, 1029, 1003, 894, 729; 1H NMR (500 MHz, CDCl3) δ 4.19 (d, J = 9.0 Hz, 1H, H-
9), 3.97 (dd, J = 9.0, 2.0 Hz, 1H, H-9), 2.97 – 2.73 (m, 1H, H-11), 2.66 – 2.44 (m, 2H, H-7), 2.34 – 2.22 
(m, 1H, H-6), 2.17 – 2.02 (m, 1H, H-11), 1.95 – 1.54 (m, 11H, H-2, H-3, H-4, H-6 and H-11), 1.48 – 1.36 
(m, 1H, H-11), 1.34 – 0.91 (m, 8H, H-1, H-12 and H-13); 13C NMR (126 MHz, CDCl3) δ 174.0, 104.9, 
77.0, 61.7, 43.8, 37.3, 36.7, 31.1, 28.7, 26.9, 26.9, 26.5, 26.4, 26.1, 24.7, 24.5, 23.7; m/z HRMS (ESI) 
found [M+H]+ 278.2117, C17H28NO2 requires 278.2115. 
 
 
7a-Cyclohexyl-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one  (207b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (30 mg, 
0.13 mmol, 63%); Rf (ethyl acetate in petroleum ether, 20%): 0.14; IR max/cm
-1 (film): 2931, 2158, 1740, 
1703, 1450, 1365, 1358, 1233, 1006; 1H NMR (500 MHz, CDCl3) δ 4.01 (d, J = 8.8 Hz, 1H, H-9), 3.94 
(d, J = 8.8 Hz, 1H, H-9), 2.63 – 2.44 (m, 2H, H-7), 2.30 (ddd, J = 12.9, 8.4, 1.4 Hz, 1H, H-6), 1.92 – 1.67 
(m, 6H, H-1, H-2, H-3, H-4, H-6), 1.59 (s, 3H, H-11), 1.41 (s, 3H, H-11), 1.28 – 0.96 (m, 6H, H-1, H-2 
and H-3); 13C NMR (126 MHz, CDCl3) δ 174.7, 105.5, 81.3, 58.1, 43.5, 36.1, 28.8, 27.2, 26.9, 26.9, 26.6, 
26.4, 26.1, 24.9; m/z HRMS (ESI) found [M+H]+ 238.1796, C14H24NO2 requires 238.1800.    
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2-{3-(5'-Oxotetrahydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-7a'-
yl)propyl}isoindoline-1,3-dione (238a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (62 mg, 
0.16 mmol, 81%); Rf (ethyl acetate in petroleum ether, 25%): 0.31; IR max/cm
-1 (film): 2932, 2860, 1773, 
1706, 1395, 1360, 1228, 1188, 1063, 1030, 998, 914, 720; 1H NMR (500 MHz, CDCl3) δ 7.85 (dd, J = 
5.5, 3.0 Hz, 2H, H-2), 7.73 (dd, J = 5.5, 3.0 Hz, 2H, H-1), 4.23 (d, J = 9.1 Hz, 1H, H-12), 3.97 (dd, J = 
9.1, 1.9 Hz, 1H, H-12), 3.81 – 3.63 (m, 2H, H-5), 2.74 – 2.68 (m, 1H, H-14), 2.51 (ddd, J = 17.1, 9.8, 2.5 
Hz, 1H, H-10), 2.51 (dd, J = 17.1, 9.5 Hz, 1H, H-10), 2.23 – 2.14 (m, 1H, H-9), 2.14 – 2.03 (m, 1H, H-
14), 1.97 – 1.65 (m, 8H, H-6, H-7, H-9, H-14, H-15 and H-16), 1.64 – 1.53 (m, 1H, H-15), 1.48 – 1.38 
(m, 1H, H-14), 1.32 – 1.16 (m, 2H, H-15), 1.09 – 0.96 (m, 1H, H-16); 13C NMR (126 MHz, CDCl3) δ 
172.8, 168.3, 134.0, 132.0, 123.3, 102.0, 77.5, 61.6, 37.9, 36.8, 36.0, 33.2, 32.5, 30.9, 24.5, 24.4, 23.7, 
23.5; m/z HRMS (ESI) found [M+H]+ 383.1969, C22H27N2O4 requires 383.1970.    
 
 
2-{3-(3,3-Dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl)propyl}isoindoline-1,3-dione 
(238b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (54 mg, 
0.16 mmol, 79%); Rf (ethyl acetate in petroleum ether, 25%): 0.23; IR max/cm
-1 (film): 2976, 2952, 1773, 
1704, 1466, 1396, 1366, 1273, 1124, 1058, 1002, 882, 721, 667; 1H NMR (500 MHz, CDCl3) δ 7.85 (dd, 
J = 5.5, 3.0 Hz, 2H, H-2), 7.73 (dd, J = 5.5, 3.0 Hz, 2H, H-1), 4.00 (d, J = 9.2 Hz, 1H, H-12), 3.94 (d, J = 
8.9 Hz, 1H, H-12), 3.81 – 3.64 (m, 2H, H-5), 2.63 (ddd, J = 17.0, 12.3, 8.0 Hz, 1H, H-10), 2.51 (dd, 1H, J 
= 17.0, 11.9 Hz, H-10), 2.20 (ddd, J = 12.3, 8.0, 0.8 Hz, 1H, H-9), 2.02 – 1.66 (m, 5H, H-6, H-7 and H-9), 
1.55 (s, 3H, H-14), 1.40 (s, 3H, H-14); 13C NMR (126 MHz, CDCl3) δ 173.5, 168.3, 134.1, 132.0, 123.3, 
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102.6, 81.6, 58.1, 37.9, 35.4, 33.0, 32.5, 26.7, 24.5, 23.5; m/z HRMS (ESI) found [M+H]+  343.1656, 
C20H25N2O4 requires 343.1652.   
 
 
7a'-{(Benzyloxy)methyl}dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-
one (239a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 15% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (50 mg, 
0.16 mmol, 79%); Rf (ethyl acetate in petroleum ether, 20%): 0.31; IR max/cm
-1 (film): 2928, 2858, 1695, 
1453, 1367, 1272, 1108. 1028, 991, 738, 699; 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.27 (m, 5H, H-1, H-
2 and H-3), 4.63 (d, J = 12.2 Hz, 1H, H-5), 4.56 (d, J = 12.2 Hz, 1H, H-5), 4.25 (d, J = 9.0 Hz, 1H, H-11), 
4.00 (dd, J = 9.0, 1.9 Hz, 1H, H-11), 3.59 (d, J = 10.1 Hz, 1H, H-6), 3.46 (d, J = 10.1 Hz, 1H, H-6), 2.78 
– 2.67 (m, 2H, H-9 and H-13), 2.52 (dd, J = 15.0, 8.8 Hz, 1H, H-9), 2.39 (dd, J = 11.9, 8.8, Hz, 2H, H-8), 
2.12 – 1.99 (m, 1H, H-13), 1.92 (apparent q, J = 6.2, 1H, H-8), 1.88 – 1.80 (m, 1H, H-14), 1.72 – 1.56 (m, 
3H, H-13, H-14 and H-15), 1.51 – 1.42 (m, 1H, H-13), 1.30 – 1.17 (m, 2H, H-14), 1.06 – 0.90 (m, 1H, H-
15); 13C NMR (126 MHz, CDCl3) δ 174.0, 137.7, 128.5, 127.8, 127.7, 101.1, 78.5, 73.6, 71.1, 61.8, 36.6, 
36.3, 31.9, 31.1, 24.6, 24.5, 23.7; m/z HRMS (ESI) found [M+H]+ 316.1908, C19H26NO2 requires 
316.1907.    
 
 
7a-{(Benzyloxy)methyl}-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (239b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (41 mg, 
0.15 mmol, 74%); Rf (ethyl acetate in petroleum ether, 20%): 0.23; IR max/cm
-1 (film): 2973, 2870, 1698, 
1454, 1365, 1264, 1199, 1104, 1071, 1029, 1001, 738, 698, 618; 1H NMR (500 MHz, CDCl3) δ 7.43 – 
7.29 (m, 5H, Ar-H), 4.63 (d, J = 12.2 Hz, 1H, H-5), 4.56 (d, J = 12.2 Hz, 1H, H-5), 4.04 (d, J = 8.7 Hz, 
1H, H-11), 3.97 (d, J = 8.7 Hz, 1H, H-11), 3.60 (dd, J = 10.1, 0.6 Hz, 1H, H-6), 3.49 (d, J = 10.1 Hz, 1H, 
H-6), 2.72 (ddd, J = 16.8, 12.0, 8.0 Hz, 1H, H-9), 2.51 – 2.32 (m, 2H, H-8 and H-9), 1.96 (td, J = 12.2, 
Experimental 
 
142| 
9.8 Hz, 1H, H-8), 1.57 (s, 3H, H-13), 1.36 (s, 3H, H-13); 13C NMR (126 MHz, CDCl3) δ 174.6, 137.7, 
128.5, 127.9, 127.7, 101.6, 82.6, 73.6, 71.2, 58.4, 35.7, 32.0, 26.5, 24.5; m/z HRMS (ESI) found [M+H]+ 
276.1589, C16H22NO3 requires 276.1593. 
 
 
7a'-{3-(1-Tosylpiperidin-4-yl)propyl}dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-
b]oxazol)-5'(6'H)-one (240a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 25% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (75 mg, 
0.16 mmol, 80%); Rf (ethyl acetate in petroleum ether, 40%): 0.33; IR max/cm
-1 (film): 2930, 1694, 1598, 
1462, 1395, 1340, 1165, 1059, 986, 933, 769, 728; 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.2 Hz, 
2H, H-4), 7.32 (d, J = 8.2 Hz, 2H, H-3), 4.22 (d, J = 9.0 Hz, 1H, H-16), 3.92 (dd, J = 9.1, 1.8 Hz, 1H, H-
16), 3.81 – 3.73 (m, 2H, H-6), 2.76 – 2.57 (m, 2H, H-18 and H-14), 2.49 (dd, J = 17.0, 9.1 Hz, 1H, H-14), 
2.43 (s, 3H, H-1), 2.26 – 2.13 (m, 3H, H-6 and H-13), 2.10 – 2.00 (m, 1H, H-11), 1.95 – 1.80 (m, 2H, H-
10 and H-13), 1.79 – 1.63 (m, 5H, H-10, H-11, H-18, H-19 and H-20), 1.48 – 1.35 (m, 2H, H-10 and H-
18), 1.35 – 1.09 (m, 10H, H-7, H-8, H9, H-18 and H-19), 1.07 – 0.94 (m, 1H, H-20); 13C NMR (126 
MHz, CDCl3) δ 172.8, 143.4, 133.2, 129.6, 127.7, 102.3, 61.5, 46.4, 36.8, 36.3, 36.2, 36.0, 35.2, 32.6, 
31.6, 31.5, 30.9, 29.7, 24.5, 24.4, 23.7, 23.0, 21.5, 21.3; m/z HRMS (ESI) found [M+H]+ 475.2615, 
C26H39N2O4S requires 475.2612. 
 
 
3,3-Dimethyl-7a-{3-(1-tosylpiperidin-4-yl)propyl}tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(240b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 50% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (68 mg, 
0.16 mmol, 78%); Rf (ethyl acetate in petroleum ether, 40%): 0.21; IR max/cm
-1 (film): 2934, 1694, 1461, 
1338, 1164, 1093, 1034, 1002, 930, 816, 729, 670; 1H NMR (500 MHz, CDCl3) δ 7.64 (d, J = 8.2 Hz, 
2H, H-4), 7.32 (d, J = 7.9 Hz, 2H, H-3), 3.96 (d, J = 9.0 Hz, 1H, H-16), 3.93 (d, J = 9.0 Hz, 1H, H-16), 
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3.77 (d, J = 11.6 Hz, 2H, H-6), 2.61 (ddd, J = 17.0, 12.1, 8.0 Hz, 1H, H-14), 2.52 – 2.45 (m, 1H, H-14), 
2.43 (s, 3H, H-1), 2.24 – 2.14 (m, 3H, H-6 and H-13), 1.92 (dd, J = 17.1, 12.1 Hz, 1H, H-13), 1.80 – 1.67 
(m, 2H, H-8 and H-11), 1.63 – 1.56 (m, 2H, H-9), 1.55 (s, 3H, H-18), 1.38 (s, 3H, H-18), 1.33 – 1.12 (m, 
6H, H-7, H-9 and H-11); 13C NMR (126 MHz, CDCl3) δ 173.5, 143.4, 133.2, 129.6, 127.7, 102.9, 81.5, 
58.0, 46.4, 46.3, 36.3, 36.0, 35.5, 35.2, 32.6, 31.5, 31.5, 26.7, 24.5, 21.5, 21.2; m/z HRMS (ESI) found 
[M+H]+  435.2310, C23H35N2O4S requires 435.2312.    
 
 
Methyl 3-{5'-oxotetrahydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazo)-7a'-
yl)}propanoate (241a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (43 mg, 
0.15 mmol, 77%); Rf (ethyl acetate in petroleum ether, 25%): 0.19; IR max/cm
-1 (film): 2932, 2860, 1736, 
1694, 1452, 1380, 1260, 1175, 1029, 992, 913, 666; 1H NMR (500 MHz, CDCl3) δ 4.26 (d, J = 9.2 Hz, 
1H, H-9), 4.00 (dd, J = 9.2, 2.0 Hz, 1H, H-9), 3.72 (s, 3H, H-1), 2.77 – 2.64 (m, 2H, H-7 and H-11), 2.59 
– 2.34 (m, 3H, H-7 and H-3), 2.32 – 2.23 (m, 1H, H-4), 2.22 – 2.08 (m, 2H, H-6 and H-11), 2.02 – 1.90 
(m, 2H, H-4 and H-6), 1.88 – 1.71 (m, 3H, H-11, H-12 and H-13), 1.65 – 1.59 (m, 1H, H-12), 1.46 (d, J = 
12.2 Hz, 1H, H-11), 1.35 – 1.18 (m, 2H, H-12), 1.10 – 0.99 (m, 1H, H-13); 13C NMR (126 MHz, CDCl3) 
δ 173.4, 172.7, 101.6, 77.6, 61.7, 51.9, 36.7, 35.9, 32.4, 30.9, 30.6, 29.3, 24.5, 24.4, 23.7; m/z HRMS 
(ESI) found [M+H]+ 282.1704, C15H24NO4 requires 282.1700.    
 
 
Methyl 3-(3,3-dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl)propanoate (241b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (38 mg, 
0.16 mmol, 78%); Rf (ethyl acetate in petroleum ether, 25%): 0.17; IR max/cm
-1 (film): 2973, 1735, 1697, 
1438, 1367, 1261, 1195, 1174, 1033, 1002, 809, 670; 1H NMR (500 MHz, CDCl3) δ 4.02 (dd, J = 8.9, 0.5 
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Hz, 1H, H-9), 3.94 (d, J = 8.9 Hz, 1H, H-9), 3.69 (s, 3H, H-1), 2.67 (ddd, J = 17.0, 12.2, 8.0 Hz, 1H, H-
7), 2.55 – 2.34 (m, 3H, H-3 and H-7), 2.30 – 2.22 (m, 1H, H-4), 2.18 (ddd, J = 12.4, 8.0, 0.8 Hz, 1H, H-
6), 2.00 – 1.90 (m, 2H, H-4 and H-6), 1.55 (s, 3H, H-11), 1.42 (s, 3H, H-11); 13C NMR (126 MHz, 
CDCl3) δ 173.4, 173.3, 102.2, 81.7, 58.2, 51.9, 35.3, 32.4, 30.4, 29.2, 26.5, 24.6; m/z HRMS (ESI) found 
[M+H]+ 242.1387, C12H20NO4 requires 242.1387. 
 
 
7a'-(2-Hydroxypropan-2-yl)dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-
5'(6'H)-one (242a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 40% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (15 mg, 
0.04 mmol, 19%); Rf (ethyl acetate in petroleum ether, 50%): 0.21; IR max/cm
-1 (film): 3409 (br), 2932, 
1705, 1456, 1358, 1168, 1019, 876, 812; 1H NMR (500 MHz, CDCl3) δ 4.30 (dd, J = 8.1, 2.0 Hz, 1H, H-
7), 4.21 (d, J = 8.1 Hz, 1H, H-7), 2.78 – 2.70 (m, 1H, H-9), 2.69 (ddd, J = 16.1, 11.8, 6.5 Hz, 1H, H-5), 
2.52 (ddd, J = 16.8, 9.6, 0.9 Hz 1H, H-5), 2.29 (ddd, J = 13.0, 8.3, 0.9 Hz, 1H, H-4), 2.09 – 2.02 (m, 2H, 
H-9), 1.95 – 1.80 (m, 2H, H-4 and H-10), 1.75 – 1.68 (m, 1H, H-11), 1.53 (s, 1H, H-10), 1.36 (s, 3H, H-
1), 1.34 – 1.31 (m, 1H, H-9), 1.29 (s, 3H, H-1), 1.27 – 1.20 (m, 2H H-10), 1.02 – 0.93 (m, 1H, H-11); 13C 
NMR (126 MHz, CDCl3) δ 177.8, 106.3, 79.8, 64.2, 36.9, 35.1, 33.1, 32.8, 32.0, 25.9, 25.0, 24.9, 24.5, 
24.1; m/z HRMS (ESI) found [M+H]+  254.1751, C14H24NO3 requires 254.1751. 
 
 
(E)-7a'-(Hept-5-en-1-yl)dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-
one (243a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (45 mg, 
0.15 mmol, 74%); Rf (ethyl acetate in petroleum ether, 25%): 0.35; IR max/cm
-1 (film): 2929, 2858, 1694, 
1454, 1378, 1087, 1030, 966, 899, 730; 1H NMR (500 MHz, CDCl3) δ 5.51 – 5.32 (m, 2H, H-2 and H-3), 
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4.23 (d, J = 9.1 Hz, 1H, H-12), 3.95 (dd, J = 9.1, 2.0 Hz, 1H, H-12), 2.75 – 2.68 (m, 1H, H-14), 2.65 (ddd, 
J = 16.5, 12.2, 7.4 Hz, 1H, H-10), 2.49 (ddd, J = 16.5, 8.0, 0.8 Hz 1H, H-10), 2.20 (ddd, J = 12.2, 8.0, 0.8 
Hz, 1H, H-9), 2.15 – 2.05 (m, 1H, H-14), 2.05 – 1.96 (m, 2H, H-4), 1.96 – 1.49 (m, 10H, H-1, H-7, H-9 
and H-14, H-15 and H-16), 1.49 – 1.18 (m, 6H, H-5, H-6, H-14, H-15), 1.10 – 0.99 (m, 1H, H-16); 13C 
NMR (126 MHz, CDCl3) δ 172.9, 131.0, 125.2, 102.6, 77.4, 61.4, 36.8, 36.1, 35.9, 32.6, 32.4, 30.9, 29.6, 
24.5, 24.5, 23.7, 23.5, 17.9; m/z HRMS (ESI) found [M+H]+ 292.2274, C18H30NO2 requires 292.2276. 
 
 
(E)-7a-(Hept-5-en-1-yl)-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (243b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (38 mg, 
0.15 mmol, 77%); Rf (ethyl acetate in petroleum ether, 25%): 0.27; IR max/cm
-1 (film): 2934, 1698, 1457, 
1366, 1270, 1230, 1041, 1002, 965, 841, 711, 666; 1H NMR (500 MHz, CDCl3) δ 5.57 – 5.29 (m, 2H, H-
2 and H-3), 3.99 (d, J = 8.8 Hz, 1H, H-12), 3.95 (d, J = 8.8 Hz, 1H, H-12), 2.65 (ddd, J = 17.0, 12.3, 8.1 
Hz, 1H, H-10), 2.48 (ddd, J = 17.0, 9.7, 0.8 Hz, 1H, H-10), 2.22 (ddd, J = 12.3, 8.1, 0.8 Hz, 1H, H-9), 
2.05 – 1.89 (m, 3H, H-4 and H-9), 1.85 – 1.76 (m, 1H, H-7), 1.70 – 1.59 (m, 4H, H-4 and H-7), 1.56 (s, 
3H, H-14), 1.41 (s, 3H, H-14), 1.47 – 1.30 (m, 4H, H-5 and H-6); 13C NMR (126 MHz, CDCl3) δ 173.6, 
130.9, 125.2, 103.1, 81.6, 57.9, 35.7, 35.6, 32.6, 32.4, 29.6, 26.7, 24.6, 23.5, 17.9; m/z HRMS (ESI) 
found [M+H]+ 252.1955, C15H26NO2 requires 252.1958.    
 
 
9b'-Ethyl-2'H-spiro(cyclohexane-1,3'-oxazolo[2,3-a]isoindol)-5'(9b'H)-one (252) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (49 mg, 
0.18 mmol, 90%); Rf (ethyl acetate in petroleum ether, 25%): 0.31; IR max/cm
-1 (film): 2928, 2358, 1706, 
1455, 1369, 1087, 1030, 662; 1H NMR (500 MHz, CDCl3) δ  7.74 – 7.70 (m, 1H, H-8), 7.54 (dd, J = 7.4, 
1.2 Hz, 1H, H-6), 7.50 – 7.43 (m, 2H, H-5 and H-8), 4.37 (d, J = 8.8 Hz, 1H, H-11), 4.28 (dd, J = 8.8, 1.8 
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Hz, 1H, H-11), 2.94 – 2.78 (m, 1H, H-13), 2.25 – 2.04 (m, 3H, H-2 and H-13), 1.99 – 1.91 (m, 1H, H-13), 
1.91 – 1.84 (m, 1H, H-14), 1.84 – 1.74 (m, 1H, H-15), 1.68 – 1.59 (m, 1H, H-14), 1.47 – 1.38 (m, 1H, H-
13), 1.36 – 1.23 (m, 2H, H-14), 1.22 – 1.08 (m, 1H, H-15), 0.64 (t, J = 7.4 Hz, 3H, H-1); 13C NMR (126 
MHz, CDCl3) δ 170.2, 145.3, 134.8, 132.4, 129.8, 123.7, 121.6, 102.6, 79.5, 63.1, 37.9, 31.1, 28.9, 24.7, 
24.4, 23.9, 8.0; m/z HRMS (ESI) found [M+H]+ 272.1641, C17H22NO2 requires 272.1645. 
 
 
7a'-Phenethyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one (259a) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (45 mg, 
0.15 mmol, 74%); Rf (ethyl acetate in petroleum ether, 25%): 0.23; IR max/cm
-1 (film): 2932, 2859, 2250, 
1684, 1455, 1384, 1262, 1087, 1028, 907, 804, 729, 698; 1H NMR (500 MHz, CDCl3) δ 7.30 (t, J = 7.5 
Hz, 2H, H-3), 7.24 – 7.18 (m, 3H, H-1 and H-2), 4.28 (d, J = 9.1 Hz, 1H, H-11), 3.99 (dd, J = 9.1, 1.9 Hz, 
1H, H-11), 2.81 – 2.62 (m, 4H, H-5, H-9 and H-13), 2.54 (dd, J = 17.1, 9.6 Hz, 1H, H-9), 2.27 (dd, J = 
12.4, 7.9 Hz, 1H, H-8), 2.19 – 2.06 (m, 2H, H-6 and H-13), 2.04 – 1.92 (m, 2H, H-6 and H-8), 1.89 – 1.80 
(m, 1H, H-14), 1.79 – 1.65 (m, 2H, H-13 and H-15), 1.60 (d, J = 11.9 Hz, 1H, H-14), 1.47 (d, J = 12.7 
Hz, 1H, H-13), 1.36 – 1.18 (m, 2H, H-14), 1.09 – 0.98 (m, 1H, H-15); 13C NMR (126 MHz, CDCl3) δ 
172.9, 141.2, 128.6, 128.2, 126.1, 102.2, 61.6, 37.8, 36.8, 36.1, 32.6, 30.9, 30.5, 29.7, 24.6, 24.5, 23.7; 
m/z HRMS (ESI) found [M+H]+ 300.1956, C19H26NO2 requires 300.1958. 
 
 
3,3-Dimethyl-7a-phenethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (259b) 
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 20% ethyl acetate in petroleum ether, provided the title compound as a pale yellow oil (18 mg, 
0.07 mmol, 35%); Rf (ethyl acetate in petroleum ether, 20%): 0.14; IR max/cm
-1 (film): 2949, 2156, 1698, 
1455, 1374, 1367, 1230, 1030, 749, 701, 665; 1H NMR (500 MHz, CDCl3) δ 7.35 – 7.30 (m, 2H, Ar-H), 
7.25 – 7.20 (m, 3H, Ar-H), 4.05 (d, J = 8.9 Hz, 1H, H-11), 4.01 (d, J = 8.9 Hz, 1H, H-11), 2.83 – 2.65 (m, 
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3H, H-5 and H-9), 2.54 (ddd, J = 17.0, 9.7, 0.8 Hz, 1H, H-9), 2.31 (ddd, J = 12.5, 8.1, 0.8 Hz, 1H, H-8), 
2.21 – 2.13 (m, 1H, H-6), 2.08 – 1.95 (m, 2H, H-6 and H-8), 1.61 (s, 3H, H-13), 1.44 (s, 3H, H-13); 13C 
NMR (126 MHz, CDCl3) δ 173.6, 141.2, 128.6, 128.2, 126.1, 102.8, 81.6, 58.1, 37.6, 35.5, 32.6, 30.4, 
26.7, 24.6; m/z HRMS (ESI) found [M+H]+ 260.1639, C16H22NO2 requires 260.1643. 
 
 
7a'-(Cyclopropylmethyl)dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-
one (264) and 7a'-Ethyl-6'-spirocyclopropyldihydro-2'H-spiro(cyclohexane-1,3'-
pyrrolo[2,1-b]oxazol)-5'(6'H)-one (265)  
 
Prepared according to General Procedure D.  Purification by flash chromatography on silica gel, eluting 
with 0 to 15% ethyl acetate in petroleum ether, provided the title compounds 7a'-
(cyclopropylmethyl)dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 264 
as a pale yellow oil (14 mg, 0.06 mmol, 28%) and 7a'-ethyl-6'-spirocyclopropyldihydro-2'H-
spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 265 as a pale yellow oil (28 mg, 0.11 
mmol, 57%). 
 
7a'-(Cyclopropylmethyl)dihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 
(264):  
 
Rf (ethyl acetate in petroleum ether, 25%): 0.28; IR max/cm
-1 (film): 2926, 2860, 1698, 1455, 1373, 1272, 
1230, 1190, 1029, 937, 824, 703, 673; 1H NMR (500 MHz, CDCl3) δ 4.26 (d, J = 9.1 Hz, 1H, H-8), 4.00 
(dd, J = 9.1, 2.0 Hz, 1H, H-8), 2.81 – 2.68 (m, 2H, H-6 and H-10), 2.52 (ddd, J = 17.2, 8.6, 0.6 Hz, 1H, 
H-6), 2.41 (ddd, J = 12.2, 8.0, 0.6 Hz, 1H, H-5), 2.17 – 2.05 (m, 1H, H-10), 2.03 – 1.89 (m, 1H, H-5), 
1.88 – 1.81 (m, 1H, H-11), 1.80 – 1.67 (m, 3H, H-3, H-10 and H-12), 1.60 (dd, J = 14.2, 7.1 Hz, 2H, H-3 
and H-11), 1.49 – 1.42 (m, 1H, H-10), 1.35 – 1.17 (m, 2H, H-11), 1.11 – 0.96 (m, 1H, H-12), 0.81 – 0.70 
(m, 1H, H-2), 0.59 – 0.47 (m, 2H, H-1), 0.21 – 0.12 (m, 2H, H-1); 13C NMR (126 MHz, CDCl3) δ 173.2, 
102.9, 77.6, 61.5, 40.8, 36.8, 36.4, 33.1, 31.0, 24.6, 24.5, 23.7, 6.1, 4.7, 4.4; m/z HRMS (ESI) found 
[M+H]+ 250.1803, C15H24NO2 requires 250.1802.    
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7a'-Ethyl-6'-spirocyclopropyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 
(265):  
 
Rf (ethyl acetate in petroleum ether, 25%): 0.30; IR max/cm
-1 (film): 2928, 2860, 1696, 1453, 1374, 1225, 
1129, 1043, 1026, 987, 906, 845, 824, 742, 700; 1H NMR (500 MHz, CDCl3) δ 4.23 (d, J = 9.0 Hz, 1H, 
H-8), 3.96 (dd, J = 9.0, 2.0 Hz, 1H, H-8), 2.78 – 2.62 (m, 1H, H-10), 2.29 (d, J = 12.4 Hz, 1H, H-4), 2.14 
– 2.06 (m, 1H, H-10), 1.93 (d, J = 12.4 Hz, 1H, H-4), 1.88 – 1.68 (m, 5H, H-2, H-10, H-11 and H-12), 
1.63 – 1.59 (m, 1H, H-11), 1.50 – 1.43 (m, 1H, H-10), 1.35 – 1.16 (m, 3H, H-6 and H-11), 1.13 – 1.01 (m, 
1H, H-12), 1.01 – 0.92 (m, 4H, H-1 and H-6), 0.82 – 0.74 (m, 1H, H-6), 0.60 (ddd, J = 9.4, 7.0, 4.4 Hz, 
1H, H-6); 13C NMR (126 MHz, CDCl3) δ 175.4, 100.6, 77.0, 61.9, 40.3, 37.2, 31.2, 29.8, 26.6, 24.7, 24.6, 
23.8, 15.6, 11.2, 8.2; m/z HRMS (ESI) found [M+H]+ 250.1803, C15H24NO2 requires 250.1802.   
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5.4 C–H carbonylation:  Access to -keto carboxylic acid 
 
 
4-Oxohexanoic acid (268) 
 
7a'-Ethyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 185 (50 mg, 0.22 
mmol) was heated in a 1:1 mixture of 3 N HCl and tetrahydrofuran (8 mL) at reflux for 4 hours.  The 
reaction mixture was cooled and extracted with ethyl acetate.  The combined organic extracts were 
washed with brine, dried and concentrated in vacuo.  The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 5% methanol in dichloromethane, affording the title 
compound as a white solid (27 mg, 0.21 mmol, 93%); Rf (dichloromethane in methanol, 5%): 0.15; IR 
max/cm
-1 (film): 3200 (br), 2980, 1706, 1563, 1405, 1368, 1203, 1165, 1116, 953, 830; 1H NMR (400 
MHz, CDCl3) δ 2.73 (t, J = 9.5 Hz, 2H, H-3), 2.64 (t, J = 9.5 Hz, 2H, H-5), 2.48 (q, J = 7.3 Hz, 2H, H-2), 
1.08 (t, J = 7.3 Hz, 3H, H-6); 13C NMR (400 MHz, CDCl3) δ 209.7, 177.9, 36.8, 36.3, 28.0, 8.1.  The 
physical data were identical in all respect to that previously reported.167 
 
 
4-Cyclohexyl-4-oxobutanoic acid (269) 
 
7a'-Cyclohexyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 207a (20 mg, 0.07 
mmol) was heated in a 1:1 mixture of 3 N HCl and dioxane (2.5 mL) at reflux for 8 hours.  The reaction 
mixture was cooled and extracted with ethyl acetate.  The combined organic extracts were washed with 
brine, dried and concentrated in vacuo.  The crude product was purified by flash chromatography on silica 
gel, eluting with 0 to 5% methanol in dichloromethane, affording the title compound as a white paste (12 
mg, 0.06 mmol, 91%); Rf (dichloromethane in methanol, 5%): 0.23; IR max/cm
-1 (film):  3210-2530 (v. 
br), 2934, 2851, 1686, 1411, 1317, 1222, 1187, 1145, 1102, 921, 890, 801, 779; 1H NMR (400 MHz, 
CDCl3) δ 2.75 (t, J = 6.4 Hz, 2H, H-3), 2.62 (t, J = 6.4 Hz, 2H, H-2), 2.42 – 2.30 (m, 1H, H-5), 1.95 – 
1.53 (m, 4H, H-6), 1.44 – 1.12 (m, 6H, H-7 and H-8); 13C NMR (101 MHz, CDCl3) δ 211.9, 178.1, 50.7, 
34.8, 28.5, 27.7, 25.8, 25.6.  The physical data were identical in all respect to that previously 
reported.168 
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8-(1,3-Dioxoisoindolin-2-yl)-4-oxooctanoic acid (270) 
 
2-{3-(3,3-Dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl}propyl)isoindoline-1,3-dione 238b (15 
mg, 0.05 mmol) was heated in a 3:1 mixture of 3 N HCl and dioxane (2 mL) at reflux for 16 hours.  The 
reaction mixture was cooled and extracted with ethyl acetate.  The combined organic extracts were 
washed with brine, dried and concentrated in vacuo.  The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 5% methanol in dichloromethane, affording the title 
compound as a white solid (12.9 mg, 0.04 mmol, 89%); M.p.: 73–76 ºC; Rf (dichloromethane in 
methanol, 5%): 0.29; IR max/cm
-1 (film): 3100-2545 (v. br), 1704, 1696, 1397, 1334, 1134, 1053, 998, 
836, 719; 1H NMR  (500 MHz, CDCl3) δ 7.84 (dd, J = 5.4, 3.0 Hz, 2H, H-10), 7.72 (dd, J = 5.4, 3.0 Hz, 
2H, H-11), 3.71 (t, J = 6.7 Hz, 2H, H-7), 2.73 (t, J = 6.3 Hz, 2H, H-3), 2.63 (t, J = 6.3 Hz, 2H, H-2), 2.53 
(t, J = 7.1 Hz, 2H, H-5), 2.05 – 1.92 (m, 2H, H-6), 1.25 (s, 1H, OH); 13C NMR (126 MHz, CDCl3) δ 
207.5, 168.5, 168.4, 134.0, 132.0, 123.3, 39.6, 37.1, 36.9, 29.7, 22.6; m/z HRMS (ESI) found [M-H]- 
290.1026, C12H13O4 requires 290.1023. 
 
 
5-(Benzyloxy)-4-oxopentanoic acid (271) 
 
7a-{(benzyloxy)methyl}-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 239b (15 mg, 0.05 
mmol) was heated in a 1:1 mixture of 3 N HCl and dioxane (2 mL) at reflux for 12 hours.  The reaction 
mixture was cooled and extracted with ethyl acetate.  The combined organic extracts were washed with 
brine, dried and concentrated in vacuo.  The crude product was purified by flash chromatography on silica 
gel, eluting with 0 to 5% methanol in dichloromethane, affording the title compound as a pale green solid 
(11 mg, 0.05 mmol, 92%); M.p.: 53–55 ºC; Rf (dichloromethane in methanol, 5%): 0.35; IR max/cm
-1 
(film): 3300-2630 (v. br), 1709, 1398, 1206, 1151, 1090, 1028, 912, 740, 699; 1H NMR (500 MHz, 
MeOD) δ 7.49 – 7.22 (m, 5H, H-8, H-9 and H-10), 4.58 (s, 2H, H-6), 4.12 (s, 2H, H-5), 2.73 (t, J = 6.3 
Hz, 2H, H-3), 2.57 (t, J = 6.3 Hz, 2H, H-2); 13C NMR (126 MHz, MeOD) δ 209.4, 176.4, 138.9, 129.5, 
129.1, 128.9, 75.8, 74.3, 34.4, 28.4; m/z HRMS (ESI) found [M-H]- 221.0816, C12H13O4 requires 
221.0819.  
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5.5 C–H carbonylation:  C-Methylation of -lactam 185 
 
 
(6'R, 7a'S)-7a'-Ethyl-6'-methyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (±) (272) 
 
To a solution of 7a'-ethyldihydro-2'H-spiro(cyclohexane-1,3'-pyrrolo[2,1-b]oxazol)-5'(6'H)-one 185 (50 
mg, 0.22 mmol, 1.0 equiv) in dry tetrahydrofuran (2 mL) at -78 ºC was added LHMDS (1 M in 
tetrahydrofuran; 0.26 mL, 0.26 mmol, 1.2 equiv) dropwise.  The resulting solution was stirred at this 
temperature for 30 mins, followed by addition of methyl iodide (55 L, 0.88 mmol, 4.0 equiv). The 
reaction mixture was allowed to warm to room temperature and stirred for 3 hours.  The reaction mixture 
was quenched with saturated aqueous ammonium chloride and extracted with ethyl acetate.  The 
combined organic extracts were washed with brine, dried and concentrated in vacuo to yield an 8:1 
mixture of diastereoisomers (determined by 1H NMR analysis).  The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 10% ethyl acetate in petroleum ether, affording the major 
diastereoisomer as a pale brown oil (41 mg, 0.17 mmol, 78%).  
 
Rf (ethyl acetate in petroleum ether, 25%): 0.35; IR max/cm-1 (film): 2933, 2860, 1696, 1454, 1382, 1264, 
1107, 1028, 968, 900, 848, 736, 697; 1H NMR (500 MHz, CDCl3) δ 4.22 (d, J = 9.0 Hz, 1H, H-8), 3.93 
(dd, J = 9.0, 2.0 Hz, 1H, H-8), 2.84 – 2.67 (m, 2H, H-5 and H-10), 2.42 (dd, J = 12.1, 7.3 Hz, 1H, H-4), 
2.11 (ddd, J = 15.6, 8.7, 2.8 Hz, 1H, H-10), 1.89 – 1.77 (m, 2H, H-2 and H-11), 1.76 – 1.48 (m, 5H, H-2, 
H-4, H-10, H-11 and H-12), 1.44 – 1.37 (m, 1H, H-10), 1.34 – 1.18 (m, 2H, H-11), 1.17 (d, J = 7.1 Hz, 
3H, H-6), 1.08 – 0.99 (m, 1H, H-12), 0.96 (t, J = 7.5 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 175.4, 
100.1, 77.0, 61.4, 41.5, 41.1, 36.7, 31.0, 28.6, 24.6, 24.5, 23.7, 16.0, 8.5; m/z HRMS (ESI) found 
[M+H]+, 238.1801, C14H24NO2 requires 238.1802. 
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5.6 C–H carbonylation:  Unexpected products from ring-opening of -lactam 
185 
 
 
N-{1-(Hydroxymethyl)cyclohexyl}-4-oxohexanamide (276) 
 
To a solution of 7a'-ethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one 185 (50 
mg, 0.22 mmol, 1.0 equiv) in dry 1,2-dichloroethane (2 mL) was added titanium tetrachloride (1M in 
dichloromethane; 0.22 ml, 0.22 mmol, 1.0 equiv) followed by allyltrimethylsilane (0.10 ml, 0.66 mmol, 
3.0 equiv).  The resulting solution was heated at 80 oC for 6 hours.  The reaction mixture was allowed to 
warm to room temperature and quenched with saturated aqueous ammonium chloride and extracted with 
ethyl acetate.  The crude product was purified by flash chromatography on silica gel, eluting with 0 to 
20% ethyl acetate in petroleum ether, affording the title compound as a colourless oil (10 mg, 0.04 mmol, 
18%); Rf (ethyl acetate in petroleum ether, 20%): 0.31; IR max/cm
-1 (film): 3510 (br), 2992, 2930, 1770, 
1692, 1272, 1240, 1003, 998, 912, 907, 865, 792; 1H NMR (500 MHz, CDCl3) δ 3.95 (s, 2H, H-11), 2.78 
(t, J = 7.5 Hz, 2H, H-4), 2.59 (t, J = 7.5 Hz, 2H, H-5), 2.48 (q, J = 7.3 Hz, 2H, H-2), 1.84 – 1.46 (m, 7H, 
H-8, H-9 and H-10), 1.38 – 1.21 (m, 3H, H-8 and H-10), 1.08 (t, J = 7.3 Hz, 3H, H-1); 13C NMR  (126 
MHz, CDCl3) δ 209.6, 164.9, 70.6, 66.3, 38.2, 37.5, 36.0, 25.1, 23.0, 22.2, 7.8; m/z HRMS (ESI) found 
[M+H]+, 224.1674, C13H24NO3 requires 242.1678.   
 
 
5-Ethyl-1-{1-(hydroxymethyl)cyclohexyl}-1H-pyrrol-2(5H)-one (277) 
 
To a solution of 7a'-ethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one 185 (50 
mg, 0.22 mmol, 1.0 equiv) in dry 1,2-dichloroethane (2 mL) at -78 ºC was added boron trifluoride 
etherate complex (27 µL, 0.22 mmol, 1.0 equiv) followed by allyltrimethylsilane (0.10 ml, 0.66 mmol, 
3.0 equiv).  The resulting solution was stirred at this temperature for 30 mins, then warmed to room 
temperature and stirred for 30 mins, followed by further heating at 80 oC for 5 hours.  The reaction 
mixture was allowed to warm to room temperature and quenched with saturated aqueous ammonium 
chloride and extracted with ethyl acetate.  The crude product was purified by flash chromatography on 
silica gel, eluting with 0 to 20% ethyl acetate in petroleum ether, affording the title compound as a pale 
Experimental 
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yellow oil (26 mg, 0.11 mmol, 52%); Rf (ethyl acetate in petroleum ether, 20%): 0.22; IR max/cm
-1 
(film): 3365 (br), 2933, 2864, 1654, 1448, 1385, 1215, 1059, 910, 828, 808, 733; 1H NMR (500 
MHz, CDCl3) δ 6.97 (dd, J = 5.9, 1.9 Hz, 1H, H-4), 6.07 (dd, J = 5.9, 1.4 Hz, 1H, H-5), 5.49 (s, 1H, H-9), 
4.38 (ddd, J = 6.2, 2.9, 1.4 Hz, 1H, H-3), 3.99 – 3.77 (m, 2H, H-8), 2.20 – 1.91 (m, 3H, H-2, H-10 and H-
11), 1.75 – 1.48 (m, 9H, H-2, H-10 and H-11), 1.34 – 1.18 (m, 2H, H-12), 0.84 (t, J = 7.4 Hz, 3H, H-1);  
13C NMR (126 MHz, CDCl3) δ 174.2, 148.5, 127.6, 66.9, 63.6, 62.9, 31.8, 30.5, 26.7, 25.2, 22.9, 22.6, 
8.2; m/z HRMS (ESI) found [M+H]+, 224.1645, C13H22NO2 requires 224.1645. 
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154| 
5.7 Synthesis of TMP-astemizole 287:  Literature route to astemizole  
 
 
1-(4-Fluorobenzyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 
(299) 
 
To 2-chloro-1-(4-fluorobenzyl)benzimidazole (760 mg, 2.92 mmol, 1.0 equiv) was added 2,2,6,6-
tetramethylpiperidin-4-amine (1.0 mL, 5.84 mmol, 2.0 equiv) and the mixture heated at 125 ºC for 16 
hours.  The reaction mixture was cooled and diluted with dichloromethane before washing with saturated 
aqueous sodium bicarbonate, dried (magnesium sulfate) and concentrated in vacuo.  The crude product 
was purified by flash chromatography on silica gel, eluting with 0 to 40% methanol in dichloromethane, 
affording the title compound as a pale yellow oil (855 mg, 2.25 mmol, 77%); Rf (methanol in 
dichloromethane, 20%): 0.19; IR max/cm
-1 (film): 2972, 1604, 1572, 1533, 1363, 1220, 1156, 1080, 
1025, 953, 846, 734; 1H NMR (500 MHz, CDCl3) δ 7.52 (d, J = 7.9 Hz, 1H, H-13), 7.17 – 7.07 (m, 3H, 
H-10 and H-18), 7.06 – 6.99 (m, 4H, H-11, H-12 and H-17), 5.05 (s, 2H, H-15), 4.30 (tt, J = 8.5, 6.0 Hz 
1H, H-6), 3.60 (d, J = 7.4 Hz, 1H, H-7), 2.07 (dd, J = 12.6, 3.9 Hz, 2H, H-5eq), 1.31 (s, 6H, H-3 or H-4), 
1.14 (s, 6H, H-3 or H-4), 0.86 (t, J = 11.6 Hz, 2H, H-5ax); 13C NMR (126 MHz, CDCl3) δ 162.4 (d, 
1J C-F 
= 247.2 Hz), 153.3, 142.5, 134.6, 131.2, 128.1 (d, 3J C-F = 8.1 Hz), 121.5, 119.8, 116.2 (d, 
2J C-F = 21.8 
Hz), 116.1, 107.1, 51.6, 46.3, 45.8, 45.0, 34.7, 28.5; 19F NMR (376 MHz, CDCl3) δ -113.73; m/z HRMS 
(ESI) found [M+H]+ 381.2454, C23H30F N4 requires 381.2454. 
 
 
1-(4-Fluorobenzyl)-N-(4-methoxyphenethyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-
benzo[d]imidazol-2-amine (301) 
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A mixture of 1-(4-fluorobenzyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 299 
(50 mg, 0.13 mmol, 1.0 equiv) and potassium carbonate (54 mg, 0.39 mmol, 3.0 equiv) were stirred in 1-
(2-bromoethyl)-4-methoxybenzene (0.15 mL, 0.91 mmol, 7.0 equiv) at 120 ºC for 20 hours.  The reaction 
mixture was cooled and partitioned between ethyl acetate and water.  The organic extract was washed 
with brine, dried (magnesium sulfate) and concentrated in vacuo.  The crude product was purified by flash 
chromatography on triethylamine-pretreated silica gel, eluting with 0 to 30% methanol in 
dichloromethane, affording the title compound as an orange oil (23 mg, 0.04 mmol, 34%); Rf  (methanol 
in dichloromethane, 20%): 0.34; IR max/cm
-1 (film): 2916, 1656, 1611, 1511, 1499, 1363, 1247, 1225, 
1157, 1036, 908, 812, 731; 1H NMR (500 MHz, CDCl3) δ 7.20 (dd, J = 8.5, 5.3 Hz, 2H, H-23), 7.10 (d, J 
= 8.6 Hz, 2H, H-10), 7.03 (t, J = 8.7 Hz, 2H, H-24), 6.95 (t, J = 7.5 Hz, 1H, H-17), 6.87 (t, J = 7.5 Hz, 
1H, H-18), 6.81 (d, J = 8.6 Hz, 2H, H-11), 6.78 (d, J = 7.6 Hz, 1H, H-19), 6.63 (d, J = 7.5 Hz, 1H, H-16), 
5.04 (s, 2H, H-21)  4.20 – 4.05 (m, 2H, H-7), 4.00 – 3.86 (m, 1H, H-6), 3.78 (s, 3H, H-13), 3.04 – 2.92 
(m, 2H, H-8), 1.62 (dd, J = 13.0, 3.3 Hz, 2H, H-5eq), 1.31 – 1.18 (m, 2H, H-5ax), 1.13 (s, 6H, H-3 or H-
4), 0.98 (s, 6H, H-3 or H-4); 13C NMR (126 MHz, CDCl3) δ 162.1 (d, 
1J C-F = 245.8 Hz), 158.3, 144.7, 
133.0, 132.8, 132.5, 130.6, 129.9, 127.8 (d, 3J C-F = 4.9 Hz), 120.8, 120.2, 115.7 (d, 
2J C-F = 21.6 Hz), 
114.0, 106.1, 55.2, 51.4, 48.3, 46.6, 44.4, 34.5, 33.1, 28.2; 19F NMR (376 MHz, CDCl3) δ -115.16; m/z 
HRMS (ESI) found [M+H]+ 515.3186, C32H40FN4O requires 515.3181.  
 
 
 
Tert-butyl (1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)(2,2,6,6-tetramethylpiperidin-4-
yl)carbamate (302) 
 
To a solution of 1-(4-fluorobenzyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 
301 (100 mg, 0.26 mmol, 1.0 equiv) in tetrahydrofuran (4 mL) was added cesium carbonate (342 mg, 
1.05 mmol, 4.0 equiv) and di-tert-butyl carbonate (229 mg, 1.05 mmol, 4.0 equiv).  The resulting mixture 
was stirred at room temperature for 16 hours.  Another portion of di-tert-butyl carbonate (342 mg, 1.05 
mmol, 4.0 equiv) was added and the reaction stirred at room temperature for a further 5 hours.  The 
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reaction mixture was partitioned between dichloromethane and water.  The aqueous layer was separated 
and extracted with dichloromethane.  The combined organic extract was washed with brine, dried 
(magnesium sulfate) and concentrated in vacuo.  The crude product was purified by flash chromatography 
on triethylamine-pretreated silica gel, eluting with 0 to 5% methanol in dichloromethane, affording the 
title compound as a white solid (82 mg, 0.17 mmol, 67%); M.p.: 120–122 °C; Rf (methanol in 
dichloromethane, 5%): 0.28; IR max/cm
-1 (film): 2940, 1733, 1670, 1603, 1488, 1342, 1246, 1219, 1149, 
1082, 853, 749, 672; 1H NMR (400 MHz, CDCl3) δ 7.45 (d, J = 7.8 Hz, 1H, H-15), 7.30 (dd, J = 8.6, 5.4 
Hz, 2H, H-19), 7.03 – 6.93 (m, 3H, H-13 and H-20), 6.87 (t, J = 7.8 Hz, 1H, H-14), 6.62 (d, J = 7.7 Hz, 
1H, H-12), 4.93 (s, 2H, H-17), 4.04 (tt, J = 11.5, 3.9 Hz, 1H, H-6), 2.53 (s, 1H, H-1) 1.82 (dd, J = 12.7, 
3.8 Hz, 2H, H-5eq), 1.65 (s, 9H, H-9), 1.24 (s, 6H, H-3 or H-4), 1.13 (s, 6H, H-3 or H-4), 1.08 – 1.01 (m, 
2H, H-5ax); 13C NMR (126 MHz, CDCl3) δ 162.0 (d, 
1J C-F = 245.0 Hz), 150.2, 140.7, 134.0, 132.9, 129.2 
(d, 3J C-F = 7.5 Hz), 129.1, 124.0, 119.6, 115.3 (d, 
2J C-F = 21.4 Hz), 113.9, 106.5, 84.1, 51.0, 49.9, 46.9, 
44.7, 35.1, 28.7, 28.2; 19F NMR (376 MHz, CDCl3) δ -115.60; m/z HRMS (ESI) found [M+H]
+ 
481.2975, C26H38FN4O2 requires 481.2973. 
 
 
Benzyl (1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-yl)(2,2,6,6-tetramethylpiperidin-4-
yl)carbamate (304) 
 
To a solution of 1-(4-fluorobenzyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 
301 (190 mg, 0.50 mmol, 1.0 equiv) in tetrahydrofuran (4 mL) was added potassium carbonate (276 mg, 
2.00 mmol, 4.0 equiv) and 4-toluenesulfonyl chloride (380 mg, 2.00 mmol, 4.0 equiv).  The resulting 
mixture was stirred at 70 ºC for 10 hours.  The reaction mixture was partitioned between ethyl acetate and 
saturated aqueous sodium bicarbonate.  The aqueous layer was separated and extracted with ethyl acetate.  
The combined organic extract was washed with brine, dried (magnesium sulfate) and concentrated in 
vacuo.  The crude product was purified by flash chromatography on triethylamine-pretreated silica gel, 
eluting with 0 to 2% methanol in dichloromethane, affording the title compound as a brown oil (166 mg, 
0.31 mmol, 62%); Rf  (methanol in dichloromethane, 2%): 0.27; IR max/cm
-1 (film): 294058, 1675, 1583, 
1423, 1300, 1289, 1226, 1082, 821, 711; 1H NMR (400 MHz,  CDCl3) δ 7.93 (d, J = 7.5 Hz, 2H, H-8), 
7.67 (dd, J = 6.8, 2.1 Hz, 1H, H-14), 7.54 (dd, J = 6.9, 2.2 Hz, 1H, H-17), 7.38 (d, J = 7.3 Hz, 2H, H-9), 
7.30 – 7.20 (m, 4H, H-15, H-16 and H-21), 6.97 (t, J = 7.8 Hz, 2H, H-22), 5.12 (s, 2H, H-19), 4.27 – 4.08 
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(m, 1H, H-6), 2.36 (s, 3H, H-11), 1.87 (dd, J = 12.4, 3.1 Hz, 2H, H-5eq), 1.50 (dd, J = 12.4, 7.5 Hz, 2H, 
H-5ax), 1.22 (s, 6H, H-3 or H-4), 1.16 (s, 6H, H-3 or H-4); 13C NMR (125 MHz, CDCl3) δ 163.0 (d, 
1J C-F  
= 262.3 Hz), 156.6, 142.7, 140.5, 138.6, 136.5, 131.5,  130.6 (d, 3J C-F  = 6.7 Hz), 129.8, 128.1, 122.8, 
121.5, 116.1, 115.0 (d, 2J C-F  = 26.7 Hz), 111.5, 50.0, 49.9, 47.2, 42.7, 30.2, 21.1, 19.4; 19F NMR (376 
MHz, CDCl3) δ -111.30; m/z HRMS (ESI) found [M+H]
+ 535.6876, C30H36FN4O2S requires 535.6879. 
 
 
5.8 Synthesis of TMP-astemizole 287:  Phthalimide route 
 
 
2-(2,2,6,6-Tetramethylpiperidin-4-yl)isoindoline-1,3-dione (305) 
 
A mixture of 4-amino-2,2,6,6-tetramethylpiperidine (1.00 g, 6.40 mmol, 1.0 equiv) and phthalic 
anhydride (1.0 g, 6.76 mmol, 1.1 equiv) were stirred in acetic acid (5 mL) under reflux for 1 hour. The 
reaction mixture was cooled and acetic acid was removed by azeotrope with toluene. The residue was 
diluted with dichloromethane and treated with saturated aqueous sodium bicarbonate until the aqueous 
layer reached ~pH = 8.  The aqueous phase was then extracted with dichloromethane and the combined 
organic phases were dried (magnesium sulfate) and concentrated in vacuo to give the product as a 
colorless crystalline solid (1.68 g, 5.83 mmol, 91% yield); M.p.: 104–106 °C; IR max/cm
-1 (film): 2972, 
1701, 1626, 1373, 1364, 1098, 1087, 865, 712; 1H NMR (400 MHz, CDCl3) δ 7.81 (dd, J = 5.4, 3.1 Hz, 
2H, H-8), 7.69 (dd, J = 5.4, 3.0 Hz, 2H, H-9), 5.54 (s, 1H, H-1), 4.66 (tt, J = 12.8, 3.5 Hz, 1H, H-5), 2.26 
(t, J = 12.8 Hz, 2H, H-4ax), 1.64 (dd, J = 12.8, 3.4 Hz, 2H, H-4eq), 1.36 (s, 6H, H-2), 1.26 (s, 6H, H-2); 
13C NMR (126 MHz, CDCl3) δ 168.5, 133.9, 132.0, 123.0, 51.4, 44.8, 41.2, 34.7, 28.0.  The physical data 
were identical in all respect to that previously reported.169 
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2-(1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione (306) 
 
A mixture of 2-(2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione 305 (250 mg, 0.87 mmol, 1.0 
equiv) and potassium carbonate (326 mg, 2.62 mmol, 3.0 equiv) were stirred in 1-(2-bromoethyl)-4-
methoxybenzene (1.0 mL, 6.4 mmol, 7.4 equiv) at 120 ºC for 20 hours. The reaction mixture was cooled 
and partitioned between ethyl acetate and water.  The organic extract was washed with brine, dried 
(magnesium sulfate) and concentrated in vacuo.  The crude product was purified by flash chromatography 
on silica gel, eluting with 0 to 10% methanol in dichloromethane, affording the title compound as a brown 
oil (44 mg, 0.10 mmol, 12%); Rf (dichloromethane in methanol, 5%): 0.21; IR max/cm
-1 (film):  2966, 
1708, 1512, 1375, 1244, 1176, 1086, 1035, 912, 719; 1H NMR (500 MHz, CDCl3) δ 7.82 (dd, J = 5.5, 3.0 
Hz, 2H, H-14), 7.70 (dd, J = 5.5, 3.0 Hz, 2H, H-15), 7.11 (d, J = 8.6 Hz, 2H, H-4), 6.85 (d, J = 8.6 Hz, 
2H, H-3), 4.59 (ddd, J = 13.0, 8.3, 3.5 Hz, 1H, H-11), 2.73 – 2.62 (m, 2H, H-7), 2.60 – 2.57 (m, 2H, H-6), 
2.47 (t, J = 12.4 Hz, 2H, H-10ax), 1.54 (dd, J = 12.4, 3.5 Hz, 1H, H-10eq), 1.28 (s, 6H, H-8), 1.12 (s, 6H, 
H-8); 13C NMR (126 MHz, CDCl3) δ 168.6, 157.9, 133.8, 133.3, 132.0, 129.4, 123.0, 113.8, 56.0, 55.3, 
47.4, 44.1, 43.4, 41.3, 34.1, 21.4; m/z HRMS (ESI) found [M+H]+ 421.2483, C26H33N2O3 requires 
421.2486.  
 
 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-amine (307) 
 
To a solution of 2-(1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione 306 
(44 mg, 0.10 mmol, 1.0 equiv) in ethanol (2 mL) was added hydrazine hydrate (20 µL, 1.55 mmol, 5.0 
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equiv).  The reaction mixture was heated at reflux for 3 hours during which white precipitate was formed.  
The reaction mixture was concentrated in vacuo and suspended in dichloromethane.  The white 
precipitate was filtered off and the filtrate was concentrated in vacuo to yield the title compound as a pale 
yellow oil (29 mg, 0.10 mmol, 100%); IR max/cm
-1 (film):  2938, 2835, 1611, 1583, 1511, 1464, 1378, 
1366, 1243, 1175, 1111, 1036, 961, 853, 821, 743; 1H NMR (500 MHz, CDCl3) δ 7.10 (d, J = 8.6 Hz, 
2H, H-4), 6.84 (d, J = 8.6 Hz, 2H, H-3), 3.79 (s, 3H, H-1), 3.01 (ddd, J = 11.7, 8.3, 3.6 Hz, 1H, H-12), 
2.70 – 2.47 (m, 4H, H-6 and H-7), 1.69 (dd, J = 12.2, 3.1 Hz, 2H, H-11eq), 1.44 (br. s, 2H, H-13), 1.43 (s, 
6H, H-8 or H-9), 1.22 (s, 6H, H-8 or H-9), 1.28 – 1.15 (m, 2H, H-11ax); 13C NMR (126 MHz, CDCl3) δ 
157.9, 133.2, 129.4, 113.8, 55.7, 55.3, 51.5, 47.3, 42.5, 41.4, 34.3, 21.9; m/z HRMS (ESI) found [M+H]+ 
291.2433, C18H30N2O requires 291.2431.  
 
 
2-(1-Heptyl-2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione (308) 
 
A mixture of 2-(2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione 306 (500 mg, 1.74 mmol, 1.0 
equiv) and potassium carbonate (720 mg, 5.22 mmol, 3.0 equiv) were stirred in 1-iodoheptane (2.0 mL, 
12.2 mmol, 7.0 equiv) at 120 ºC  for 20 hours.  The reaction mixture was cooled and partitioned between 
ethyl acetate and water.  The organic extract was washed with brine, dried (magnesium sulfate) and 
concentrated in vacuo.  The crude product was purified by flash chromatography on triethylamine-
pretreated silica gel, eluting with 0 to 5% ethyl acetate in petroleum ether, affording the title compound as 
a colourless oil (287 mg, 0.75 mmol, 43%); Rf (ethyl acetate in petroleum ether, 10%): 0.36; IR max/cm
-1 
(film): 2926, 2855, 1769, 1710, 1467, 1374, 1336, 1177, 1086, 943, 869, 717; 1H NMR (500 MHz, 
CDCl3) δ 7.83 (dd, J = 5.4, 3.0 Hz, 2H, H-15), 7.71 (dd, J = 5.4, 3.0 Hz, 2H, H-16), 4.60 (tt, J = 13.0, 3.5 
Hz, 1H, H-12), 2.52 – 2.33 (m, 4H, H-7 and H-11ax), 1.52 (dd, J = 12.3, 3.5 Hz, 2H, H-11eq), 1.50 – 1.41 
(m, 2H, H-6), 1.36 – 1.21 (m, 8H, H-2, H-3, H-4 and H-5), 1.17 (s, 6H, H-8 or H-9), 1.14 (s, 6H, H-8 or 
H-9), 0.92 (t, J = 6.1 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 168.6, 133.8, 132.0, 123.0, 55.8, 44.6, 
44.2, 43.5, 35.7, 34.1, 32.1, 29.3, 27.5, 22.7, 21.2, 14.1; m/z HRMS (ESI) found [M+H]+ 385.2856, 
C24H37N2O2 requires 385.2855.   
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1-Heptyl-2,2,6,6-tetramethylpiperidin-4-amine (309) 
 
To a solution of  2-(1-heptyl-2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione 308 (120 mg, 0.31 
mmol, 1.0 equiv) in ethanol (2 mL) was added hydrazine hydrate (0.05 mL, 1.55 mmol, 5.0 equiv).  The 
reaction mixture was heated at reflux for 3 hours during which white precipitate was formed.  The 
reaction mixture was concentrated in vacuo and suspended in dichloromethane.  The white precipitate 
was filtered off and the filtrate was concentrated in vacuo to yield the title compound as a pale yellow oil 
(75 mg, 0.30 mmol, 97%); IR max/cm
-1 (film): 2920, 2872, 1577, 1464, 1378, 1330, 1260, 1214, 1187, 
1112, 1013, 913, 839, 722; 1H NMR (400 MHz, CDCl3) δ 3.04 – 2.91 (m, 1H, H-12), 2.40 – 2.27 (m, 2H, 
H-7), 1.65 (dd, J = 12.4, 3.7 Hz, 2H, H-11eq), 1.46 – 1.32 (m, 2H, H-6), 1.34 – 1.12 (m, 10H, H-2, H-3, 
H-4, H-5 and H-11ax), 1.08 (s, 6H, H-8 or H-9), 1.01 (s, 6H, H-8 or H-9), 0.88 (t, J = 6.8 Hz, 3H, H-1); 
13C NMR (126 MHz, CDCl3) δ 55.5, 51.7, 44.6, 42.5, 35.8, 34.2, 32.0, 29.3, 27.5, 22.7, 21.7, 14.1; m/z 
HRMS (ESI) found [M+H]+ 255.2795, C16H35N2 requires 255.2795.   
 
 
5.9 Synthesis of TMP-astemizole 287:  Dioxolane route 
 
 
7,7,9,9-Tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (132) 
 
To a mixture of 2,2,6,6-tetramethylpiperidin-4-one (2.00 g, 12.9 mmol, 1.0 equiv) in ethylene glycol (15 
mL) and dry toluene (5 mL) was added methanesulfonic acid (2.84 mL, 44 mmol, 3.4 equiv).  The 
reaction was heated at reflux with a Dean-Stark apparatus for eight hours, then cooled to 0 °C and 
basified by adding saturated aqueous sodium bicarbonate and extracted with diethyl ether.  The organic 
extract was washed with saturated aqueous sodium bicarbonate, brine, dried (magnesium sulfate) and 
concentrated in vacuo.  The crude product was purified by bulb-to-bulb distillation, affording the title 
compound as a pale yellow oil (1.39 g, 6.97 mmol, 54%); IR max/cm
-1 (film):  2953, 1355, 1233, 1089, 
959, 785; 1H NMR (500 MHz, CDCl3) δ 3.91 (s, 4H, H-6), 1.50 (s, 4H, H-4), 1.19 (s, 12H, H-2); 13C 
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NMR (126 MHz, CDCl3) δ 109.2, 63.9, 51.4, 45.3, 32.1; m/z HRMS (ESI) found [M+H]
+ 200.1642, 
C11H22NO2 requires 200.1645. 
 
 
8-Heptyl-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane  (314) 
 
A mixture of 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 132 (2.0 g, 10.1 mmol, 1.0 equiv) and 
potassium carbonate (4.18 g, 30.3 mmol, 3.0 equiv) were stirred in 1-iodoheptane (11.6 mL, 70.7 mmol, 
7.0 equiv) in a sealed oven-dried microwave tube at 120 ºC for 20 hours. The reaction mixture was cooled 
and partitioned between ethyl acetate and water.  The organic extract was washed with brine, dried 
(magnesium sulfate) and concentrated in vacuo.  The crude product was purified by flash chromatography 
on triethylamine-pretreated silica gel, eluting with 0 to 5% ethyl acetate in petroleum ether, affording the 
title compound as a pale brown oil (1.29 g, 4.34 mmol, 43%); Rf (ethyl acetate in petroleum ether, 10% - 
on triethylamine-pretreated silica plate): 0.34; IR max/cm
-1 (film): 2949, 2874, 1467, 1361, 1259, 1189, 
1082, 1013, 959, 841, 798, 733, 702; 1H NMR (500 MHz, CDCl3) δ 3.94 (s, 4H, H-12), 2.46 – 2.37 (m, 
2H, H-7), 1.66 (s, 4H, H-10), 1.49 – 1.38 (m, 2H, H-6), 1.37 – 1.17 (m, 8H, H-2, H-3, H-4 and H-5), 1.14 
(s, 12H, H-8), 0.90 (t, J = 6.9 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 107.8, 63.6, 55.7, 47.6, 44.2, 
35.9, 32.0, 29.3, 27.5, 23.0, 22.7, 14.1; m/z HRMS (ESI) found [M+H]+ 334.2376, C20H32NO3 requires 
334.2377. 
 
 
1-Heptyl-2,2,6,6-tetramethylpiperidin-4-one (315) 
 
To a solution of 8-heptyl-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 314 (100 mg, 0.34 mmol) 
in ethanol (1 mL) was added 3 N hydrochloric acid (1 mL) and stirred at 80 ºC for 2 hours. The reaction 
mixture was cooled and ethanol was removed under reduced pressure.  The mixture was basified with 
saturated aqueous sodium bicarbonate and extracted with ethyl acetate.  The combined organic extracts 
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were washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The crude product was 
purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 to 10% ethyl 
acetate in petroleum ether, affording the title compound as a yellow oil (54 mg, 0.21 mmol, 63%); Rf 
(ethyl acetate in petroleum ether, 10% - on triethylamine-pretreated silica plate): 0.29; IR max/cm
-1 
(film): 2957, 2926, 2854, 1675, 1615, 1444, 1378, 1359, 1219, 1112, 1032, 868, 770, 724; 1H NMR (500 
MHz, CDCl3) δ 2.50 (t, J = 10.0 Hz, 2H, H-7), 2.15 (s, 4H, H-10), 1.51 – 1.43 (m, 2H, H-6), 1.36 – 1.25 
(m, 8H, H-2, H-3, H-4 and H-5), 1.15 (s, 12H, H-8), 0.89 (t, J = 7.0 Hz, 3H, H-1); 13C NMR (126 MHz, 
CDCl3) δ 200.9, 52.9, 52.4, 42.5, 31.8, 30.9, 29.3, 27.6, 27.5, 22.6, 14.1; m/z HRMS (ESI) found [M+H]
+ 
254.2481, C16H32NO requires 254.2478.  
 
 
1-Heptyl-2,2,6,6-tetramethylpiperidin-4-amine (309) 
 
To 1-heptyl-2,2,6,6-tetramethylpiperidin-4-one 315 (50 mg, 0.20 mmol, 1.0 equiv) in 7 M ammonia in 
methanol (4 mL) was added titanium(IV) isopropoxide (0.12 mL, 0.40 mmol, 2.0 equiv).  The mixture 
was stirred at room temperature for 8 hours, followed by addition of sodium borohydride (31 mg, 0.80 
mmol, 4.0 equiv) and reaction mixture further stirred at this temperature for 3 hours. The reaction mixture 
was then quenched with saturated aqueous sodium bicarbonate.  The inorganic precipitate was filtered 
and the filtrate extracted with diethyl ether. The combined organic extracts were washed with brine, dried 
(magnesium sulfate) and concentrated in vacuo.  The crude product was purified by flash chromatography 
on triethylamine-pretreated silica gel, eluting with 0 to 30% ethyl acetate in petroleum ether, affording the 
title compound as a pale yellow oil (41 mg, 0.14 mmol, 38%); Rf (ethyl acetate in petroleum ether, 30% - 
on triethylamine-pretreated silica plate): 0.25; IR max/cm
-1 (film): 2920, 2872, 1577, 1464, 1378, 1330, 
1260, 1214, 1187, 1112, 1013, 913, 839, 722; 1H NMR (400 MHz, CDCl3) δ 3.04 – 2.91 (m, 1H, H-12), 
2.40 – 2.27 (m, 2H, H-7), 1.65 (dd, J = 12.4, 3.7 Hz, 2H, H-11eq), 1.46 – 1.32 (m, 2H, H-6), 1.34 – 1.12 
(m, 10H, H-2, H-3, H-4, H-5 and H-11ax), 1.08 (s, 6H, H-8 or H-9), 1.01 (s, 6H, H-8 or H-9), 0.88 (t, J = 
6.8 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 55.5, 51.7, 44.6, 42.5, 35.8, 34.2, 32.0, 29.3, 27.5, 22.7, 
21.7, 14.1; m/z HRMS (ESI) found [M+H]+ 255.2795, C16H35N2 requires 255.2795. 
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8-(4-Methoxyphenethyl)-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (311) 
 
A mixture of 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 132 (1.00 g, 5.03 mmol, 1.0 equiv) 
and potassium carbonate (2.08 g, 15.1 mmol, 3.0 equiv) were stirred in 1-(2-bromoethyl)-4-
methoxybenzene (3 mL, 19.2 mmol, 3.8 equiv) in a sealed oven-dried microwave tube at 120 ºC for 20 
hours.  The reaction mixture was cooled and partitioned between ethyl acetate and water.  The organic 
extract was washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The crude product 
was purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 to 10% ethyl 
acetate in petroleum ether, affording the title compound as a pale brown oil (602 mg, 1.81 mmol, 36%); 
Rf (ethyl acetate in petroleum ether, 10% - on triethylamine-pretreated silica plate): 0.31; IR max/cm
-1 
(film): 2953, 2880, 1611, 1511, 1364, 1243, 1188, 1080, 1037, 1011, 959, 854, 821, 730, 572, 560; 1H 
NMR (500 MHz, CDCl3) δ 7.10 (d, J = 8.7 Hz, 2H, H-4), 6.84 (d, J = 8.7 Hz, 2H, H-3), 3.93 (s, 4H, H-
12), 3.79 (s, 3H, H-1), 2.66 – 2.62 (m, 4H, H6 and H-7), 1.68 (s, 4H, H-10), 1.18 (s, 12H, H-8); 13C NMR 
(126 MHz, CDCl3) δ 157.8, 133.3, 129.4, 113.8, 107.7, 63.6, 55.9, 55.3, 47.5, 46.9, 41.4, 28.0; m/z 
HRMS (ESI) found [M+H]+ 334.2376, C20H32NO3 requires 334.2377.   
 
 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-one (312) 
 
To a solution of 8-(4-methoxyphenethyl)-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 311 (100 
mg, 0.30 mmol) in ethanol (1 mL) was added 3 N hydrochloric acid (1 mL) and stirred at 80 ºC for 2 
hours. The reaction mixture was cooled and ethanol removed under reduced pressure. The mixture was 
basified with saturated aqueous sodium bicarbonate and extracted with ethyl acetate.  The combined 
organic extracts were washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The 
crude product was purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 
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to 10% ethyl acetate in petroleum ether, affording the title compound as a yellow oil (53 mg, 0.18 mmol, 
61%); Rf (ethyl acetate in petroleum ether, 10% - on triethylamine-pretreated silica plate): 0.39; IR 
max/cm
-1 (film):  2969, 2835, 1712, 1611, 1511, 1464, 1302, 1245, 1177, 1143, 1092, 1036, 1012, 855, 
822; 1H NMR (500 MHz, CDCl3) δ 7.13 (d, J = 8.6 Hz, 2H, H-4), 6.86 (d, J = 8.7 Hz, 2H, H-3), 3.81 (s, 
3H, H-1), 2.78 – 2.72 (m, 2H, H-7), 2.72 – 2.66 (m, 2H, H-6), 2.39 (s, 4H, H-10), 1.20 (s, 12H, H-8); 13C 
NMR (126 MHz, CDCl3) δ 209.9, 158.0, 132.6, 129.4, 113.9, 60.0, 55.8, 55.3, 47.3, 41.1, 28.4; m/z 
HRMS (ESI) found [M+H]+ 290.2116, C18H28NO2 requires 290.2115.   
 
 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-amine (307) 
 
To 1-(4-methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-one 312 (50 mg, 0.17 mmol, 1.0 equiv) in 7 M 
ammonia in methanol (4 mL) was added titanium(IV) isopropoxide (0.10 mL, 0.34 mmol, 2.0 equiv).  
The mixture was stirred at room temperature for 8 hours, followed by addition of sodium borohydride (26 
mg, 0.68 mmol, 4.0 equiv) and stirred for a further 3 hours. The reaction mixture was then quenched with 
saturated aqueous sodium bicarbonate.  The inorganic precipitate was filtered and the filtrate extracted 
with diethyl ether.  The combined organic extracts were washed with brine, dried (magnesium sulfate) 
and concentrated in vacuo.  The crude product was purified by flash chromatography on triethylamine-
pretreated silica gel, eluting with 0 to 40% ethyl acetate in petroleum ether, affording the title compound 
as a pale yellow oil (38 mg, 0.13 mmol, 77%); Rf (ethyl acetate in petroleum ether, 30% - on 
triethylamine-pretreated silica plate): 0.22; IR max/cm
-1 (film): 2938, 2835, 1611, 1583, 1511, 1464, 
1378, 1366, 1243, 1175, 1111, 1036, 961, 853, 821, 743; 1H NMR (500 MHz, CDCl3) δ 7.10 (d, J = 8.6 
Hz, 2H, H-4), 6.84 (d, J = 8.6 Hz, 2H, H-3), 3.79 (s, 3H, H-1), 3.05 – 2.95 (m, 1H, H-12), 2.70 – 2.47 (m, 
4H, H-6 and H-7), 1.69 (dd, J = 12.2, 3.1 Hz, 2H, H-11eq), 1.44 (br. s, 2H, H-12), 1.43 (s, 6H, H-8 or H-
9), 1.22 (s, 6H, H-8 o H-9), 1.28 – 1.15 (m, 2H, H-11ax); 13C NMR (126 MHz, CDCl3) δ 157.9, 133.2, 
129.4, 113.8, 55.7, 55.3, 51.5, 47.3, 42.5, 41.4, 34.3, 21.8; m/z HRMS (ESI) found [M+H]+ 291.2433, 
C18H30N2O requires 291.2431.   
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5.10 Synthesis of TMP-astemizole 287:  Buchwald-Hartwig amination 
endgame 
 
 
1-(4-Fluorobenzyl)-N-{1-(4-methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl}-1H-
benzo[d]imidazol-2-amine (310) 
 
To a solution of 1-heptyl-2,2,6,6-tetramethylpiperidin-4-amine 309 (160 mg, 0.55 mmol, 1.0 equiv) in dry 
toluene (5 mL) was added bis(dibenzylideneacetone)palladium(0) (63 mg, 0.11 mmol, 0.2 equiv), sodium 
tert-butoxide (80 mg, 0.83 mmol, 1.5 equiv), rac-BINAP (137 mg, 0.22 mmol, 0.4 equiv) and 2-chloro-1-
(4-fluorobenzyl)benzimidazole (143 mg, 0.55 mmol, 1.0 equiv).  The mixture was stirred at 85 ºC for 16 
hours in a pre-heated oil bath, after which time the mixture was cooled to room temperature and filtered 
through a pad of Celite®.  The filtrate was concentrated in vacuo.  The crude product was purified by flash 
chromatography on triethylamine-pretreated silica gel, eluting with 0 to 15% ethyl acetate in petroleum 
ether, affording the title compound as a yellow solid (167 mg, 0.35 mmol, 64%); M.p.: 90–92 °C; Rf 
(ethyl acetate in petroleum ether, 15% - on triethylamine-pretreated silica plate): 0.32; IR max/cm
-1 
(film): 2929, 2875, 1618, 1602, 1558, 1509, 1464, 1390, 1360, 1249, 1224, 1158, 1080, 1015, 963, 846, 
820, 737, 703; 1H NMR (500 MHz, CDCl3) δ 7.54 (d, J = 7.8 Hz, 1H, H-19), 7.18 – 7.11 (m, 3H, H-18 
and H-23), 7.08 – 7.02 (m, 4H, H-16, H-17 and H-24), 5.05 (s, 2H, H-21), 4.31 – 4.16 (m, 1H, H-12), 
3.56 (d, J = 8.3 Hz, 1H, H-13), 2.45 – 2.34 (m, 2H, H-7), 1.96 (dd, J = 11.7, 3.2 Hz, 2H, H-11eq), 1.46 – 
1.35 (m, 2H, H-6), 1.36 – 1.17 (m, 10H, H-2, H-3, H-4 and H-5, H-11 ax), 1.14 (s, 6H, H-8 or H-9), 1.10 
(s, 6H, H-8 or H-9), 0.90 (t, J = 7.0 Hz, 3H, H-1); 13C NMR (126 MHz, CDCl3) δ 162.4 (d, 
1J C-F = 247.2 
Hz), 153.5, 142.6, 134.6, 131.2, 128.09 (d, 3J C-F = 8.2 Hz), 121.4, 119.6, 116.8, 116.2 (d, 
2J C-F = 21.7 
Hz), 107.0, 55.6, 48.1, 45.4, 45.0, 44.5, 35.8, 34.1, 32.0, 29.2, 27.4, 22.6, 21.7, 14.1; 19F NMR (376 
MHz, CDCl3) δ -113.77; m/z HRMS (ESI) found [M+H]
+ 479.3532, C30H44FN4 requires 479.3531.   
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1-(4-Fluorobenzyl)-N-{1-(4-methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl}-1H-
benzo[d]imidazol-2-amine (287) 
 
To a solution of 1-(4-methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-amine 307 (41 mg, 0.14 mmol, 
1.0 equiv) in dry toluene (1 mL) was added bis(dibenzylideneacetone)palladium(0) (16 mg, 0.03 mmol, 
0.2 equiv), sodium tert-butoxide (20 mg, 0.21 mmol, 1.5 equiv), rac-BINAP (35 mg, 0.06 mmol, 0.4 
equiv) and 2-chloro-1-(4-fluorobenzyl)benzimidazole (37 mg, 0.14 mmol, 1.0 equiv).  The mixture was 
stirred at 85 ºC for 16 hours in a pre-heated oil bath, after which time the mixture was cooled to room 
temperature and filtered through a pad of Celite®.  The filtrate was concentrated in vacuo.  The crude 
product was purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 to 
15% ethyl acetate in petroleum ether, affording the title compound as a yellow solid (44 mg, 0.09 mmol, 
61%); M.p.: 140–142 °C; Rf (ethyl acetate in petroleum ether, 20% - on triethylamine-pretreated silica 
plate): 0.31; IR max/cm
-1 (film): 2963, 1605, 1563, 1510, 1245, 1027, 908, 821, 731; 1H NMR (400 
MHz, CDCl3) δ 7.52 (d, J = 7.8 Hz, 1H, H-19), 7.18 – 6.95 (m, 9H, H-4, H-16, H-17, H-18, H-23 and H-
24), 6.84 (d, J = 8.6 Hz, 2H, H-3), 5.05 (s, 2H, H-21), 4.39 – 4.13 (m, 1H, H-12), 3.79 (s, 3H, H-1), 3.57 
(d, J = 8.0 Hz, 1H, H-13), 2.62 (s, 4H, H-6 and H-7), 1.98 (dd, J = 12.1, 3.5 Hz, 2H, H-11eq), 1.21 (s, 6H, 
H-8 or H-9), 1.19 – 1.14 (m, 2H, H-11ax), 1.12 (s, 6H, H-8 or H-9); 13C NMR (101 MHz, CDCl3) δ 162.5 
(d, 1J C-F = 247.1 Hz), 157.9, 153.5, 142.6, 134.6, 133.0, 131.2, 129.4, 128.1 (d, 
3J C-F = 8.2 Hz), 121.5, 
119.7, 116.8, 116.2 (d, 2J C-F = 21.8 Hz), 113.9, 107.0, 55.8, 55.3, 48.0, 47.2, 45.4, 45.0, 41.3, 34.2, 21.8; 
19F NMR (377 MHz, CDCl3) δ -113.72; m/z HRMS (ESI) found [M+H]
+ 515.3168, C32H40 FN4O 
requires 515.3167. 
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5.11 Synthesis of astemizole analogue 288: 
 
 
 
 
(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)methanol (316) 
 
To a solution of 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 132 (100 mg, 0.5 mmol, 1.0 equiv) 
in dry toluene (5 mL) was added palladium(II) acetate (11 mg, 0.05 mmol, 0.1 equiv) and iodobenzene 
diacetate (242 mg, 0.75 mmol, 1.5 equiv).  The flask was then fitted with a balloon filled with air and 
placed in a pre-heated bath at 70 ºC and allowed to stir at this temperature for 16 hours.  The mixture was 
then cooled and filtered through a pad of Celite® and the filter cake was washed with ethyl acetate.  The 
filtrate was then washed with saturated aqueous sodium bicarbonate, brine, dried (magnesium sulfate) and 
concentrated in vacuo.   
 
To a solution of crude acetate in methanol (5 mL) was added potassium carbonate (138 mg, 1.0 mmol, 2.0 
equiv based on 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 132).  The resulting mixture was 
stirred at room temperature for 10 hours before filtering and concentrating in vacuo.  The crude product 
was purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 to 2% 
methanol in dichloromethane, affording the title compound as a beige solid (52 mg, 0.24 mmol, 48%); 
M.p.: 63–65 °C; Rf (methanol in dichloromethane, 5% - on triethylamine-pretreated silica plate): 0.28; IR 
max/cm
-1 (film): 3320-3168(br), 2958, 1662, 1479, 1355, 1219, 1078, 1016, 949, 776; 1H NMR (500 
MHz, CDCl3) δ 4.01 – 3.84 (m, 4H, H-6 and H-7), 3.47 (d, J = 10.3 Hz, 1H, H-12), 3.07 (d, J = 10.3 Hz, 
1H, H-12), 1.77 (dd, J = 13.8, 0.9 Hz, 1H, H-4), 1.59 (dd, J = 13.5, 0.9 Hz, 1H, H-8), 1.53 (dd, J = 13.5, 
1.5 Hz, 1H, H-8), 1.44 (dd, J = 13.8, 1.5 Hz, 1H, H-4), 1.27 (s, 3H, H-10 or H-11), 1.19 (s, 3H, H-10 or 
H-11), 1.19 (s, 3H, H-2); 13C NMR (126 MHz, CDCl3) δ 108.6, 68.4, 63.9, 63.8, 54.7, 51.2, 44.8, 39.9, 
32.2, 32.0, 27.7; m/z HRMS (ESI) found [M+H]+ 216.1592, C11H22NO3 requires 215.1594. 
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7-{(Benzyloxy)methyl}-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane (317) 
 
To a solution of (7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)methanol 316 (100 mg, 0.47 
mmol, 1.0 equiv) in dry tetrahydrofuran (5 mL) at 0 ºC was added sodium hydride (60% in mineral oil; 28 
mg, 0.71 mmol, 1.5 equiv) and stirred at this temperature for 30 minutes. Benzyl bromide (0.08 mL, 0.71 
mmol, 1.5 equiv) was then added and the resulting mixture was warmed to room temperature and stirred 
at this temperature for 16 hours.  The reaction mixture was partitioned between diethyl ether and saturated 
aqueous sodium bicarbonate.  The aqueous layer was separated and extracted with diethyl ether.  The 
combined organic extract was washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  
The crude product was purified by flash chromatography on triethylamine-pretreated silica gel, eluting 
with 0 to 15% ethyl acetate in petroleum ether, affording the title compound as a pale yellow oil (101 mg, 
0.33 mmol, 71%); Rf  (ethyl acetate in petroleum ether, 10% - on triethylamine-pretreated silica plate): 
0.21; IR max/cm
-1 (film): 2961, 1495, 1454, 1356, 1203, 1088, 1034, 948, 787, 736, 697; 1H NMR (500 
MHz, CDCl3) δ 7.42 – 7.26 (m, 5H, Ar-Hs), 4.54 (d, J = 12.2 Hz, 1H, H-12), 4.50 (d, J = 12.2 Hz, 1H, H-
12), 4.03 – 3.85 (m, 4H, H-6 and H-7), 3.30 (d, J = 8.7 Hz, 1H, H-11), 3.27 (d, J = 8.7 Hz, 1H, H-11), 
1.80 (d, J = 13.5 Hz, 1H, H-4), 1.66 (dd, J = 13.4, 1.7 Hz, 1H, H-8), 1.49 – 1.40 (m, 2H, H-4 and H-8), 
1.26 (s, 3H, H-9 or H-10), 1.21 (s, 3H, H-9 or H-10), 1.18 (s, 3H, H-2); 13C NMR (126 MHz, CDCl3) δ 
138.6, 128.3, 127.5, 127.5, 109.3, 78.4, 73.1, 64.2, 63.4, 54.2, 51.1, 45.1, 39.8, 33.4, 30.8, 26.4; m/z 
HRMS (ESI) found [M+H]+ 306.2064, C18H28NO3 requires 306.2064.   
 
 
7-{(Benzyloxy)methyl}-8-(4-methoxyphenethyl)-7,9,9-trimethyl-1,4-dioxa-8-
azaspiro[4.5]decane (318) 
 
A mixture of 7-{(benzyloxy)methyl}-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane 317 (520 mg, 1.70 
mmol, 1.0 equiv) and potassium carbonate (469 mg, 3.40 mmol, 2.0 equiv) were stirred in 1-(2-
bromoethyl)-4-methoxybenzene (1.86 mL, 11.9 mmol, 7.0 equiv) in a sealed oven-dried microwave tube 
Experimental 
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at 120 ºC for 20 hours.  The reaction mixture was cooled and partitioned between ethyl acetate and water.  
The organic extract was washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The 
crude product was purified by flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate in 
petroleum ether, affording the title compound as a pale brown oil (130 mg, 0.30 mmol, 18%); Rf (ethyl 
acetate in petroleum ether, 20%): 0.25; IR max/cm
-1 (film): 2951, 2880, 1611, 1511, 1365, 1244, 1177, 
1079, 1037, 1037, 1011, 960, 822, 733, 699; 1H NMR (500 MHz, CDCl3) δ 7.37 – 7.26 (m, 5H, H-21, H-
22 and H-23), 7.02 (d, J = 8.6 Hz, 2H, H-4), 6.80 (d, J = 8.6 Hz, 2H, H-3), 4.54 (d, J = 12.2 Hz, 1H, H-
19), 4.51 (d, J = 12.2 Hz, 1H, H-19), 3.99 – 3.86 (m, 4H, H-12 and H-13), 3.79 (s, 3H, H-1), 3.58 (d, J = 
8.7 Hz, 1H, H-18), 3.33 (d, J = 8.7 Hz, 1H, H-18), 2.86– 2.72 (m, 1H, H-7), 2.71 – 2.40 (m, 3H, H-6 and 
H-7), 1.96 (d, J = 13.5 Hz, 1H, H-10), 1.70 (s, 2H, H-14), 1.62 (d, J = 13.5 Hz, 1H, H-10), 1.24 (s, 3H, H-
16 or H-17), 1.20 (s, 3H, H-16 or H-17), 1.18 (s, 3H, H-8); 13C NMR (126 MHz, CDCl3) δ 157.8, 138.8, 
133.2, 129.5, 128.3, 127.5, 127.4, 113.8, 107.6, 73.4, 63.7, 63.6, 58.9, 56.0, 55.3, 47.5, 47.0, 42.5, 40.9, 
29.71, 29.37, 27.56, 22.24; m/z HRMS (ESI) found [M+H]+ 440.2788, C27H38NO4 requires 440.2792.   
 
 
2-{(Benzyloxy)methyl}-2,6,6-trimethylpiperidin-4-one (354) 
 
To a solution of 7-{(benzyloxy)methyl}-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane 317 (100 mg, 
0.33 mmol) in ethanol (1 mL) was added 3 N hydrochloric acid (1 mL) and stirred at 80 ºC for 2 hours.  
The reaction mixture was cooled and ethanol removed under reduced pressure.  The mixture was basified 
with saturated aqueous sodium bicarbonate and extracted with ethyl acetate.  The combined organic 
extracts were washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The crude 
product was purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 to 
20% ethyl acetate in petroleum ether, affording the title compound as a yellow oil (65 mg, 0.25 mmol, 
76%); Rf (ethyl acetate in petroleum ether, 20% - on triethylamine-pretreated silica plate): 0.20; IR 
max/cm
-1 (film): 2967, 2861, 1705, 1454, 1296, 1095, 1027, 737, 698; 1H NMR (500 MHz, CDCl3) δ 
7.39 – 7.27 (m, 5H, Ar-Hs), 4.59 (d, J = 12.0 Hz, 1H, H-10), 4.53 (d, J = 12.0 Hz, 1H, H-10), 3.33 (d, J = 
8.9 Hz, 1H, H-9), 3.17 (d, J = 8.9 Hz, 1H, H-9), 2.63 (dd, J = 13.3, 0.6 Hz, 1H, H-4), 2.31 (dd, J = 13.1, 
1.6 Hz, 1H, H-6), 2.22 (dd, J = 13.1, 0.6 Hz, 1H, H-6), 2.11 (dd, J = 13.3, 1.6 Hz, 1H, H-4), 1.26 (s, 3H, 
H-7 or H-8), 1.21 (s, 3H, H-7 or H-8), 1.14 (s, 3H, H-2); 13C NMR (126 MHz, CDCl3) δ 211.3, 137.9, 
128.5, 127.8, 127.7, 77.9, 73.3, 57.9, 55.1, 54.1, 48.7, 33.3, 30.4, 26.6; m/z HRMS (ESI) found [M+H]+ 
262.1797, C16H24NO2 requires 262.1802.   
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2-{(Benzyloxy)methyl}-2,6,6-trimethylpiperidin-4-ol (355) 
 
To a solution of 2-{(Benzyloxy)methyl}-2,6,6-trimethylpiperidin-4-one 354 (700 mg, 2.68 mmol, 1.0 
equiv) in methanol (27 mL) was added sodium borohydride (204 mg, 5.36 mmol, 2.0 equiv) and stirred at 
room temperature for 2 hours.  The reaction mixture was quenched with water and methanol was removed 
in vacuo.  The mixture was then partitioned between dichloromethane and water.  The layers were 
separated and the aqueous layer extracted with dichloromethane.  The combined organic extracts were 
washed with brine, dried (magnesium sulfate) and concentrated in vacuo to yield the title compound as an 
inseparable 3:1 mixture of diastereoisomers (determined by 1H NMR of the crude mixture) as a yellow oil 
(520 mg, 1.98 mmol, 74%).  The crude alcohol was then taken on to the subsequent protection step 
without further purification.  IR max/cm
-1 (film): 3319 (br.), 2958, 2858, 1454, 1366, 1191, 1098, 1075, 
1051, 738, 698; m/z HRMS (ESI) found [M+H]+ 264.1957, C16H26NO2 requires 264.1958.  Major 
diastereoisomer: 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.30 (m, 5H, Ar-Hs), 4.57 (d, J = 12.3 Hz, 1H, H-
10), 4.50 (d, J = 12.3 Hz, 1H, H-10), 4.01 – 3.88 (m, 1H, H-5), 3.36 (d, J = 8.9 Hz, 1H, H-9), 3.31 (d, J = 
8.9 Hz, 1H, H-9), 2.04 (ddd, J = 12.6, 4.3, 2.0 Hz, 1H, H-4), 1.85 (ddd, J = 12.3, 4.1, 2.0 Hz, 1H, H-6), 
1.19 (s, 3H, H-2), 1.18 (s, 3H, H-7 or H-8), 1.15 (d, J = 9.1 Hz, 1H, H-6), 1.14 (s, 3H, H-7 or H-8), 1.08 
(dd, J = 12.5, 11.3 Hz, 1H, H-4); 13C NMR (126 MHz, CDCl3) δ 138.4, 128.3, 127.7, 127.5, 76.0, 73.2, 
64.8, 54.4, 51.2, 47.3, 43.3, 34.9, 30.4, 29.5.  Minor diastereoisomer: 1H NMR (500 MHz, CDCl3) δ 7.46 
– 7.31 (m, 5H, H-12, H-13 and H-14), 4.59 (d, J = 12.8 Hz, 1H, H-10), 4.55 (d, J = 12.8 Hz, 1H, H-10), 
4.14-1.10 (m, 1H, H-5), 3.27 (d, J = 8.7 Hz, 1H, H-9), 3.19 (d, J = 8.7 Hz, 1H, H-9), 1.96 (ddd, J = 12.2, 
4.2, 1.8 Hz, 1H, H-4), 1.74 (ddd, J = 12.0, 4.3, 1.8 Hz, 1H, H-6), 1.50 – 1.36 (m, 1H, H-6), 1.23 (s, 3H, 
H-7 or H-8), 1.19 (s, 3H, H-7 or H-8), 1.16 (s, 3H, H-2), 1.07 – 1.00 (m, 1H, H-4); 13C NMR (126 MHz, 
CDCl3) δ 138.3, 128.4, 127.6, 127.5, 79.6, 76.0, 64.9, 53.4, 51.5, 47.9, 42.0, 34.6, 29.1, 25.3.  
 
 
2-{(Benzyloxy)methyl}-2,6,6-trimethyl-4-{(triisopropylsilyl)oxy}piperidine (356) 
 
To a solution of 2-{(benzyloxy)methyl}-2,6,6-trimethylpiperidin-4-ol  355 (520 mg, 1.98 mmol, 1.0 equiv; 
3:1 mixture of diastereoisomers) in N,N-dimethylformamide (20 mL) at 0 oC was added imidazole (202 
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mg, 2.97 mmol, 1.5 equiv) and triisopropylsilyl chloride (0.64 ml, 2.97 mmol, 1.5 equiv).  The resulting 
pale yellow solution was warmed to room temperature and stirred for 8 hours.  The mixture was then 
partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The layers were separated 
and the organic layer was washed with water, brine, dried (magnesium sulfate) and concentrated in vacuo.  
The crude product was purified by flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate 
in petroleum ether, affording the title compound as an inseparable 3:1 mixture of diastereoisomers as a 
pale yellow oil (610 mg, 1.46 mmol, 74%); Rf (ethyl acetate in petroleum ether, 20% - on triethylamine-
pretreated silica plate): 0.29; IR max/cm
-1 (film): 2942, 2865, 1455, 1378, 1089, 1013, 882, 766, 696; m/z 
HRMS (ESI) found [M+H]+ 420.3287, C25H46NO2 requires 420.3292.  Major diastereoisomer: 1H NMR 
(500 MHz, CDCl3) δ 7.37 – 7.27 (m, 5H,  Ar-Hs), 4.52 (d, J = 12.1 Hz, 1H, H-13), 4.48 (d, J = 12.1 Hz, 
1H, H-13), 4.06 (tt, J = 10.5, 4.1 Hz, 1H, H-5), 3.31 (d, J = 8.9 Hz, 1H, H-12), 3.29 (d, J = 8.9 Hz, 1H, H-
12), 1.99 (ddd, J = 13.0, 4.2, 1.9 Hz, 1H, H-4), 1.76 (ddd, J = 12.5, 4.1, 1.9 Hz, 1H, H-8), 1.23 (dd, J = 
12.5, 10.5 Hz, 1H, H-8), 1.16 (s, 3H, H-2), 1.16 (s, 3H, H-10 or H-11), 1.15 – 1.13 (m, 1H, H-4), 1.11 (s, 
3H, H-10 or H-11), 1.08 – 1.04 (m, 21H, H-6 and H-7); 13C NMR (126 MHz, CDCl3) δ 138.5, 128.3, 
127.6, 127.4, 76.8, 73.2, 65.3, 54.3, 51.0, 47.8, 43.4, 34.8, 30.2, 29.9, 18.1, 12.3.  Minor diastereoisomer: 
1H NMR  (500 MHz, CDCl3) δ 7.36 – 7.27 (m, 5H, Ar-Hs), 4.55 (d, J = 12.2 Hz, 1H, H-13), 4.51 (d, J = 
12.1 Hz, 1H, H-13), 4.21 – 4.12 (m, 1H, H-5), 3.22 (d, J = 8.6 Hz, 1H, H-12), 3.16 (d, J = 8.6 Hz, 1H, H-
12), 1.86 (ddd, J = 12.4, 4.0, 1.7 Hz, 1H, H-4), 1.65 (ddd, J = 12.3, 4.2, 1.8 Hz, 1H, H-8), 1.51 – 1.42 (m, 
1H, H-8), 1.18 (s, 3H, H-2), 1.15 (s, 3H, H-10 or H-11), 1.12 (s, 3H, H-10 or H-11), 1.12 – 1.09 (m, 1H, 
H-4), 1.08 – 1.04 (m, 21H, H-6 and H-7); 13C NMR (126 MHz, CDCl3) δ 138.5, 128.3, 127.5, 127.4, 
79.8, 76.8, 65.3, 54.5, 51.3, 48.4, 42.6, 34.6, 29.2, 25.4, 17.7, 12.4. 
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2-{(Benzyloxy)methyl}-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-one (319) 
 
To a solution of 2-{(benzyloxy)methyl}-2,6,6-trimethyl-4-{(triisopropylsilyl)oxy}piperidine 356 (200 mg, 
0.48 mmol, 1.0 equiv, 3:1 mixture of diasteroisomers) in acetonitrile (2 mL) in a microwave tube was 
added 1-(2-bromoethyl)-4-methoxybenzene (0.23 mL, 1.43 mmol, 3.0 equiv) and potassium carbonate 
(198 mg, 1.43 mmol, 3.0 equiv).  The resulting mixture was sealed and heated at 150 ºC in the microwave 
for 4 hours.  The reaction mixture was filtered and filtrate concentrated in vacuo.  To the crude material 
was added ethanol (2 mL) and 3 N hydrochloric acid (2 mL) and the mixture heated at 80 ºC for 4 hours.  
The solution was cooled and basified to ~pH=10 with 1 N sodium hydroxide and extracted with 
dichloromethane.  The layers are separated and the aqueous layer was further extracted with 
dichloromethane.  The combined organic extracts were dried (magnesium sulfate) and concentrated in 
vacuo.   
 
The crude alcohol was then dissolved in dichloromethane (3 mL), followed by addition of N-
methylmorpholine N-oxide (56.0 mg, 0.48 mmol, 1.0 equiv – based on 2-((Benzyloxy)methyl)-2,6,6-
trimethyl-4-((triisopropylsilyl)oxy)piperidine 356) and tetrapropylammonium perruthenate (8.50 mg, 
0.024 mmol, 0.05 equiv).  The mixture was stirred at room temperature for 3 hours and filtered through a 
pad of silica gel, eluting with dichloromethane.  The solvent was then recovered under reduced pressure.  
The crude product was purified by flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate 
in petroleum ether, affording the title compound as a pale yellow oil (15.2 mg, 0.038 mmol, 8%), as well 
as 2-((benzyloxy)methyl)-2,6,6-trimethylpiperidin-4-one 354, which was recovered as a yellow oil (100 
mg, 0.38 mmol, 80%); Rf (ethyl acetate in petroleum ether, 20%): 0.26; IR max/cm
-1 (film): 2966, 1713, 
1511, 1301, 1244, 1093, 1034, 822, 737, 699; 1H NMR (500 MHz, CDCl3) δ 7.41 – 7.30 (m, 5H, H-19, 
H-20 and H-21), 7.05 (d, J = 8.5 Hz, 2H, H-4), 6.84 (d, J = 8.5 Hz, 2H, H-3), 4.59 (d, J = 12.1 Hz, 1H, H-
17), 4.55 (d, J = 12.1 Hz, 1H, H-17), 3.82 (s, 3H, H-1), 3.45 (d, J = 9.2 Hz, 1H, H-16), 3.29 (d, J = 9.2 
Hz, 1H, H-16), 2.87 – 2.67 (m, 5H, H-6, H-7 and H-10), 2.52 (d, J = 13.0 Hz, 1H, H-12), 2.36 – 2.25 (m, 
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2H, H-10 and H-12), 1.29 (s, 3H, H-14 or H-15), 1.18 (s, 3H, H-8), 1.17 (s, 3H, H-14 or H-15); 13C NMR 
(126 MHz, CDCl3) δ 210.1, 158.0, 138.1, 132.6, 129.5, 129.6, 129.4, 128.4, 127.6, 113.9, 76.8, 73.4, 
62.4, 59.6, 55.5, 55.3, 51.1, 47.3, 40.3, 30.8, 26.7, 22.3; m/z HRMS (ESI) found [M+H]+ 396.2529, 
C25H34NO3 requires 396.2533. 
 
 
2-{(Benzyloxy)methyl}-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-amine (320) 
 
To 2-{(benzyloxy)methyl}-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-one 319 (100 mg, 0.25 
mmol, 1.0 equiv) in 7 M ammonia in methanol (4 mL) was added titanium(IV) isopropoxide (0.15 mL, 
0.50  mmol, 2.0 equiv).  The mixture was stirred at room temperature for 8 hours, followed by addition of 
sodium borohydride (38 mg, 1.0 mmol, 4.0 equiv) and reaction mixture further stirred at this temperature 
for 3 hours.  The reaction mixture was then quenched with saturated aqueous sodium bicarbonate.  The 
inorganic precipitate was filtered and the filtrate extracted with diethyl ether.  The combined organic 
extracts were washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The crude 
product was purified by flash chromatography on triethylamine-pretreated silica gel, eluting with 0 to 5% 
MeOH in dichloromethane, affording the title compound as an inseparable 2:1 mixture of 
diastereoisomers (determined by 1H NMR of the crude mixture), as a pale yellow oil (51 mg, 0.13 mmol, 
52%); Rf (methanol in dichloromethane, 5% - on triethylamine-pretreated silica gel): 0.21; IR max/cm
-1 
(film): 3392, 3381, 2942, 1513, 1432, 1247, 1202, 1133, 1030, 835, 722; m/z HRMS (ESI) found 
[M+H]+ 397.2846, C25H37N2O2 requires 397.2850.  Major diastereoisomer: 1H NMR (400 MHz, CDCl3) 
δ 7.42 – 7.30 (m, 5H, H-20, H-21 and H-22), 7.10 (d, J = 8.6 Hz, 2H, H-4), 6.85 (d, J = 8.6 Hz, 2H, H-3), 
4.52 (d, J = 12.2 Hz, 1H, H-18), 4.44 (d, J = 12.2 Hz, 1H, H-18), 3.81 (s, 3H, H-1), 3.38 (d, J = 8.5 Hz, 
1H, H-17), 3.36 (d, J = 8.5 Hz, 1H, H-17), 3.19 – 3.06 (m, 1H, H-11), 2.98 – 2.79 (m, 1H, H-7), 2.73 – 
2.56 (m, 3H, H-6 and H-7), 2.18 – 2.10 (m, 1H, H-10), 1.79 – 1.68 (m, 1H, H-13), 1.36 (s, 3H, H-8), 1.34 
– 1.28 (m, 1H, H-13), 1.26 (s, 3H, H-15), 1.02 (t, J = 6.1 Hz, 1H, H-10), 0.98 (s, 3H, H-16); 13C NMR 
(126 MHz, CDCl3) δ 157.9, 138.8, 133.1, 129.4, 128.3, 127.7, 127.4, 113.8, 80.8, 73.3, 72.2, 58.9, 55.3, 
51.0, 47.2, 46.5, 42.1, 41.4, 34.5, 28.3, 23.5.  Minor diastereoisomer: 1H NMR (400 MHz, CDCl3) δ 7.41 
– 7.29 (m, 5H, H-20, H-21 and H-22), 6.99 (d, J = 8.6 Hz, 2H, H-4), 6.80 (d, J = 8.6 Hz, 2H, H-3), 4.62 
(d, J = 12.2 Hz, 1H, H-18), 4.58 (d, J = 12.2 Hz, 1H, H-18), 3.80 (s, 3H, H-1), 3.48 (d, J = 9.1 Hz, 1H, H-
Experimental 
 
174| 
17), 3.32 (d, J = 9.1 Hz, 1H, H-17), 2.99 – 2.80 (m, 2H, H-7 and H-11), 2.72 – 2.54 (m, 3H, H-6 and H-
7), 1.95 – 1.84 (m, 1H, H-10), 1.79 – 1.67 (m, 1H, H-13), 1.34 – 1.29 (m, 1H, H-13), 1.25 (s, 3H, H-8), 
1.20 (dd, J = 9.0, 5.7 Hz, 1H), 1.07 (s, 3H, H-15), 1.06 (s, 3H, H-16); 13C NMR (126 MHz, CDCl3) δ 
158.0, 138.5, 133.1, 129.5, 128.4, 127.5, 127.4, 113.8, 75.9, 73.5, 72.2, 58.7, 55.4, 51.1, 47.5, 46.9, 43.2, 
40.5, 33.9, 22.3, 18.1. 
 
 
N-{(2R,4R)-2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-yl}-
1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine (321) 
 
To a solution of 2-{(benzyloxy)methyl}-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-amine 320 (22 
mg, 0.06 mmol, 1.0 equiv; 2:1 mixture of diastereoisomers) in dry toluene (1 mL) was added 
bis(dibenzylideneacetone)palladium(0) (7.0 mg, 0.01 mmol, 0.2 equiv), sodium tert-butoxide (9.0 mg, 
0.09 mmol, 1.5 equiv), rac-BINAP (15 mg, mmol, 0.4 equiv) and 2-chloro-1-(4-
fluorobenzyl)benzimidazole (16 mg, 0.06 mmol, 1.0 equiv).  The mixture was stirred at 120 ºC for 16 
hours in a pre-heated oil bath, after which time the mixture was cooled to room temperature and filtered 
through a pad of Celite®.  The filtrate was concentrated in vacuo.  The crude product was purified by flash 
chromatography on basic alumina, eluting with 0 to 30% ethyl acetate in petroleum ether, affording the 
title compound as a yellow oil (19 mg, 0.03 mmol, 48%) as a single diasteroisomer; Rf (ethyl acetate in 
petroleum ether, 25%): 0.23; IR max/cm
-1 (film): 2924, 1604, 1563, 1510, 1368, 1245, 1175, 1077, 908, 
822, 730; 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.8 Hz, 1H, H-21), 7.39 – 7.19 (m, 5H, H-15, H-22, 
H-23, and H-29), 7.15 – 6.96 (m, 9H, H-4, H-13, H-14, H-24 and H-28), 6.82 (d, J = 8.3 Hz, 2H, H-3), 
5.04 (s, 2H, H-26), 4.56 (d, J = 12.0 Hz, 1H, H-11), 4.49 (d, J = 12.0 Hz, 1H, H-11), 4.25 – 4.10 (m, 1H, 
H-17), 3.78 (s, 3H, H-1), 3.63 (d, J = 9.2 Hz, 1H, H-10), 3.56 (d, J = 7.7 Hz, 1H, NH), 3.46 (d, J = 9.2 
Hz, 1H, H-10), 2.96 – 2.84 (m, 1H, H-7), 2.69 – 2.56 (m, 3H, H-6 and H-7), 2.35 (d, J = 12.0 Hz, 1H, H-
16), 2.03 (d, J = 9.4 Hz, 1H, H-3), 1.31 (s, 3H, H-9), 1.22 (s, 3H, H-33), 1.19 – 1.12 (m, 1H, H-31), 1.10 
(s, 3H, H-34), 1.04 – 0.93  (m, 1H, H-16); 13C NMR (101 MHz, CDCl3) δ 162.5 (d, 
1JC-F  = 247.1 Hz), 
157.9, 153.4, 142.6, 138.9, 134.6, 132.96, 131.2, 129.4, 128.3, 128.1 (d, 3JC-F  = 8.2 Hz), 127.4, 127.3, 
121.5, 119.7, 116.8, 116.2 (d, 2JC-F  = 21.7 Hz), 113.8, 107.1, 73.5, 72.6, 59.1, 55.6, 55.3, 47.7, 47.2, 45.2, 
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45.1, 43.1, 41.4, 34.4, 28.2, 23.4; 19F NMR (376 MHz, MeOD) δ -113.75; m/z HRMS (ESI) found 
[M+H]+ 621.3596, C39H46FN4O2 requires 621.3599.   
 
 
 
{(2R,4R)-4-((1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)amino)-1-(4-methoxyphenethyl)-
2,6,6-trimethylpiperidin-2-yl}methanol (288) 
 
To a solution of N-{(2R,4R)-2-((benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin -4-
yl}-1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine 321 (14 mg, 0.02 mmol, 1.0 equiv) in methanol (1 
mL) was added ammonium formate (5.0 mg, 0.08 mmol, 4.0 equiv) and 10% palladium on carbon (1 mg, 
8 µmol, 0.1 equiv).  The resulting mixture was heated at reflux for 2 hours.  The mixture was cooled to 
room temperature and filtered through a pad of celite and washed with methanol.  The filtrate was 
concentrated in vacuo.  The crude product was purified by flash chromatography on basic alumina, 
eluting with 0 to 5% methanol in dichloromethane, affording the title compound as a pale orange solid (6 
mg, 0.01 mmol, 50%); M.p.: 179–181 °C; Rf (methanol in dichloromethane, 5%): 0.26; IR max/cm
-1 
(film): 3280 (br.), 2939, 1605, 1567, 1509, 1244, 1158, 1078, 1030, 821, 737, 700; 1H NMR  (500 MHz, 
MeOD) δ 7.33 (d, J = 7.6 Hz, 1H, H-16), 7.25 – 7.16 (m, 3H, H-18 and H-24), 7.12 – 7.04 (m, 5H, H-4, 
H-19 and H-23), 6.99 – 6.95 (m, 1H, H-17), 6.85 (d, J = 8.7 Hz, 2H, H-3), 5.28 (s, 2H, H-21), 4.23 – 4.12 
(m, 1H, H-12), 3.88 (d, J = 11.4 Hz, 1H, H-10), 3.78 (s, 3H, H-1), 3.48 (d, J = 11.4 Hz, 1H, H-10), 2.95 – 
2.87 (m, 1H, H-7), 2.76 – 2.62 (m, 3H, H-6 and H-7), 2.32 – 2.25 (m, 1H, H-11), 1.87 (d, J = 12.2 Hz, 
1H, H-25), 1.56 – 1.48 (m, 1H, H-25), 1.31 (s, 3H, H-28), 1.31 (s, 3H, H-9), 1.22 – 1.15 (m, 1H, H-11), 
1.19 (s, 3H, H-29); 13C NMR (126 MHz, MeOD) δ 162.2 (d, 1JC-F  = 244.4 Hz), 158.1, 154.0, 141.4, 
133.9, 132.6, 132.4, 129.0, 128.2 (d, 3JC-F  = 8.2 Hz), 121.1, 119.4, 115.0 (d, 
2JC-F = 21.9 Hz), 114.5, 
Experimental 
 
176| 
113.5, 107.7, 62.3, 60.0, 55.6, 54.2, 46.8, 44.5, 43.8, 41.2, 41.0, 33.5, 26.5, 22.5, 20.1; 19F NMR (376 
MHz, MeOD) δ -117.20; m/z HRMS (ESI) found [M+H]+ 531.3126, C32H40FN4O2 requires 531.3130. 
 
 
5.12 Towards the synthesis of astemizole analogue 289/335 
 
 
 
 
2,2,6-Trimethyl-1-azaspiro[bicyclo[4.2.0]octane-4,2'-[1,3]dioxolan]-8-one (128) 
 
To a dried 25 mL round bottom flask was charged palladium acetate (11 mg, 0.05 mmol, 0.1 equiv), 
copper(II) acetate (9.0 mg, 0.05 mmol, 0.1 equiv) followed by solution of 7,7,9,9-tetramethyl-1,4-dioxa-
8-azaspiro[4.5]decane 132 (100 mg, 0.5 mmol, 1.0 equiv) in dry toluene (5 mL).  A reflux condenser was 
fitted and a balloon of carbon monoxide and a balloon of air were attached to the condenser with a 
septum.  The flask was placed in a pre-heated oil bath at 120 ºC and stirred at this temperature for 16 
hours.  The reaction mixture was then cooled to room temperature and filtered through a pad of Celite®, 
eluting with ethyl acetate.  The filtrate was washed with saturated aqueous ammonium chloride, saturated 
aqueous sodium bicarbonate, brine, dried (magnesium sulfate) and concentrated in vacuo.  The crude 
product was purified by flash chromatography on silica gel, eluting with 0 to 10% diethyl ether in 
dichloromethane, affording the title compound as an orange oil (70 mg, 0.03 mmol, 62%); Rf  (diethyl 
ether in dichloromethane, 10%): 0.26; IR max/cm
-1 (film): 2971, 1737, 1326, 1094, 667; 1H NMR (500 
MHz, CDCl3) δ 4.01 (2H, td, J = 6.0 Hz, 0.4 Hz, H-7 or H-8), 3.93-3.86 (2H, m, H-7 or H-8), 2.68 (2H, 
d, J = 14.4 Hz, H-2), 2.00 (1H, dd, J = 13.2, 1.6 Hz, H-5), 1.71-1.65 (3H, m, H-5 and H-9), 1.63 (3H, s, 
H-11 or H-12), 1.54 (3H, s, H-3), 1.32 (3H, s, H-11 or H-12); 13C NMR (126 MHz, CDCl3) δ 165.4, 
108.1, 64.9, 63.3, 55.0, 53.3, 52.6, 46.0, 42.8, 29.2, 27.2, 25.4; m/z HRMS (ESI) found [M+H]+ 
226.1437, C12H20NO3 requires 226.1438.   
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2-(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)ethanol (333) and 2,2,6-trimethyl-1-
azaspiro(bicyclo[4.2.0]octane-4,2'-[1,3]dioxolane) (334) 
 
To a solution of 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 128 (1.2 g, 5.33 mmol, 1.0 equiv) 
in dry tetrahydrofuran (50 mL) at 0 ºC was added lithium aluminium hydride (4.40 mL, 10.7 mmol, 2.0 
equiv; 2.4 M solution in tetrahydrofuran).  The resulting solution was warmed to room temperature and 
stirred for 3 hours.  The mixture was then cooled to 0 ºC and quenched with water (0.4 mL), 1 N sodium 
hydroxide (1.2 mL), water (0.4 mL), followed by addition of magnesium sulfate.  The resulting slurry was 
stirred at this temperature for 20 mins and filtered.  The filter cake was washed with diethyl ether and the 
filtrate concentrated in vacuo.  The crude product was purified by flash chromatography on triethylamine-
pretreated silica gel, eluting with 0 to 5% MeOH in dichloromethane, affording 2-(7,9,9-trimethyl-1,4-
dioxa-8-azaspiro[4.5]decan-7-yl)ethanol 333 as a white solid (842 mg, 3.68 mmol, 69%) and 2,2,6-
trimethyl-1-azaspiro(bicyclo[4.2.0]octane-4,2'-[1,3]dioxolane) 334 (124 mg, 0.59 mmol, 11%) as a 
colourless oil. 
 
2-(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)ethanol (333):  
 
M.p.: 50–52ºC; Rf (methanol in dichloromethane, 5% - on triethylamine-pretreated silica plate): 0.32; IR 
max/cm
-1 (film): 3463-3170 (br), 2959, 1480, 1357, 1232, 1087, 1035, 950, 840, 790, 774; 1H NMR (400 
MHz, CDCl3) δ 4.00 – 3.94 (m, 2H, H-6 or H-7), 3.94 – 3.89 (m, 2H, H-6 or H-7), 3.86 (dt, J = 6.5, 4.3 
Hz, 2H, H-13), 1.94 – 1.88 (m, 1H, H-12), 1.85 (d, J = 13.9 Hz, 1H, H-4), 1.67 (d, J = 13.8 Hz, 1H, H-5) , 
1.62 (dd, J = 13.8, 1.7 Hz, 1H, H-5), 1.58 (ddd, J = 10.5, 5.4, 2.1 Hz, 1H, H-12), 1.52 (dd, J = 13.9, 1.4 
Hz, 1H, H-4), 1.40 (s, 3H, H-2), 1.32 (s, 3H, H-10 or H-11), 1.27 (s, 3H, H-10 or H-11); 13C NMR (101 
MHz, CDCl3) δ 108.1, 64.3, 63.6, 59.7, 56.2, 52.6, 44.5, 42.5, 42.4, 33.1, 30.6, 28.6; m/z HRMS (ESI) 
found [M+H]+ 230.1752, C12H24NO3 requires 230.1751.   
 
2,2,6-Trimethyl-1-azaspiro(bicyclo[4.2.0]octane-4,2'-[1,3]dioxolane) (334):  
 
Rf (methanol in dichloromethane, 5% - on triethylamine-pretreated silica plate): 0.40; IR max/cm
-1 (film): 
1641, 1454, 1361, 1189, 1086, 1032, 895, 805, 735, 698; 1H NMR (500 MHz, CDCl3) δ 4.04 – 3.95 (m, 
2H, H-7 or H-8), 3.92 – 3.82 (m, 2H, H-7 or H-8), 3.22 (dt, J = 9.2, 6.9 Hz, 1H, H-1), 3.16 – 3.05 (m, 1H, 
H-1), 2.01 (dd, J = 17.2, 9.4 Hz, 1H, H-2), 1.92 (d, J = 13.7 Hz, 1H, H-5), 1.67 – 1.54 (m, 3H, H-2, H-5 
and H-9), 1.42 (dd, J = 13.7, 2.3 Hz, 1H, H-9), 1.36 (s, 3H, H-4), 1.18 (s, 3H, H-11 or H-12), 0.96 (s, 3H, 
Experimental 
 
178| 
H-11 or H-12); 13C NMR (126 MHz, CDCl3) δ 108.9, 64.7, 63.5, 62.9, 53.1, 43.3, 38.7, 37.8, 32.9, 29.9, 
29.2, 28.1; m/z HRMS (ESI) found [M+H]+ 212.1575, C12H22NO2 requires 212.1752. 
 
 
7-(2-(Benzyloxy)ethyl)-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane (336) 
 
To a solution of 2-(7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)ethanol 333 (900 mg, 3.93 
mmol, 1.0 equiv) in dry tetrahydrofuran (40 mL) at 0 ºC was added sodium hydride (60% in mineral oil; 
314 mg, 5.90  mmol, 1.5 equiv) and stirred at this temperature for 30 minutes. Benzyl bromide (0.94 mL, 
5.90 mmol, 1.5 equiv) was then added and the resulting mixture was warmed to room temperature and 
stirred at this temperature for 16 hours.  The reaction mixture was partitioned between diethyl ether and 
saturated aqueous sodium bicarbonate.  The aqueous layer was separated and extracted with diethyl ether.  
The combined organic extract was washed with brine, dried (magnesium sulfate) and concentrated in 
vacuo.  The crude product was purified by flash chromatography on triethylamine-pretreated silica gel, 
eluting with 0 to 25% ethyl acetate in petroleum ether, affording the title compound as a pale yellow oil 
(927 mg, 2.91 mmol, 74%); Rf (ethyl acetate in petroleum ether, 10% - on triethylamine-pretreated silica 
plate): 0.20; IR max/cm
-1 (film): 2953, 2877, 1454, 1358, 1228, 1090, 1034, 948, 787, 735, 698; 1H NMR 
(500 MHz, CDCl3) δ 7.35 – 7.31 (m, 3H, H-16 and H-17), 7.30 – 7.26 (m, 2H, H-15), 4.49 (s, 2H, H-13), 
3.96 – 3.86 (m, 4H, H-6 and H-7), 3.62 (t, J = 7.0 Hz, 2H, H-12), 1.97 (dt, J = 13.8, 6.8 Hz, 1H, H-11), 
1.77 (dt, J = 13.8, 7.1 Hz, 1H, H-11), 1.65 – 1.45 (m, 4H, H-4 and H-8), 1.22 (s, 3H, H-2), 1.21 (s, 3H, H-
9 or H-10), 1.16 (s, 3H, H-9 or H-10); 13C NMR (126 MHz, CDCl3) δ 138.6, 128.3, 127.6, 127.5, 109.1, 
73.0, 67.2, 63.9, 63.7, 53.1, 51.1, 45.5, 44.0, 42.8, 32.4, 32.0, 29.5; m/z HRMS (ESI) found [M+H]+ 
320.2221, C19H30NO3 requires 320.2220.   
 
 
2-{(Benzyloxy)ethyl}-2,6,6-trimethylpiperidin-4-one (359) 
 
To a solution of 7-{2-(benzyloxy)ethyl}-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane 336 (1.40 g, 
4.39 mmol, 1.0 equiv) in ethanol (10 mL) was added 3 N hydrochloric acid (10 mL) and stirred at 80 ºC 
for 2 hours.  The reaction mixture was cooled and ethanol removed under reduced pressure.  The mixture 
was basified with saturated aqueous sodium bicarbonate and extracted with ethyl acetate.  The combined 
organic extracts were washed with brine, dried (magnesium sulfate) and concentrated in vacuo.  The 
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crude product was purified by flash chromatography on silica gel, eluting with 0 to 50% ethyl acetate in 
petroleum ether, affording the title compound as a yellow oil (1.20 g, 4.39 mmol, 100%); Rf (ethyl acetate 
in petroleum ether, 50%): 0.19; IR max/cm
-1 (film): 2965, 2864, 1703, 1454, 1365, 1292, 1215, 1098, 
736, 697; 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.29 (m, 5H, Ar-Hs), 4.51 (s, 2H, H-11), 3.72 – 3.57 (m, 
2H, H-10), 2.42 (d, J = 13.2 Hz, 1H, H-4 ), 2.28 (d, J = 13.3 Hz, 1H, H-6), 2.25 (d, J = 13.3 Hz, 1H, H-6), 
2.21 (dd, J = 13.2, 1.0 Hz, 1H, H-4), 1.82 (t, J = 6.4 Hz, 2H, H-9), 1.23 (s, 3H, H-2), 1.22 (s, 3H, H-7 or 
H-8), 1.20 (s, 3H, H-7 or H-8); 13C NMR (126 MHz, CDCl3) δ 211.1, 138.2, 128.4, 127.8, 127.7, 73.2, 
66.9, 57.0, 54.9, 54.2, 52.5, 43.4, 32.9, 31.5, 29.8; m/z HRMS (ESI) found [M+H]+ 276.1957, C17H26NO2 
requires 276.1958. 
 
 
2-{2-(Benzyloxy)ethyl}-2,6,6-trimethylpiperidin-4-ol (360) 
 
To a solution of 2-{(benzyloxy)methyl}-2,6,6-trimethylpiperidin-4-one 359 (1.20 g, 4.39  mmol, 1.0 equiv) 
in methanol (50 mL) was added sodium borohydride (332 mg, 8.78 mmol, 2.0 equiv) and stirred at room 
temperature for 2 hours.  The reaction mixture was quenched with water and methanol was removed in 
vacuo.  The mixture was then partitioned between dichloromethane and water.  The layers were separated 
and the aqueous layer extracted with dichloromethane.  The combined organic extracts were washed with 
brine, dried (magnesium sulfate) and concentrated in vacuo to yield the title compound as an inseparable 
1.5:1 mixture of diastereoisomers (determined by 1H NMR of the crude material) as a yellow oil (1.1 g, 
3.97 mmol, 90%).  The crude alcohol was then taken on to the subsequent protection step without further 
purification.  IR max/cm
-1 (film): 3340 (br.), 2929, 1455, 1366, 1222, 1098, 1051, 1028, 735, 697; m/z 
HRMS (ESI) found [M+H]+ 278.2115, C17H28NO2 requires 278.2115.  Major diastereoisomer: 1H NMR  
(500 MHz, CDCl3) δ 7.38 – 7.29 (m, 5H, Ar-Hs), 4.53 (d, J = 11.9 Hz, 1H, H-12), 4.50 (d, J = 11.8 Hz, 
1H, H-12), 4.15 – 4.02 (m, 1H, H-5), 3.73 – 3.56 (m, 2H, H-11), 2.06 – 1.88 (m, 3H, H-4, H-7 and H-10), 
1.81 – 1.65 (m, 1H, H-10), 1.17 (s, 3H, H-8 or H-9), 1.15 (s, 3H, H-8 or H-9), 1.14 (s, 3H, H-2), 1.07 – 
0.94 (m, 2H, H-4 and H-7); 13C NMR (126 MHz, CDCl3) δ 138.6, 128.4, 127.6, 127.5, 73.1, 67.6, 64.7, 
53.3, 51.6, 48.2, 48.0, 39.3, 35.1, 31.7, 28.8.  Minor diastereoisomer: 1H NMR  (500 MHz, CDCl3) δ 
7.38 – 7.29 (m, 5H, Ar-Hs), 4.53 (d, J = 11.9 Hz, 1H, H-12), 4.50 (d, J = 11.8 Hz, 1H, H-12), 4.15 – 4.02 
(m, 1H, H-5), 3.73 – 3.56 (m, 2H, H-11), 2.06 – 1.88 (m, 2H, H-7 and H-10), 1.84 (ddd, J = 12.0, 4.1, 1.9 
Hz, 1H, H-4), 1.81 – 1.65 (m, 1H, H-10), 1.22 (s, 3H, H-8 or H-9), 1.20 (s, 3H, H-8 or H-9), 1.12 (s, 3H, 
H-2), 1.07 – 0.94 (m, 2H, H-4 and H-7); 13C NMR (126 MHz, CDCl3) δ 138.4, 128.4, 127.7, 127.6, 73.1, 
66.7, 65.0, 53.7, 51.3, 48.1, 45.7, 39.3, 34.9, 29.5, 28.0 
Experimental 
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2-{2-(Benzyloxy)ethyl}-2,6,6-trimethyl-4-{(triisopropylsilyl)oxy}piperidine (361) 
 
To a solution of 2-{2-(benzyloxy)ethyl}-2,6,6-trimethylpiperidin-4-ol 360 (1.10 g, 3.96 mmol, 1.0 equiv; 
1.5:1 mixture of diastereoisomers) in N,N-dimethylformamide (40 mL) at 0 oC was added imidazole (404 
mg, 5.94 mmol, 1.5 equiv) and triisopropylsilyl chloride (1.27 ml, 5.94 mmol, 1.5 equiv).  The resulting 
pale yellow solution was warmed to room temperature and stirred for 8 hours.  The mixture was then 
partitioned between ethyl acetate and saturated aqueous sodium bicarbonate.  The layers were separated 
and the organic layer was washed with water, brine, dried (magnesium sulfate) and concentrated in vacuo.  
The crude product was purified by flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate 
in petroleum ether, affording the title compound as an inseparable 1.5:1 mixture of diastereoisomers as a 
pale yellow oil (1.31 mg, 3.13 mmol, 79%); Rf (ethyl acetate in petroleum ether, 20% - on triethylamine-
pretreated silica plate): 0.32; IR max/cm
-1 (film): 2938, 2865, 1455, 1363, 1223, 1089, 1014, 882, 733, 
636; m/z HRMS (ESI) found [M+H]+ 434.3446, C26H48NO2Si requires 434.3449.  Major 
diastereoisomer: 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.29 (m, 5H, Ar-Hs), 4.53 (d, J = 12.0 Hz, 1H, H-
12), 4.51 (d, J = 12.0 Hz, 1H, H-12), 4.14 (tt, J = 11.0, 4.1 Hz, 1H, H-5), 3.68 – 3.57 (m, 2H, H-13), 2.07 
– 1.81 (m, 3H,  H-4, H-8 and H-12), 1.75 – 1.66 (m, 1H, H-12), 1.16 (s, 3H, H-10 or H-11), 1.13 (s, 3H, 
H10 or H-11), 1.12 (s, 3H, H-2), 1.10 – 0.98 (m, 25H, H-4, H-6, H-7 and H-8); 13C NMR (126 MHz, 
CDCl3) δ 138.6, 128.4, 127.7, 127.5, 73.2, 67.6, 65.1, 53.2, 51.5, 48.8, 48.7, 39.5, 35.0, 31.8, 28.7, 18.1, 
12.3.  Minor diastereoisomer: 1H NMR  (500 MHz, CDCl3) δ 7.38 – 7.29 (m, 5H, Ar-Hs), 4.53 (d, J = 
12.0 Hz, 1H, H-12), 4.51 (d, J = 12.0 Hz, 1H, H-12), 4.10 – 4.05 (m, 1H, H-5), 3.68 – 3.57 (m, 2H, H-
13), 2.07 – 1.81 (m, 3H, H-4, H-8 and H-12), 1.75 – 1.66 (m, 1H, H-12), 1.10 – 0.98 (m, 34H, H-2, H-4, 
H-6, H-7, H-8, H-10 and H-11); 13C NMR (126 MHz, CDCl3) δ 138.6, 128.4, 127.7, 127.5, 73.0, 66.8, 
65.4, 53.6, 51.3, 46.3, 45.7, 39.5, 35.0, 31.8, 28.1, 18.2, 12.4. 
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2-{2-(Benzyloxy)ethyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy}piperidine (363) 
 
To a solution of 2-{2-(benzyloxy)ethyl}-2,6,6-trimethyl-4-{(triisopropylsilyl)oxy}piperidine 361 (200 mg, 
0.46 mmol, 1.0 equiv, 2:1 mixture of diasteroisomers) in acetonitrile (2 mL) in a microwave tube was 
added 1-(2-bromoethyl)-4-methoxybenzene (0.22 mL, 1.38 mmol, 3.0 equiv) and potassium carbonate 
(191 mg, 1.38 mmol, 3.0 equiv).  The resulting mixture was sealed and heated at 150 ºC in the microwave 
for 4 hours.  The reaction mixture was filtered and filtrate concentrated in vacuo.  To the crude material 
was added ethanol (2 ml) and 3 N hydrochloric acid (2 ml) and the mixture heated at 80 ºC for 4 hours.  
The solution was cooled and basified to ~pH=10 with 1 N sodium hydroxide and extracted with 
dichloromethane.  The layers were separated and the aqueous layer was further extracted with 
dichloromethane.  The combined organic extracts were dried (magnesium sulfate) and concentrated in 
vacuo.   
 
The crude alcohol was then dissolved in dichloromethane (3 mL), followed by addition of N-
methylmorpholine N-oxide (54.0 mg, 0.46 mmol, 1.0 equiv – based on 2-{2-(benzyloxy)ethyl}-2,6,6-
trimethyl-4-{(triisopropylsilyl)oxy}piperidine 361) and tetrapropylammonium perruthenate (8.1 mg, 0.023 
mmol, 0.05 equiv).  The mixture was stirred at room temperature for 3 hours and filtered through a pad of 
silica gel, eluting with dichloromethane.  The solvent was then recovered under reduced pressure.  The 
crude product was purified by flash chromatography on silica gel, eluting with 0 to 20% ethyl acetate in 
petroleum ether, affording the title compound as a pale yellow oil (18.9 mg, 0.046 mmol, 10%), as well as 
2-{(benzyloxy)ethyl}-2,6,6-trimethylpiperidin-4-one 359, which was recovered as a yellow oil (95 mg, 
0.35 mmol, 76%); Rf (ethyl acetate in petroleum ether, 20%): 0.30; IR max/cm
-1 (film):  2966, 1714, 
1611, 1511, 1364, 1245, 1176, 1094, 1034, 822, 698; 1H NMR (500 MHz, CDCl3) δ 7.39 – 7.29 (m, 5H, 
H-20, H-21 and H-22), 7.12 (d, J = 8.7 Hz, 2H, H-4), 6.87 (d, J = 8.7 Hz, 2H, H-3), 4.51 (s, 2H, H-18), 
3.82 (s, 3H, H-18), 3.61 (t, J = 6.6 Hz, 2H, H-17), 2.78 – 2.66 (m, 4H, H-6 and H-7), 2.59 (dd, J = 13.0, 
Experimental 
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1.5 Hz, 1H, H-10), 2.42 (dd, J = 12.7, 1.5 Hz, 1H, H-12), 2.34 (dd, J = 12.7, 1.8 Hz, 1H, H-12), 2.29 (dd, 
J = 13.0, 1.8 Hz, 1H, H-10), 2.03 – 1.94 (m, 2H, H-16), 1.89 – 1.79 (m, 1H, H-16), 1.26 (s, 3H, H-14 or 
H-15), 1.20 (s, 6H, H-8, and H-14 or H-15); 13C NMR (126 MHz, CDCl3) δ 210.0, 158.0, 138.2, 132.6, 
129.4, 128.4, 127.7, 127.6, 113.9, 73.1, 67.2, 61.9, 59.9, 55.7, 55.3, 52.6, 47.4, 40.5, 40.1, 30.0, 27.6, 
25.6; m/z HRMS (ESI) found [M+H]+ 410.2692, C26H36NO3 requires 410.2690. 
 
 
5.13 Alternative strategies to install the 4-methoxyphenylethyl unit 
 
 
2-(4-Methoxyphenyl)-1-(7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decan-8-yl)ethanone 
(338) 
 
To a solution of 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 132 (50 mg, 0.25 mmol, 1.0 equiv) 
in dry toluene (0.5 mL) was added sodium hydride (20 mg, 0.50 mmol; 60% dispersion in oil, 2.0 equiv).  
The resulting mixture was stirred at room temperature for 10 mins followed by addition of 4-
methoxyphenylacetyl chloride (0.09 mL, 0.50 mmol, 2.0 equiv).  The reaction mixture was then heated at 
reflux for 16 hours and cooled.  The mixture was then quenched with saturated sodium bicarbonate and 
extracted with ethyl acetate.  The combined organic extract was washed with brine, dried (magnesium 
sulfate) and concentrated in vacuo.  The crude product was purified by flash chromatography on 
triethylamine-pretreated silica gel, eluting with 0 to 30% ethyl acetate in petroleum ether, affording the 
title compound as a brown solid (63 mg, 0.18 mmol, 72%); M.p.: 48–50 °C; Rf (ethyl acetate in 
petroleum ether, 30% - on triethylamine-pretreated silica plate): 0.30; IR max/cm
-1 (film): 2962, 1728, 
1666, 1516, 1251, 1164, 1144, 809, 763, 694; 1H NMR (500 MHz, CDCl3) δ 7.21 (d, J = 8.8 Hz, 2H, H-
4), 6.86 (d, J = 8.7 Hz, 2H, H-3), 4.34 (dd, J = 5.4, 4.3 Hz, 2H, H-13 or H-14), 3.92 – 3.83 (m, 2H, H-13 
or H-14), 3.79 (s, 3H, H-1), 3.60 (s, 2H, H-6), 1.91 (s, 4H, H-11), 1.21 (s, 6H, H-9 or H-10), 1.18 (s, 6H, 
H-9 or H-10); 13C NMR (126 MHz, CDCl3) δ 171.9, 158.7, 151.0, 130.3, 125.9, 114.0, 102.7, 64.1, 63.1, 
55.3, 40.4, 40.3, 32.8, 30.3; m/z HRMS (ESI) found [M+H]+ 348.2170, C20H30NO4 requires 348.2169.   
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2,2,6,6-Tetramethylpiperidin-1-yl benzoate (339) 
 
To a solution of 2,2,6,6,-tetramethylpiperidine (3.00 g, 20 mmol, 1.0 equiv) in N,N-dimethylformamide 
(20 mL) was added dibenzoyl peroxide (5.80 g, 24 mmol, 1.2 equiv) and dipotassium phosphate (17.5 g, 
100 mmol, 5.0 equiv).  The mixture was stirred at room temperature for 16 hours and filtered.  The filtrate 
was partitioned between water and diethyl ether.  The organic layer was washed with water, dried 
(magnesium sulfate) and concentrated in vacuo.   The crude product was purified by flash 
chromatography on silica gel, eluting with 0 to 10% ethyl acetate in petroleum ether, affording the title 
compound as a white solid (700 mg, 2.68 mmol, 13%); Rf (ethyl acetate in petroleum ether, 10%): 0.27; 
IR max/cm
-1 (film): 2978, 1741, 1449, 1363, 1249, 104, 906, 717; 1H NMR (400 MHz, CDCl3) δ 8.10 (d, 
J = 7.1 Hz, 2H, H-3), 7.59 (t, J = 7.4 Hz, 1H, H-1), 7.48 (t, J = 7.6 Hz, 2H, H-2), 1.94 – 1.41 (m, 6H, H-9 
and H-10), 1.30 (s, 6H, H-7 or H-8), 1.14 (s, 6H, H-7 or H-8); 13C NMR (101 MHz, CDCl3) δ 166.4, 
132.8, 129.8, 129.6, 128.4, 60.4, 39.1, 32.0, 20.9, 17.0.  The physical data were identical in all respect to 
that previously reported.146 
 
 
8-Ethyl-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (341) 
 
A mixture of 7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane 132 (1.0 g, 5.05 mmol, 1.0 equiv) and 
potassium carbonate (2.09 g, 15.2 mmol, 3.0 equiv) were stirred in iodoethane (2.8 mL, 35.4 mmol, 7.0 
equiv) in a sealed oven-dried microwave tube at 120 ºC for 20 hours. The reaction mixture was cooled 
and partitioned between ethyl acetate and water.  The organic extract was washed with brine, dried 
(magnesium sulfate) and concentrated in vacuo.  The crude product was purified by flash chromatography 
on triethylamine-pretreated silica gel, eluting with 0 to 10% ethyl acetate in petroleum ether, affording the 
title compound as a pale yellow solid (500 mg, 2.20 mmol, 44%); M.p.: 54–56 °C; Rf (ethyl acetate in 
petroleum ether, 10% - on triethylamine-pretreated silica plate): 0.33; IR max/cm
-1 (film): 2969, 2884, 
1478, 1356, 1185, 1086, 947, 796, 726; 1H NMR (400 MHz, CDCl3) δ 3.94 (s, 4H, H-7), 2.56 (q, J = 7.1 
Hz, 2H, H-2), 1.66 (s, 4H, H-5), 1.14 (s, 12H, H-4), 1.05 (t, J = 7.1 Hz, 3H, H-1); 13C NMR (101 MHz, 
Experimental 
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CDCl3) δ 107.8, 63.6, 55.8, 47.6, 37.3, 27.9, 20.9; m/z HRMS (ESI) found [M+H]
+ 228.1956, C13H26NO2 
requires 228.1958.   
 
 
References 
 
185| 
6 References 
 
(1)  King, A. O.; Negishi, E.; Villani, F. J.; Silveira, A. J. Org. Chem. 1978, 43, 358. 
(2)  Negishi, E.; King, A. O.; Okukado, N. J. Org. Chem. 1977, 42, 1821. 
(3)  King, A. O.; Okukado, N.; Negishi, E. J. Chem. Soc. Chem. Commun. 1977, 683. 
(4)  Heck, R. F.; Nolley, J. P. J. Org. Chem. 1972, 37, 2320. 
(5)  Dieck, H. A.; Heck, R. F. J. Am. Chem. Soc. 1974, 96, 1133. 
(6)  Miyaura, N.; Yanagi, T.; Suzuki, A. Synth. Commun. 2006, 11, 513. 
(7)  Miyaura, N.; Yamada, K.; Suzuki, A. Tetrahedron Lett. 1979, 20, 3437. 
(8)  Miyaura, N.; Suzuki, A. J. Chem. Soc. Chem. Commun. 1979, 866. 
(9)  Baudoin, O. Chem. Soc. Rev. 2011, 40, 4902. 
(10)  Chen, X.; Engle, K. M.; Wang, D.-H.; Yu, J.-Q. Angew. Chem. Int. Ed. 2009, 48, 5094. 
(11)  Blanksby, S. J.; Ellison, G. B. Acc. Chem. Res. 2003, 36, 255. 
(12)  Bordwell, F. G. Acc. Chem. Res. 1988, 21, 456. 
(13)  Crabtree, R. H. J. Organomet. Chem. 2004, 689, 4083. 
(14)  Deprez, N. R.; Kalyani, D.; Krause, A.; Sanford, M. S. J. Am. Chem. Soc. 2006, 128, 
4972. 
(15)  Labinger, J. A.; Bercaw, J. E. Nature 2002, 417, 507. 
(16)  Waterman, R. Organometallics 2013, 32, 7249. 
(17)  Crabtree, R. H. Chem. Rev. 1995, 95, 987. 
(18)  Arndtsen, B. A.; Bergman, R. G.; Mobley, T. A.; Peterson, T. H. Acc. Chem. Res. 1995, 
28, 154. 
(19)  Jones, W. D.; Feher, F. J. Acc. Chem. Res. 1989, 22, 91. 
(20)  Lee, H.-S.; Kim, S.-H.; Kim, J.-N. Bull. Korean Chem. Soc. 2010, 31, 238. 
(21)  Shi, Z.; Li, B.; Wan, X.; Cheng, J.; Fang, Z.; Cao, B.; Qin, C.; Wang, Y. Angew. Chem. 
Int. Ed. 2007, 46, 5554. 
References 
 
186| 
(22)  Gorelsky, S. I.; Lapointe, D.; Fagnou, K. J. Am. Chem. Soc. 2008, 130, 10848. 
(23)  Lapointe, D.; Fagnou, K. Chem. Lett. 2010, 39, 1118. 
(24)  García-Cuadrado, D.; de Mendoza, P.; Braga, A. A. C.; Maseras, F.; Echavarren, A. M. J. 
Am. Chem. Soc. 2007, 129, 6880. 
(25)  Lafrance, M.; Fagnou, K. J. Am. Chem. Soc. 2006, 128, 16496. 
(26)  Cope, A. C.; Siekman, R. W. J. Am. Chem. Soc. 1965, 87, 3272. 
(27)  Dupont, J.; Consorti, C. S.; Spencer, J. Chem. Rev. 2005, 105, 2527. 
(28)  Dyker, G. Angew. Chem. Int. Ed. 1999, 38, 1698. 
(29)  Dunina, V. V; Zalevskaya, O. A.; Potapov, V. M. Russ. Chem. Rev. 1988, 57, 250. 
(30)  Lyons, T. W.; Sanford, M. S. Chem. Rev. 2010, 110, 1147. 
(31)  Ryabov, A. D. Chem. Rev. 1990, 90, 403. 
(32)  Cope, A. C.; Friedrich, E. C. J. Am. Chem. Soc. 1968, 90, 909. 
(33)  R. Fahey, D. J. Organomet. Chem. 1971, 27, 283. 
(34)  Tremont, S. J. J. Am. Chem. Soc. 1984, 106, 5759. 
(35)  Byers, P. K.; Canty, A. J.; Skelton, B. W.; White, A. H. J. Chem. Soc. Chem. Commun. 
1986, 1722. 
(36)  Canty, A. J.; Denney, M. C.; van Koten, G.; Skelton, B. W.; White, A. H. 
Organometallics 2004, 23, 5432. 
(37)  Ryabov, A. D.; Sakodinskaya, I. K.; Yatsimirsky, A. K. J. Chem. Soc. Dalt. Trans. 1985, 
2629. 
(38)  Davies, D. L.; Donald, S. M. A.; Macgregor, S. A. J. Am. Chem. Soc. 2005, 127, 13754. 
(39)  Giri, R.; Maugel, N.; Li, J.-J.; Wang, D.-H.; Breazzano, S. P.; Saunders, L. B.; Yu, J.-Q. J. 
Am. Chem. Soc. 2007, 129, 3510. 
(40)  Giri, R.; Chen, X.; Yu, J.-Q. Angew. Chem. Int. Ed. 2005, 44, 2112. 
(41)  Giri, R.; Liang, J.; Lei, J.-G.; Li, J.-J.; Wang, D.-H.; Chen, X.; Naggar, I. C.; Guo, C.; 
Foxman, B. M.; Yu, J.-Q. Angew. Chem. Int. Ed. 2005, 44, 7420. 
(42)  Giri, R.; Wasa, M.; Breazzano, S. P.; Yu, J.-Q. Org. Lett. 2006, 8, 5685. 
References 
 
187| 
(43)  Chan, K. S. L.; Wasa, M.; Wang, X.; Yu, J.-Q. Angew. Chem. Int. Ed. 2011, 50, 9081. 
(44)  Wasa, M.; Engle, K. M.; Yu, J.-Q. J. Am. Chem. Soc. 2009, 131, 9886. 
(45)  Yoo, E. J.; Wasa, M.; Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 17378. 
(46)  Reddy, B. V. S.; Reddy, L. R.; Corey, E. J. Org. Lett. 2006, 8, 3391. 
(47)  Shabashov, D.; Daugulis, O. J. Am. Chem. Soc. 2010, 132, 3965. 
(48)  Wasa, M.; Engle, K. M.; Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 3680. 
(49)  Kalyani, D.; Dick, A. R.; Anani, W. Q.; Sanford, M. S. Org. Lett. 2006, 8, 2523. 
(50)  Hull, K. L.; Anani, W. Q.; Sanford, M. S. J. Am. Chem. Soc. 2006, 128, 7134. 
(51)  Desai, L. V.; Malik, H. A.; Sanford, M. S. Org. Lett. 2006, 8, 1141. 
(52)  Kalyani, D.; Dick, A. R.; Anani, W. Q.; Sanford, M. S. Tetrahedron 2006, 62, 11483. 
(53)  Chiong, H. A.; Pham, Q.-N.; Daugulis, O. J. Am. Chem. Soc. 2007, 129, 9879. 
(54)  Bernardes, G. J. L.; Chalker, J. M.; Errey, J. C.; Davis, B. G. J. Am. Chem. Soc. 2008, 
130, 5052. 
(55)  Wang, D.-H.; Mei, T.-S.; Yu, J.-Q. J. Am. Chem. Soc. 2008, 130, 17676. 
(56)  Mei, T.-S.; Giri, R.; Maugel, N.; Yu, J.-Q. Angew. Chem. Int. Ed. 2008, 47, 5215. 
(57)  Li, G.; Wan, L.; Zhang, G.; Leow, D.; Spangler, J.; Yu, J.-Q. J. Am. Chem. Soc. 2015, 
137, 4391. 
(58)  Simmons, E. M.; Hartwig, J. F. Nature 2012, 483, 70. 
(59)  Lu, Y.; Wang, D.-H.; Engle, K. M.; Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 5916. 
(60)  Lawrence, S. A. Amines: Synthesis, Properties and Applications; Cambridge University 
Press, 2004. 
(61)  Omae, I. Chem. Rev. 1979, 79, 287. 
(62)  Wang, J.-R.; Fu, Y.; Zhang, B.-B.; Cui, X.; Liu, L.; Guo, Q.-X. Tetrahedron Lett. 2006, 
47, 8293. 
(63)  Zaitsev, V. G.; Shabashov, D.; Daugulis, O. J. Am. Chem. Soc. 2005, 127, 13154. 
(64)  Dupont, J.; Consorti, C. S.; Spencer, J. Chem. Rev. 2005, 105, 2527. 
References 
 
188| 
(65)  Canty, A. J.; Patel, J.; Rodemann, T.; Ryan, J. H.; Skelton, B. W.; White, A. H. 
Organometallics 2004, 23, 3466. 
(66)  Gou, F.-R.; Wang, X.-C.; Huo, P.-F.; Bi, H.-P.; Guan, Z.-H.; Liang, Y.-M. Org. Lett. 
2009, 11, 5726. 
(67)  Zhao, Y.; Chen, G. Org. Lett. 2011, 13, 4850. 
(68)  Zhao, Y.; He, G.; Nack, W. A.; Chen, G. Org. Lett. 2012, 14, 2948. 
(69)  Zhang, S.-Y.; He, G.; Nack, W. A.; Zhao, Y.; Li, Q.; Chen, G. J. Am. Chem. Soc. 2013, 
135, 2124. 
(70)  He, G.; Chen, G. Angew. Chem. Int. Ed. 2011, 50, 5192. 
(71)  He, G.; Zhao, Y.; Zhang, S.; Lu, C.; Chen, G. J. Am. Chem. Soc. 2012, 134, 3. 
(72)  Nadres, E. T.; Daugulis, O. J. Am. Chem. Soc. 2012, 134, 7. 
(73)  He, G.; Lu, C.; Zhao, Y.; Nack, W. A.; Chen, G. Org. Lett. 2012, 14, 2944. 
(74)  Zhang, S.-Y.; He, G.; Zhao, Y.; Wright, K.; Nack, W. A.; Chen, G. J. Am. Chem. Soc. 
2012, 134, 7313. 
(75)  Cui, W.; Chen, S.; Wu, J.-Q.; Zhao, X.; Hu, W.; Wang, H. Org. Lett. 2014, 16, 4288. 
(76)  Li, J.-J.; Mei, T.-S.; Yu, J.-Q. Angew. Chem. Int. Ed. 2008, 47, 6452. 
(77)  Mei, T.-S.; Wang, X.; Yu, J.-Q. J. Am. Chem. Soc. 2009, 131, 10806. 
(78)  Wang, X.; Mei, T.-S.; Yu, J.-Q. J. Am. Chem. Soc. 2009, 131, 7520. 
(79)  Chu, L.; Wang, X.-C.; Moore, C. E.; Rheingold, A. L.; Yu, J.-Q. J. Am. Chem. Soc. 2013, 
135, 16344. 
(80)  Thuy-Boun, P. S.; Villa, G.; Dang, D.; Richardson, P.; Su, S.; Yu, J.-Q. J. Am. Chem. Soc. 
2013, 135, 17508. 
(81)  Chu, L.; Xiao, K.-J.; Yu, J.-Q. Science 2014, 346, 451. 
(82)  Chan, K. S. L.; Wasa, M.; Chu, L.; Laforteza, B. N.; Miura, M.; Yu, J.-Q. Nat. Chem. 
2014, 6, 146. 
(83)  Chan, K. S. L.; Fu, H.-Y.; Yu, J.-Q. J. Am. Chem. Soc. 2015, 137, 2042. 
(84)  Rodríguez, N.; Romero-Revilla, J. A.; Fernández-Ibáñez, M. Á.; Carretero, J. C. Chem. 
Sci. 2013, 4, 175. 
References 
 
189| 
(85)  Mei, T.-S.; Leow, D.; Xiao, H.; Laforteza, B. N.; Yu, J.-Q. Org. Lett. 2013, 15, 3058. 
(86)  Wang, C.; Zhang, L.; Chen, C.; Han, J.; Yao, Y.; Zhao, Y. Chem. Sci. 2015, 6, 4610. 
(87)  Tang, R.-Y.; Li, G.; Yu, J.-Q. Nature 2014, 507, 215. 
(88)  Lazareva, A.; Daugulis, O. Org. Lett. 2006, 8, 5211. 
(89)  Feng, R.; Yao, J.; Liang, Z.; Liu, Z.; Zhang, Y. J. Org. Chem. 2013, 78, 3688. 
(90)  Tan, P. W.; Haughey, M.; Dixon, D. J. Chem. Commun. 2015, 51, 4406. 
(91)  Yang, J. Org. Biomol. Chem. 2015, 13, 1930. 
(92)  Dong, Z.; Wang, J.; Dong, G. J. Am. Chem. Soc. 2015, 137, 5887. 
(93)  Bressy, C.; Alberico, D.; Lautens, M. J. Am. Chem. Soc. 2005, 127, 13148. 
(94)  Catellani, M.; Frignani, F.; Rangoni, A. Angew. Chem. Int. Ed.  1997, 36, 119. 
(95)  Orito, K.; Horibata, A.; Nakamura, T.; Ushito, H.; Nagasaki, H.; Yuguchi, M.; Yamashita, 
S.; Tokuda, M. J. Am. Chem. Soc. 2004, 126, 14342. 
(96)  Orito, K.; Miyazawa, M.; Nakamura, T.; Horibata, A.; Ushito, H.; Nagasaki, H.; Yuguchi, 
M.; Yamashita, S.; Yamazaki, T.; Tokuda, M. J. Org. Chem. 2006, 71, 5951. 
(97)  Haffemayer, B.; Gulias, M.; Gaunt, M. J. Chem. Sci. 2011, 2, 312. 
(98)  López, B.; Rodriguez, A.; Santos, D.; Albert, J.; Ariza, X.; Garcia, J.; Granell, J. Chem. 
Commun. 2011, 47, 1054. 
(99)  Albert, J.; Ariza, X.; Calvet, T.; Font-Bardia, M.; Garcia, J.; Granell, J.; Lamela, A.; 
López, B.; Martinez, M.; Ortega, L.; Rodriguez, A.; Santos, D. Organometallics 2013, 32, 
649. 
(100)  Fuchita, Y.; Yoshinaga, K.; Hanaki, T.; Kawano, H.; Kinoshita-Nagaoka, J. J. Organomet. 
Chem. 1999, 580, 273. 
(101)  Beesley, R. M.; Ingold, C. K.; Thorpe, J. F. J. Chem. Soc. Trans. 1915, 107, 1080. 
(102)  Li, H.; Cai, G.-X.; Shi, Z.-J. Dalton Trans. 2010, 39, 10442. 
(103)  Cai, G.; Fu, Y.; Li, Y.; Wan, X.; Shi, Z. J. Am. Chem. Soc. 2007, 129, 7666. 
(104)  Littke, A. F.; Fu, G. C. Angew. Chem. Int. Ed. 2002, 41, 4176. 
(105)  Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37, 320. 
References 
 
190| 
(106)  Roy, S.; Gregg, B. T.; Gribble, G. W.; Le, V.-D.; Roy, S. Tetrahedron 2011, 67, 2161. 
(107)  Furuya, T.; Kamlet, A. S.; Ritter, T. Nature 2011, 473, 470. 
(108)  Ma, J.-A.; Cahard, D. Chem. Rev. 2004, 104, 6119. 
(109)  Miura, M.; Feng, C.-G.; Ma, S.; Yu, J.-Q. Org. Lett. 2013, 15, 5258. 
(110)  Miyata, J.; Kasahara, C.; Asano, T.; Ito, S.; Seki, N.; Kato, Y.; Morikawa, N.; Nozaki, K.; 
Nishimura, K.; Akamatsu, H.; Taguchi, Y.; Yamaguchi, T.; Abe, Y.; Ohkubo, M.; 
Watanabe, T.; Ohta, M.; Takeuchi, M. Bioorg. Med. Chem. Lett. 2012, 22, 5681. 
(111)  Chen, C.; Wu, D.; Guo, Z.; Xie, Q.; Reinhart, G. J.; Madan, A.; Wen, J.; Chen, T.; Huang, 
C. Q.; Chen, M.; Chen, Y.; Tucci, F. C.; Rowbottom, M.; Pontillo, J.; Zhu, Y.-F.; Wade, 
W.; Saunders, J.; Bozigian, H.; Struthers, R. S. J. Med. Chem. 2008, 51, 7478. 
(112)  Rodríguez, A.; Albert, J.; Ariza, X.; Garcia, J.; Granell, J.; Farràs, J.; La Mela, A.; 
Nicolás, E. J. Org. Chem. 2014, 79, 9578. 
(113)  McNally, A.; Haffemayer, B.; Collins, B. S. L.; Gaunt, M. J. Nature 2014, 510, 129. 
(114)  Smalley, A. P.; Gaunt, M. J. J. Am. Chem. Soc. 2015, 137, 10632. 
(115)  He, C.; Gaunt, M. J. Angew. Chem. Int. Ed. 2015, 54, 1. 
(116)  Engle, K. M.; Thuy-Boun, P. S.; Dang, M.; Yu, J.-Q. J. Am. Chem. Soc. 2011, 133, 18183. 
(117)  Engle, K. M.; Wang, D.-H.; Yu, J.-Q. J. Am. Chem. Soc. 2010, 132, 14137. 
(118)  Calleja, J.; Pla, D.; Gorman, T. W.; Domingo, V.; Haffemayer, B.; Gaunt, M. J. Nat. 
Chem. 2015, 7, 1009. 
(119)  Pirnot, M. T.; Rankic, D. A.; Martin, D. B. C.; MacMillan, D. W. C. Science 2013, 339, 
1593. 
(120)  Petronijević, F. R.; Nappi, M.; MacMillan, D. W. C. J. Am. Chem. Soc. 2013, 135, 18323. 
(121)  Huang, Z.; Sam, Q. P.; Dong, G. Chem. Sci. 2015, 6, 5491. 
(122)  Terao, Y.; Kametani, Y.; Wakui, H.; Satoh, T.; Miura, M.; Nomura, M. Tetrahedron 2001, 
57, 5967. 
(123)  Gürbüz, N.; Özdemir, I.; Çetinkaya, B. Tetrahedron Lett. 2005, 46, 2273. 
(124)  Neufeldt, S. R.; Sanford, M. S. Org. Lett. 2010, 12, 532. 
 
References 
 
191| 
(125)  Li, S.-H.; Wang, J.; Niu, X.-M.; Shen, Y.-H.; Zhang, H.-J.; Sun, H.-D.; Li, M.-L.; Tian, 
Q.-E.; Lu, Y.; Cao, P.; Zheng, Q.-T. Org. Lett. 2004, 6, 4327. 
(126)  Satoshi Omura, Atsushi Hirano, Yuzuru Iwai, R. M. J. Antibiot.  1979, 786. 
(127)  Liu, H.; Shi, G.; Pan, S.; Jiang, Y.; Zhang, Y. Org. Lett. 2013, 15, 4098. 
(128)  Saget, T.; Perez, D.; Cramer, N. Org. Lett. 2013, 15, 1354. 
(129)  Hoshiya, N.; Kobayashi, T.; Arisawa, M.; Shuto, S. Org. Lett. 2013, 15, 6202. 
(130)  Burgess, L. E.; Meyers, A. I. J. Am. Chem. Soc. 1991, 113, 9858. 
(131)  Janssens, F.; Torremans, J.; Janssen, M.; Stokbroekx, R. a; Luyckx, M.; Janssen, P. a. J. 
Med. Chem. 1985, 28, 1925. 
(132)  Ponti, F. De; Poluzzi, E.; Cavalli, A.; Recanatini, M.; Montanaro, N. Drug Saf. 2002, 25, 
263. 
(133)  Pearlstein, R.; Vaz, R.; Rampe, D. J. Med. Chem. 2003, 46, 2017. 
(134)  Sanguinetti, M. C.; Tristani-Firouzi, M. Nature 2006, 440, 463. 
(135)  Fernandez, D.; Ghanta, A.; Kauffman, G. W.; Sanguinetti, M. C. J. Biol. Chem. 2004, 
279, 10120. 
(136)  Cavalli, A.; Poluzzi, E.; De Ponti, F.; Recanatini, M. J. Med. Chem. 2002, 45, 3844. 
(137)  Fish, L. R.; Gilligan, M. T.; Humphries, A. C.; Ivarsson, M.; Ladduwahetty, T.; Merchant, 
K. J.; O’Connor, D.; Patel, S.; Philipps, E.; Vargas, H. M.; Hutson, P. H.; MacLeod, A. M. 
Bioorg. Med. Chem. Lett. 2005, 15, 3665. 
(138)  Xu, J.; Wei, L.; Mathvink, R.; He, J.; Park, Y.-J.; He, H.; Leiting, B.; Lyons, K. A.; 
Marsilio, F.; Patel, R. A.; Wu, J. K.; Thornberry, N. A.; Weber, A. E. Bioorg. Med. Chem. 
Lett. 2005, 15, 2533. 
(139)  deParrodi, C. A.; Quintero-Cortés, L.; Sandoval-Ramírez, J. Synth. Commun. 1996, 26, 
3323. 
(140)  Hong, Y.; Senanayake, C. H.; Xiang, T.; Vandenbossche, C. P.; Tanoury, G. J.; Bakale, R. 
P.; Wald, S. A. Tetrahedron Lett. 1998, 39, 3121. 
(141)  Fernandes, A. C.; Romão, C. C. J. Mol. Catal. A Chem. 2007, 272, 60. 
(142)  Das, S.; Addis, D.; Zhou, S.; Junge, K.; Beller, M. J. Am. Chem. Soc. 2010, 132, 1770. 
 
References 
 
192| 
(143)  Hanada, S.; Tsutsumi, E.; Motoyama, Y.; Nagashima, H. J. Am. Chem. Soc. 2009, 131, 
15032. 
(144)  Reeves, J. T.; Tan, Z.; Marsini, M. A.; Han, Z. S.; Xu, Y.; Reeves, D. C.; Lee, H.; Lu, B. 
Z.; Senanayake, C. H. Adv. Synth. Catal. 2013, 355, 47. 
(145)  Zhou, S.; Junge, K.; Addis, D.; Das, S.; Beller, M. Angew. Chem. Int. Ed. 2009, 48, 9507. 
(146)  Berman, A. M.; Johnson, J. S. J. Am. Chem. Soc. 2004, 126, 5680. 
(147)  Rucker, R. P.; Whittaker, A. M.; Dang, H.; Lalic, G. Angew. Chem. Int. Ed. 2012, 51, 
3953. 
(148)  Utsunomiya, M.; Kuwano, R.; Kawatsura, M.; Hartwig, J. F. J. Am. Chem. Soc. 2003, 
125, 5608. 
(149)  Utsunomiya, M.; Hartwig, J. F. J. Am. Chem. Soc. 2004, 126, 2702. 
(150)  Ku, Y.-Y. Y.; Grieme, T.; Pu, Y.-M. M.; Bhatia, A. V.; King, S. a. Tetrahedron Lett. 
2005, 46, 1471. 
(151)  Ohmura, T.; Torigoe, T.; Suginome, M. Chem. Commun. 2014, 50, 6333. 
(152)  Caldwell, J. J.; Craig, D.; East, S. P. ARKIVOC 2007, 2007, 67. 
(153)  Chou, S.; Nelson, J. A.; Spencer, T. A. J. Org. Chem. 1974, 39, 2356. 
(154)  Galeta, J.; Tenora, L.; Man, S.; Potáček, M. Tetrahedron 2013, 69, 7139. 
(155)  Beutner, G. L.; Kuethe, J. T.; Kim, M. M.; Yasuda, N. J. Org. Chem. 2009, 74, 789. 
(156)  Aikawa, K.; Okamoto, T.; Mikami, K. J. Am. Chem. Soc. 2012, 134, 10329. 
(157)  Brunner, H.; Stöhr, F. Eur. J. Org. Chem. 2000, 2000, 2777. 
(158)  Bergbreiter, D. E.; Lalonde, J. J. J. Org. Chem. 1987, 52, 1601. 
(159)  Izquierdo, J.; Rodríguez, S.; González, F. V. Org. Lett. 2011, 13, 3856. 
(160)  Géant, P.-Y.; Martínez, J.; Salom-Roig, X. J. Eur. J. Org. Chem. 2012, 2012, 62. 
(161)  Clive, D. L. J.; Hisaindee, S. J. Org. Chem. 2000, 65, 4923. 
(162)  Ito, M.; Kitahara, S.; Ikariya, T. J. Am. Chem. Soc. 2005, 127, 6172. 
(163)  Persson, T.; Nielsen, J. Org. Lett. 2006, 8, 3219. 
References 
 
193| 
(164)  Jean, M.; Renault, J.; Uriac, P.; Capet, M.; van de Weghe, P. Org. Lett. 2007, 9, 3623. 
(165)  Coe, J. W.; Bianco, K. E.; Boscoe, B. P.; Brooks, P. R.; Cox, E. D.; Vetelino, M. G. J. 
Org. Chem. 2003, 68, 9964. 
(166)  D’Accolti, L.; Dinoi, A.; Fusco, C.; Russo, A.; Curci, R. J. Org. Chem. 2003, 68, 7806. 
(167)  Nunez, M. T.; Martin, V. S. J. Org. Chem. 1990, 55, 1928. 
(168)  Shinkai, H.; Ozeki, H.; Motomura, T.; Ohta, T.; Furukawa, N.; Uchida, I. J. Med. Chem. 
1998, 41, 5420. 
(169)  Vamecq, J.; Lambert, D.; Poupaert, J. H.; Masereel, B.; Stables, J. P. J. Med. Chem. 1998, 
41, 3307. 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
194| 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Appendix – 1H and 13C NMR spectra of key 
compounds 
Appendix – 1H and 13C NMR spectra of key compounds 
 
195| 
Content of 1H and 13C spectra 
7.1 Palladium(II)-catalysed carbonylation: N,O-Ketal substrates......................................... 200 
2,2-Diethyl-3-oxa-1-azaspiro[4.5]decane (183) ..................................................................... 200 
2,2-Diethyl-4,4-dimethyloxazolidine (191) ........................................................................... 201 
2,2-Diethyl-3-oxa-1-azaspiro[4.5]decane (198a) ................................................................... 202 
2-Ethyl-2,4,4-trimethyloxazolidine (198b) ............................................................................ 203 
2-Isopropyl-2-methyl-3-oxa-1-azaspiro[4.5]decane (199a) .................................................. 204 
2-Isopropyl-2,4,4-trimethyloxazolidine (199b) ..................................................................... 205 
2-Ethyl-2-propyl-3-oxa-1-azaspiro[4.5]decane (200a) .......................................................... 206 
2-Ethyl-2-propyl-3-oxa-1-azaspiro[4.5]decane (200b) .......................................................... 207 
2-Cyclohexyl-2-ethyl-3-oxa-1-azaspiro[4.5]decane (201a) .................................................. 208 
2-Cyclohexyl-2-ethyl-4,4-dimethyloxazolidine (201b) ......................................................... 209 
2-(Tert-butyl)-3-oxa-1-azaspiro[4.5]decane (202a) ............................................................... 210 
2-{3-(2-Ethyl-4,4-dimethyloxazolidin-2-yl)propyl}isoindoline-1,3-dione (231b) ............... 212 
2-((Benzyloxy)methyl)-2-ethyl-3-oxa-1-azaspiro[4.5]decane (232a) ................................... 213 
2-((Benzyloxy)methyl)-2-ethyl-4,4-dimethyloxazolidine (232b) .......................................... 214 
2-Ethyl-2-(3-[1-tosylpiperidin-4-yl]propyl)-3-oxa-1-azaspiro[4.5]decane (233a) ................ 215 
2-Ethyl-4,4-dimethyl-2-(3-[1-tosylpiperidin-4-yl]propyl)oxazolidine (233b) ...................... 216 
Methyl 3-(2-ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propanoate (234a) ............................... 217 
Methyl 3-(2-ethyl-4,4-dimethyloxazolidin-2-yl)propanoate (234b) ...................................... 218 
2-(2-Ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propan-2-ol (235a) .......................................... 219 
(E)-2-Ethyl-2-(hept-5-en-1-yl)-3-oxa-1-azaspiro[4.5]decane (236a) .................................... 220 
(E)-2-Ethyl-2-(hept-5-en-1-yl)-4,4-dimethyloxazolidine (236b) .......................................... 221 
2-(But-3-en-1-yl)-2-ethyl-4,4-dimethyloxazolidine (237b) ................................................... 222 
Ethyl 2-(2-ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)acetate (246a) ......................................... 223 
Ethyl 2-(2-ethyl-4,4-dimethyloxazolidin-2-yl)acetate (246b) ............................................... 224 
Appendix – 1H and 13C NMR spectra of key compounds 
 
196| 
2-Ethyl-2-(trifluoromethyl)-3-oxa-1-azaspiro[4.5]decane (248) ........................................... 225 
2-Ethyl-2-phenyl-3-oxa-1-azaspiro[4.5]decane (251) ........................................................... 227 
2-Ethyl-4,4-dimethyl-2-(4-nitrophenyl)oxazolidine (256) .................................................... 228 
2-Ethyl-2-phenethyl-3-oxa-1-azaspiro[4.5]decane (258a) .................................................... 229 
2-Ethyl-4,4-dimethyl-2-phenethyloxazolidine (258b) ........................................................... 230 
2-(Cyclopropylmethyl)-2-ethyl-3-oxa-1-azaspiro[4.5]decane (263) ..................................... 231 
2-(Cyclopropylmethyl)-2-ethyl-4,4-dimethyloxazolidine (267) ............................................ 232 
7.2 Palladium(II)-catalysed carbonylation: Carbonylation products .................................... 233 
7a'-Ethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (185) ....... 233 
7a'-Ethyl-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(7a'H)-one (186) .................. 234 
7a-Ethyl-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (192) ............................... 235 
7a'-Methyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (204a) .. 236 
3,3,7a-Trimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (204b) ..................................... 237 
7',7a'-Dimethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (205a)
........................................................................................................................... 238 
3,3,7,7a-Tetramethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (205b) .............................. 239 
7a'-Propyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (206a) ... 240 
3,3,7a-Trimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (206b) ..................................... 241 
7a'-Cyclohexyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (207a)
........................................................................................................................... 242 
7a-Cyclohexyl-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one  (207b) .................. 243 
2-(3-(5'-Oxotetrahydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-7a'-
yl)propyl)isoindoline-1,3-dione (238a) ............................................................ 244 
2-(3-(3,3-Dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl)propyl)isoindoline-1,3-dione 
(238b) ................................................................................................................ 245 
7a'-((Benzyloxy)methyl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-
one (239a) ......................................................................................................... 246 
Appendix – 1H and 13C NMR spectra of key compounds 
 
197| 
7a-((Benzyloxy)methyl)-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (239b) ... 247 
7a'-(3-(1-Tosylpiperidin-4-yl)propyl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-
b]oxazol]-5'(6'H)-one (240a) ............................................................................ 248 
3,3-Dimethyl-7a-(3-(1-tosylpiperidin-4-yl)propyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(240b) ................................................................................................................ 249 
Methyl 3-(5'-oxotetrahydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-7a'-
yl)propanoate (241a) ......................................................................................... 250 
Methyl 3-(3,3-dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl)propanoate (241b) .... 251 
7a'-(2-Hydroxypropan-2-yl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (242a) ............................................................................................. 252 
(E)-7a'-(Hept-5-en-1-yl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-
one (243a) ......................................................................................................... 253 
(E)-7a-(Hept-5-en-1-yl)-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (243b) .... 254 
9b'-Ethyl-2'H-spiro[cyclohexane-1,3'-oxazolo[2,3-a]isoindol]-5'(9b'H)-one (252) .............. 255 
7a'-Phenethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (259a)
........................................................................................................................... 256 
3,3-Dimethyl-7a-phenethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (259b) .................... 257 
7a'-(Cyclopropylmethyl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-
one (264) ........................................................................................................... 258 
7a'-Ethyl-6'-spirocyclopropyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (265) ............................................................................................... 259 
7.3 Palladium(II)-catalysed carbonylation:  -Keto carboxylic acids ................................... 260 
8-(1,3-Dioxoisoindolin-2-yl)-4-oxooctanoic acid (270) ........................................................ 260 
5-(Benzyloxy)-4-oxopentanoic acid (271) ............................................................................. 261 
7.4 Palladium(II)-catalysed carbonylation: C-Methylation of -lactam 185 ........................ 262 
(6'R, 7a'S)-7a'-Ethyl-6'-methyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (±) (272) ......................................................................................... 262 
7.5 Synthesis of TMP-astemizole 287 .................................................................................. 263 
Appendix – 1H and 13C NMR spectra of key compounds 
 
198| 
1-(4-Fluorobenzyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 
(299) .................................................................................................................. 263 
1-(4-Fluorobenzyl)-N-(4-methoxyphenethyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-
benzo[d]imidazol-2-amine (301) ...................................................................... 264 
2-(2,2,6,6-Tetramethylpiperidin-4-yl)isoindoline-1,3-dione (305) ........................................ 266 
2-(1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione (306) 267 
7,7,9,9-Tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (132) ................................................. 268 
8-(4-Methoxyphenethyl)-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (311) ......... 269 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-one (312) ...................................... 270 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-amine (307) .................................. 271 
1-(4-Fluorobenzyl)-N-(1-(4-methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl)-1H-
benzo[d]imidazol-2-amine (287) ...................................................................... 272 
7.6 Synthesis of astemizole analogue 288............................................................................. 274 
(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)methanol (316) ................................ 274 
7-((Benzyloxy)methyl)-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane (317) .................. 275 
7-((Benzyloxy)methyl)-8-(4-methoxyphenethyl)-7,9,9-trimethyl-1,4-dioxa-8 azaspiro 
[4.5]decane (318) .............................................................................................. 276 
2-((Benzyloxy)methyl)-2,6,6-trimethylpiperidin-4-one (354) ............................................... 277 
2-((Benzyloxy)methyl)-2,6,6-trimethylpiperidin-4-ol (355) ................................................. 278 
2-((Benzyloxy)methyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy)piperidine (356) .............. 279 
2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-one (319) ...... 280 
2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-amine (320) .. 281 
N-((2R,4R)-2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-yl)-1-
(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine (321) .................................... 282 
((2R,4R)-4-((1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)amino)-1-(4-methoxyphenethyl)-
2,6,6-trimethylpiperidin-2-yl)methanol (288) .................................................. 284 
7.7 Attempted synthesis of astemizole analogue 289/335 .................................................... 286 
Appendix – 1H and 13C NMR spectra of key compounds 
 
199| 
2,2,6-Trimethyl-1-azaspiro[bicyclo[4.2.0]octane-4,2'-[1,3]dioxolan]-8-one (128) ............... 286 
2-(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)ethanol (333) ................................ 287 
7-(2-(Benzyloxy)ethyl)-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane (336) .................. 288 
2-((Benzyloxy)ethyl)-2,6,6-trimethylpiperidin-4-one (359) .................................................. 289 
2-(2-(Benzyloxy)ethyl)-2,6,6-trimethylpiperidin-4-ol (360) ................................................. 290 
2-(2-(Benzyloxy)ethyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy)piperidine (361) .............. 291 
2-(2-(Benzyloxy)ethyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy)piperidine (363) .............. 292 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
200| 
7.1 Palladium(II)-catalysed carbonylation: N,O-Ketal substrates 
 
2,2-Diethyl-3-oxa-1-azaspiro[4.5]decane (183) 
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201| 
2,2-Diethyl-4,4-dimethyloxazolidine (191) 
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202| 
2,2-Diethyl-3-oxa-1-azaspiro[4.5]decane (198a) 
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203| 
2-Ethyl-2,4,4-trimethyloxazolidine (198b) 
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204| 
2-Isopropyl-2-methyl-3-oxa-1-azaspiro[4.5]decane (199a) 
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205| 
2-Isopropyl-2,4,4-trimethyloxazolidine (199b) 
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206| 
2-Ethyl-2-propyl-3-oxa-1-azaspiro[4.5]decane (200a) 
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207| 
2-Ethyl-2-propyl-3-oxa-1-azaspiro[4.5]decane (200b) 
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208| 
2-Cyclohexyl-2-ethyl-3-oxa-1-azaspiro[4.5]decane (201a) 
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209| 
2-Cyclohexyl-2-ethyl-4,4-dimethyloxazolidine (201b) 
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210| 
2-(Tert-butyl)-3-oxa-1-azaspiro[4.5]decane (202a) 
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211| 
2-{3-(2-Ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propyl}isoindoline-1,3-dione (231a) 
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212| 
2-{3-(2-Ethyl-4,4-dimethyloxazolidin-2-yl)propyl}isoindoline-1,3-dione (231b) 
 
 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
213| 
2-((Benzyloxy)methyl)-2-ethyl-3-oxa-1-azaspiro[4.5]decane (232a) 
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214| 
2-((Benzyloxy)methyl)-2-ethyl-4,4-dimethyloxazolidine (232b) 
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215| 
2-Ethyl-2-(3-[1-tosylpiperidin-4-yl]propyl)-3-oxa-1-azaspiro[4.5]decane (233a) 
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216| 
2-Ethyl-4,4-dimethyl-2-(3-[1-tosylpiperidin-4-yl]propyl)oxazolidine (233b) 
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217| 
Methyl 3-(2-ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propanoate (234a) 
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218| 
Methyl 3-(2-ethyl-4,4-dimethyloxazolidin-2-yl)propanoate (234b) 
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219| 
2-(2-Ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)propan-2-ol (235a) 
 
 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
220| 
(E)-2-Ethyl-2-(hept-5-en-1-yl)-3-oxa-1-azaspiro[4.5]decane (236a) 
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221| 
(E)-2-Ethyl-2-(hept-5-en-1-yl)-4,4-dimethyloxazolidine (236b) 
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222| 
2-(But-3-en-1-yl)-2-ethyl-4,4-dimethyloxazolidine (237b) 
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223| 
Ethyl 2-(2-ethyl-3-oxa-1-azaspiro[4.5]decan-2-yl)acetate (246a) 
 
 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
224| 
Ethyl 2-(2-ethyl-4,4-dimethyloxazolidin-2-yl)acetate (246b) 
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225| 
2-Ethyl-2-(trifluoromethyl)-3-oxa-1-azaspiro[4.5]decane (248) 
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226| 
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227| 
2-Ethyl-2-phenyl-3-oxa-1-azaspiro[4.5]decane (251)  
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228| 
2-Ethyl-4,4-dimethyl-2-(4-nitrophenyl)oxazolidine (256) 
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229| 
2-Ethyl-2-phenethyl-3-oxa-1-azaspiro[4.5]decane (258a) 
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230| 
2-Ethyl-4,4-dimethyl-2-phenethyloxazolidine (258b) 
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231| 
2-(Cyclopropylmethyl)-2-ethyl-3-oxa-1-azaspiro[4.5]decane (263) 
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232| 
2-(Cyclopropylmethyl)-2-ethyl-4,4-dimethyloxazolidine (267) 
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233| 
7.2 Palladium(II)-catalysed carbonylation: Carbonylation products 
 
7a'-Ethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (185) 
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234| 
7a'-Ethyl-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(7a'H)-one (186) 
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235| 
7a-Ethyl-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (192) 
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236| 
7a'-Methyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (204a) 
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237| 
3,3,7a-Trimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (204b) 
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238| 
7',7a'-Dimethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one 
(205a)  
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239| 
3,3,7,7a-Tetramethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (205b) 
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240| 
7a'-Propyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (206a) 
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241| 
3,3,7a-Trimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (206b) 
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242| 
7a'-Cyclohexyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (207a) 
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243| 
7a-Cyclohexyl-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one  (207b) 
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244| 
2-(3-(5'-Oxotetrahydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-7a'-
yl)propyl)isoindoline-1,3-dione (238a) 
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245| 
2-(3-(3,3-Dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl)propyl)isoindoline-1,3-dione 
(238b) 
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246| 
7a'-((Benzyloxy)methyl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-
one (239a) 
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247| 
7a-((Benzyloxy)methyl)-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (239b) 
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248| 
7a'-(3-(1-Tosylpiperidin-4-yl)propyl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-
b]oxazol]-5'(6'H)-one (240a) 
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249| 
3,3-Dimethyl-7a-(3-(1-tosylpiperidin-4-yl)propyl)tetrahydropyrrolo[2,1-b]oxazol-5(6H)-one 
(240b) 
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250| 
Methyl 3-(5'-oxotetrahydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-7a'-
yl)propanoate (241a) 
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251| 
Methyl 3-(3,3-dimethyl-5-oxohexahydropyrrolo[2,1-b]oxazol-7a-yl)propanoate (241b) 
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252| 
7a'-(2-Hydroxypropan-2-yl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (242a) 
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253| 
(E)-7a'-(Hept-5-en-1-yl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-
one (243a) 
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254| 
(E)-7a-(Hept-5-en-1-yl)-3,3-dimethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (243b) 
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255| 
9b'-Ethyl-2'H-spiro[cyclohexane-1,3'-oxazolo[2,3-a]isoindol]-5'(9b'H)-one (252) 
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256| 
7a'-Phenethyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-one (259a) 
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257| 
3,3-Dimethyl-7a-phenethyltetrahydropyrrolo[2,1-b]oxazol-5(6H)-one (259b) 
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258| 
7a'-(Cyclopropylmethyl)dihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-5'(6'H)-
one (264) 
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259| 
7a'-Ethyl-6'-spirocyclopropyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (265) 
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260| 
7.3 Palladium(II)-catalysed carbonylation:  -Keto carboxylic acids 
 
8-(1,3-Dioxoisoindolin-2-yl)-4-oxooctanoic acid (270) 
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261| 
5-(Benzyloxy)-4-oxopentanoic acid (271) 
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262| 
7.4 Palladium(II)-catalysed carbonylation: C-Methylation of -lactam 185  
(6'R, 7a'S)-7a'-Ethyl-6'-methyldihydro-2'H-spiro[cyclohexane-1,3'-pyrrolo[2,1-b]oxazol]-
5'(6'H)-one (±) (272) 
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263| 
7.5 Synthesis of TMP-astemizole 287 
1-(4-Fluorobenzyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-benzo[d]imidazol-2-amine 
(299) 
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264| 
1-(4-Fluorobenzyl)-N-(4-methoxyphenethyl)-N-(2,2,6,6-tetramethylpiperidin-4-yl)-1H-
benzo[d]imidazol-2-amine (301) 
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265| 
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266| 
2-(2,2,6,6-Tetramethylpiperidin-4-yl)isoindoline-1,3-dione (305) 
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267| 
2-(1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl)isoindoline-1,3-dione (306) 
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268| 
7,7,9,9-Tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (132) 
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269| 
8-(4-Methoxyphenethyl)-7,7,9,9-tetramethyl-1,4-dioxa-8-azaspiro[4.5]decane (311) 
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270| 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-one (312) 
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271| 
1-(4-Methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-amine (307) 
 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
272| 
1-(4-Fluorobenzyl)-N-(1-(4-methoxyphenethyl)-2,2,6,6-tetramethylpiperidin-4-yl)-1H-
benzo[d]imidazol-2-amine (287) 
 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
273| 
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274| 
7.6 Synthesis of astemizole analogue 288 
(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)methanol (316) 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
275| 
7-((Benzyloxy)methyl)-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane (317) 
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276| 
7-((Benzyloxy)methyl)-8-(4-methoxyphenethyl)-7,9,9-trimethyl-1,4-dioxa-8 azaspiro 
[4.5]decane (318) 
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277| 
2-((Benzyloxy)methyl)-2,6,6-trimethylpiperidin-4-one (354) 
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278| 
2-((Benzyloxy)methyl)-2,6,6-trimethylpiperidin-4-ol (355) 
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279| 
2-((Benzyloxy)methyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy)piperidine (356) 
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280| 
2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-one (319) 
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281| 
2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-amine (320) 
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282| 
N-((2R,4R)-2-((Benzyloxy)methyl)-1-(4-methoxyphenethyl)-2,6,6-trimethylpiperidin-4-yl)-
1-(4-fluorobenzyl)-1H-benzo[d]imidazol-2-amine (321) 
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284| 
((2R,4R)-4-((1-(4-Fluorobenzyl)-1H-benzo[d]imidazol-2-yl)amino)-1-(4-methoxyphenethyl)-
2,6,6-trimethylpiperidin-2-yl)methanol (288) 
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286| 
7.7 Attempted synthesis of astemizole analogue 289/335 
2,2,6-Trimethyl-1-azaspiro[bicyclo[4.2.0]octane-4,2'-[1,3]dioxolan]-8-one (128) 
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287| 
2-(7,9,9-Trimethyl-1,4-dioxa-8-azaspiro[4.5]decan-7-yl)ethanol (333) 
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288| 
7-(2-(Benzyloxy)ethyl)-7,9,9-trimethyl-1,4-dioxa-8-azaspiro[4.5]decane (336) 
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289| 
2-((Benzyloxy)ethyl)-2,6,6-trimethylpiperidin-4-one (359) 
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290| 
2-(2-(Benzyloxy)ethyl)-2,6,6-trimethylpiperidin-4-ol (360) 
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291| 
2-(2-(Benzyloxy)ethyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy)piperidine (361) 
 
 
 
 
Appendix – 1H and 13C NMR spectra of key compounds 
 
292| 
2-(2-(Benzyloxy)ethyl)-2,6,6-trimethyl-4-((triisopropylsilyl)oxy)piperidine (363) 
 
 
 
 
